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Abstract
The availability and demand for proton therapy is rapidly expanding
across the globe. One of the key decisions that must be made in the pro-
curement process by all new centres is which proton treatment planning
system (TPS) to purchase. The first topic of this thesis is therefore to
evaluate the performance of three different proton TPSs in the planning
of ten meningioma patients. The comparison is built upwards from the
beam commissioning and attempts are made to make as many variables
as possible consistent between systems. Few statistically significant dif-
ferences were found between the plans, although differences between the
systems (such as layer spacing and spot positioning) are discussed. It is
hoped this work will be of general use to the whole proton physics com-
munity and will encourage further development of proton TPSs from
vendors.
One of the major sources of range uncertainty in current proton treat-
ment planning is due to the necessary conversion of the patient’s X-ray
computed tomography (CT) dataset from CT numbers to relative stop-
ping powers (RSPs). The remainder of the thesis looks to address this.
The stoichiometric procedure is considered the most accurate method to
generate the X-ray CT to RSP calibration curve. In the third chapter
of the thesis an investigation is made into the errors of this procedure:
specifically, the theoretical calculation of the RSP, step four of the pro-
cess. The impact of these errors on the proton beam range is calculated
for both phantom and patient cases.
It has been suggested that proton radiography could offer a solution
to the uncertainty in this calibration curve. The fourth chapter of the
thesis therefore looks at a novel method of proton radiography, which
involves taking the dose ratio of two pristine Bragg peaks. The inves-
tigation proceeds with a theoretical analysis of the application limits of
the technique, together with an experimental validation of the theoretical
approach.
The fifth chapter of the thesis demonstrates an approach that uses proton
radiography to improve the calibration curve. Assuming the information
in the proton radiograph to be correct, the calibration curve can be opti-
mised by comparison with a digitally reconstructed radiograph through
the X-ray CT. The function of this optimiser is validated on synthetic
datasets and its application is demonstrated with real measurements on
plastic and real tissue phantoms. The technique is also shown to of-
fer an improvement in the water-equivalent path length prediction at a
therapeutic depth.
Acknowledgements
I would firstly like to thank my supervisors, Professor Gary Royle, Pro-
fessor Adam Gibson (both University College London, UCL) and Dr El
Hassane Bentefour (Ion Beam Applications), for their continual guid-
ance and assistance throughout my studies and without whom this work
would not have been possible. I am very grateful to Dr Hsiao-Ming Lu
for his superb guidance and support during my time at Massachusetts
General Hospital (MGH).
I would also like to show my appreciation to Dr Ivan Rosenberg (Uni-
versity College London Hospital, UCLH), with whom I discussed many
aspects of my work and analysis. I am also indebted to Dr Chris Ainsley
at The Hospital of the University of Pennsylvania (UPenn) for his great
support in my attempts to commission their beam and for his specialist
expertise throughout the treatment planning project. I would like to
acknowledge Derek D’Souza, Chris Stacey and the radiotherapy physics
team at UCLH for their support in this work. The guidance of Maura
Kirk, also of UPenn, was critical in beam geometry selection and other
planning enquiries. I would also like to thank the patience, support and
plan verification provided by the support staff of Varian, Philips and
Elekta.
From my time at MGH I would first like to thank Dr Mauro Testa, for his
enduring support during all the proton radiography measurements (that
often extended deep into the night). Dr Gregory Sharp also receives
my gratitude for his Plastimatch modifications, his patience and for his
expert opinion throughout the project. I would like to thank Dr Joao
Seco for his inspiration and direction in the work of assessing range
effects. I would like to acknowledge the support of the operators at
MGH, without whom the late night measurements would not have been
possible.
I would like to gratefully acknowledge the financial support received from
the Engineering and Physical Sciences Research Council (UK) and Ion
Beam Applications (Louvain-La-Neuve, Belgium), who have allowed me
to complete this work. I also owe gratitude to the UCL Graduate School,
who funded the secondment to UPenn, and to the Institute of Physics
and Engineering in Medicine and the Institute of Physics for funding
trips to conferences.
From a personal aspect, I would also like to pay tribute to the group on
Cox 3 who made my time at MGH so enjoyable and got me hooked on
American coffee.
I would like to thank the spirit and atmosphere engendered by all the
students and staff of the Radiation Physics group at UCL. 11 o’clock
will forever be associated with tea time and questionable biscuits.
I could not be more grateful στην αγάpiη μου, for the emotional and
scientific support throughout the entirety. Η αγάpiη σου kept me strong
when I needed it most and I feel so lucky to have you by my side.
I would like show my appreciation to my grandparents, Irene and Patrick,
who have shown me nothing but encouragement since my first days at
school.
Finally, I reserve special praise for my parents, John and Elaine, and
brother Liam, for their love and support throughout the (many) years
of study. Without your continual positivity I would not be where I am
today.
Contents
Contents 6
1 Introduction 10
1.1 Range uncertainty . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1.2 Major results and novelty . . . . . . . . . . . . . . . . . . . . . . . . 13
2 Proton treatment planning system comparison 15
2.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.1.1 The systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.1.2 Previous treatment planning system comparisons . . . . . . . 16
2.1.3 Delivery modes . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.1.4 Optimisation . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2.1.5 Meningioma . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.1.6 Proton beam commissioning . . . . . . . . . . . . . . . . . . . 20
2.2 Aim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.2.1 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.3 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.3.1 Proton beam commissioning . . . . . . . . . . . . . . . . . . . 26
2.3.2 Treatment Approach . . . . . . . . . . . . . . . . . . . . . . . 32
2.3.3 Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.3.4 Target volumes and OARs . . . . . . . . . . . . . . . . . . . . 33
2.3.5 Planning strategy . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.3.6 Layer spacing, spot spacing and spot positions . . . . . . . . . 34
2.3.7 Optimisation options and dose calculation parameters . . . . . 35
2.3.8 Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.4.1 Proton beam commissioning . . . . . . . . . . . . . . . . . . . 37
6
CONTENTS
2.4.2 Treatment planning comparison . . . . . . . . . . . . . . . . . 40
2.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
2.5.1 Proton beam commissioning . . . . . . . . . . . . . . . . . . . 49
2.5.2 Treatment planning comparison . . . . . . . . . . . . . . . . . 54
2.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
2.6.1 Proton beam commissioning . . . . . . . . . . . . . . . . . . . 59
2.6.2 Treatment planning comparison . . . . . . . . . . . . . . . . . 59
3 Uncertainties in computing the relative stopping power 60
3.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.1.1 Producing the calibration curve . . . . . . . . . . . . . . . . . 61
3.1.2 Errors in the calibration curve . . . . . . . . . . . . . . . . . . 68
3.2 Aim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
3.2.1 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
3.3 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . 73
3.3.1 Computation of the RSP . . . . . . . . . . . . . . . . . . . . . 73
3.3.2 Range errors . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
3.3.3 Systematic errors in the current stoichiometric calibration pro-
cedure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
3.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
3.4.1 Computation of the RSP . . . . . . . . . . . . . . . . . . . . . 77
3.4.2 Range errors . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
3.4.3 Systematic errors in the current stoichiometric calibration pro-
cedure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
3.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
3.5.1 Computation of the RSP . . . . . . . . . . . . . . . . . . . . . 84
3.5.2 Range errors - Gammex phantom . . . . . . . . . . . . . . . . 84
3.5.3 Range errors - patient cases . . . . . . . . . . . . . . . . . . . 85
3.5.4 Systematic errors in the current stoichiometric calibration pro-
cedure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
3.5.5 How to correct the stoichiometric calibration . . . . . . . . . . 86
3.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
4 Dose ratio proton radiography 88
4.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
4.1.1 Classical proton radiography . . . . . . . . . . . . . . . . . . . 89
7
CONTENTS
4.1.2 Single-detector proton radiography . . . . . . . . . . . . . . . 89
4.1.3 Dose measurement for proton radiography . . . . . . . . . . . 90
4.1.4 Aim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
4.2 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . 92
4.2.1 Theoretical limits . . . . . . . . . . . . . . . . . . . . . . . . . 92
4.2.2 Application to patient sites . . . . . . . . . . . . . . . . . . . 95
4.2.3 Experimental demonstration in a single-detector CMOS APS . 97
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
4.3.1 Theoretical limits . . . . . . . . . . . . . . . . . . . . . . . . . 99
4.3.2 Application to patient sites . . . . . . . . . . . . . . . . . . . 101
4.3.3 Experimental demonstration in a single-detector CMOS APS . 104
4.3.4 Validation of theoretical predictions . . . . . . . . . . . . . . . 104
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
4.4.1 Theoretical limits . . . . . . . . . . . . . . . . . . . . . . . . . 105
4.4.2 Application to patient sites . . . . . . . . . . . . . . . . . . . 106
4.4.3 Experimental demonstration in a single-detector CMOS APS . 107
4.4.4 Study limitations . . . . . . . . . . . . . . . . . . . . . . . . . 108
4.4.5 Outlook of the dose ratio technique . . . . . . . . . . . . . . . 109
4.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
5 Patient-specific calibration using proton radiography 111
5.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
5.1.1 Improving the calibration curve with proton radiography . . . 112
5.1.2 The ‘time-resolved’ principle . . . . . . . . . . . . . . . . . . . 113
5.2 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . 116
5.2.1 Optimisation scheme . . . . . . . . . . . . . . . . . . . . . . . 116
5.2.2 Validation of the optimiser against synthetic datasets . . . . . 119
5.2.3 Proton radiographic measurements . . . . . . . . . . . . . . . 122
5.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
5.3.1 Validation of the optimiser . . . . . . . . . . . . . . . . . . . . 126
5.3.2 Single material, multiple material and heterogeneous phantoms126
5.3.3 Optimisation against time-resolved proton radiographs . . . . 130
5.3.4 Estimation of the WEPL at the therapeutic depth . . . . . . . 132
5.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
5.4.1 Validation of the optimiser . . . . . . . . . . . . . . . . . . . . 134
8
CONTENTS
5.4.2 Optimisation against time-resolved proton radiographs . . . . 136
5.4.3 Estimation of the WEPL at a therapeutic depth . . . . . . . . 137
5.4.4 Technique limitations . . . . . . . . . . . . . . . . . . . . . . . 137
5.4.5 Application to other proton radiographic techniques . . . . . . 139
5.4.6 Introduction into the proton treatment planning workflow . . 139
5.4.7 Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
5.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
6 Overall conclusions and final remarks 142
6.1 Treatment planning system comparison . . . . . . . . . . . . . . . . . 142
6.2 Errors in the HU-RSP calibration curve . . . . . . . . . . . . . . . . . 143
6.2.1 Range effects . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
6.2.2 Dose ratio proton radiography . . . . . . . . . . . . . . . . . . 143
6.2.3 Reducing range uncertainty with proton radiography . . . . . 144
6.3 Areas for future work . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
Appendix A: Gamma Analysis 147
References 149
9
Chapter 1
Introduction
The physical properties of protons can, in some cases, allow for an improved dose
distribution compared with conventional X-ray radiotherapy (Isacsson et al. [1996];
Lee et al. [1994]; Miralbell et al. [1997]). The Bragg peak, characterised by a sharp
distal and lateral penumbra and shown in figure 1.1, makes it possible to limit the
dose to critical structures in ways that are not possible with X-ray radiotherapy
(Wilson [1946]). Additionally, the low entrance doses ensure that the integral dose
deposited is always lower for protons than photons (Paganetti [2012]). This sparing
of surrounding normal organs from low- and mid-dose levels can help to lower the
probability of radiation-induced secondary malignancies (Chung et al. [2008]).
This distinct advantage has led to the use of proton therapy for a variety of indi-
cations, including ocular treatments using low proton energies (Damato et al. [2005];
Kacperek [2009]), cranio-spinal irradiations (Archambeau et al. [2000]), lung can-
cer (Moyers et al. [2001]) and a variety of paediatric treatments (Merchant [2009]),
among others. Falling construction costs has led to a significant increase in the in-
terest in, and availability of, proton beam therapy (Peggs [2002]). As of 2010, over
60,000 patients had received part or all of their radiation therapy from proton beams
(Bouyon-Monteau et al. [2010]). Since 2010, 9 new centres have opened worldwide,
with a further 30 planned to open by the end of 2016 (PTCOG [2013]). Many
of these new centres are opening with pencil beam scanning (PBS) rather than
the traditional passive scattering techniques, driven by improved efficiency (pas-
sive techniques require patient-specific apertures and compensators for each field)
and potentially lower neutron dose (Hall [2006]) (because of the absence of physical
beam spreading and shaping devices in the nozzle). Further details of the techniques
available in proton therapy are detailed in section 2.1.3.
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Figure 1.1: Example Bragg peaks from the proton beam at The Hospital of the University
of Pennsylvania.
1.1 Range uncertainty
Given that the major advantage of proton therapy over photon therapy is the dis-
tinctive Bragg peak, which is relied upon to shape the dose, it is imperative that
the proton beam range (the depth in tissue that protons reach) is well known. The
uncertainty on this position, known as ‘range uncertainty’, requires additional mar-
gins to be added to the treatment volume (compared to photon therapy), limiting
its efficacy. As such there is huge interest in the development of a technique that
can accurately predict or measure the proton range. Such a device or technique will
lead to further reduction of treatment planning margins, reduced toxicity, better
outcomes and thus wider use of proton therapy.
Range uncertainty arises from a number of sources, both systematic and random
in nature. A detailed review of the systematic errors, which forms a large part of
this thesis, is given in section 3.1.2. Paganetti [2012] demonstrated that one of the
largest uncertainties derives from inhomogeneities in the patient volume, leading to a
degradation of the Bragg peak shape (Urie et al. [1986]). Assuming inhomogeneities
simply shift the Bragg peak position ignores the fact that protons take somewhat
curved paths due to multiple Coulomb scattering (MCS). Urie et al. [1986] showed
that the deviation of protons from a straight line due to inhomogeneities leads to
drastic changes in the Bragg peak shape (if measured beyond the patient) and the
dose distribution within the patient.
In addition to patient inhomogeneities, range uncertainty arises from other sources
deriving from the patient imaging, i.e. in the measured computed tomography (CT)
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number, and uncertainties in calculating the relative stopping power (RSP) of the
tissue. Random uncertainties are largely related to the position of the target rela-
tive to the beam and are thought to blur out over a typical fractionation scheme.
However, for some indications this is not the case as the patient anatomy is known
to change slowly and systematically (Knopf and Lomax [2013]).
The Bragg peak shape means that patient positioning errors in proton ther-
apy can result in drastic changes in the dose distribution, unlike photon therapy
which usually results in a simple shift of the dose (Knopf and Lomax [2013]). Cur-
rently proton range uncertainty is ‘managed’ by designing plans that are ‘robust’
against such uncertainties. One such approach is the careful selection of treatment
field directions, such that the sparing of a critical structure is reliant on the lateral
penumbra and not the distal fall-off. Another approach, suggested by Rietzel et al.
[2006] and Thomas [2006] but to our knowledge not currently used in the clinic any-
where, is to design beam-specific planning target volumes (PTVs) that have larger
margins at the distal edge to account for both the weighting of the dose at the Bragg
peak and the systematic errors.
In general, proton treatment planning uses a generic margin recipe of 3.5% of
the range (water-equivalent, to the distal edge) plus an additional absolute value.
Paganetti [2012] explains that the historical 3.5% value originates from the addition
(in quadrature) of the CT number uncertainty using 1980’s CT technology (2%)
and the conversion from CT Hounsfield units (HU) to RSPs (1%), multiplied by
1.5 standard deviations. The MD Anderson Proton Therapy Center, the Loma
Linda University Medical Center and the Hospital of the University of Pennsylvania
(‘UPenn’, with whom a collaboration was formed for chapter 2 of this thesis) all
use a margin recipe of 3.5% + 3mm. At Massachusetts General Hospital (‘MGH’,
where chapter 5 of this thesis was conducted), a margin of 3.5% + 1mm is used.
The overriding aim of this thesis is to reduce the 3.5% value to a lower level.
There are a multitude of methods to measure the proton beam range within
the patient: from implantable dosimeters (Gottschalk et al. [2011]; Lu [2008b])
to prompt gamma imaging (Min et al. [2006]; Verburg et al. [2013]) and positron
emission tomography (Parodi et al. [2005]). For a complete list the reader is directed
towards the comprehensive review of Knopf and Lomax [2013].
In this thesis we aim to address the problem of range uncertainty, not by mea-
surement of the beam in vivo, but by a better characterisation of the patient tissues.
An improved estimation of the RSP distribution within the patient will reduce pro-
ton range uncertainty and will ultimately allow for a reduction in PTV margins. We
investigate the applicability of proton radiography as a tool for this purpose.
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1.2 Major results and novelty
The work in this thesis is separated into four chapters:
• All new proton centres must decide which proton treatment planning system
(TPS) to purchase. In the first chapter of this thesis the performance of three
commercial proton TPSs (Eclipse, Pinnacle3 and XiO) are evaluated, through
the planning of ten meningioma patients. To date there have been no such
works anywhere in the literature, largely because there was previously little
choice. Following commissioning of the same beam data on each system, the
same ten patients were planned with as many variables as possible consistent
between systems.
It was found that both Eclipse and Pinnacle3 produced beam models within
clinically-accepted tolerances (the beam model of XiO was not assessed). In
the version tested, Eclipse overestimated the build-up (by up to 2.5%) for
energies E ≥ 175MeV and Pinnacle3 consistently overestimated the Bragg
peak depth, with a maximum distal R50 (the depth at which the dose falls to
50% of the Bragg peak maximum) error of 0.5mm.
Few statistically significant differences were found between the plans, although
there were clear differences in the layer spacing and spot positioning. Such
information may prove useful to the proton physics community and it is hoped
it will encourage further development of proton TPSs from vendors.
As discussed in section 1.1, the conversion of the patient’s X-ray CT dataset from
CT numbers to RSPs contributes 0.5-1.8% to proton range uncertainty. The overall
aim of the work in chapters 3, 4 and 5 in this thesis is to minimise this error.
• There are numerous formulae (Bichsel, Janni, ICRU, Schneider) for computing
the theoretical stopping power of tissues, a critical part of the stoichiomet-
ric calibration procedure. It is not clear (i) which of these formulae should
be used, and (ii) the magnitude of errors each introduces. With respect to
measurements in a proton beam, it was found that there was a systematic
underestimation of the RSP between -0.6% to -2.1% for all approaches except
Janni (which overestimated by 0.5%) for seven Gammex inserts. These er-
rors translated into overestimations in the beam range of 1.1% to 1.5% (-0.3%
underestimation for Janni).
By developing a gold standard that matched our measurements, it was shown
that the agreement across 73 human tissues was 0.04±0.37% (mean± standard
deviation) when using the Schneider approximation with the ICRU elemental
ionisation energies and a water ionisation energy of 78 eV.
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• Proton radiography has been mooted as a potential solution to the range
uncertainty introduced by the calibration curve, as it generates a direct map
of the patient RSPs (i.e. no need to convert from CT numbers). The limits and
applicability of a novel method of single-detector proton radiography, which
involves taking the dose ratio of two pristine Bragg peaks, is determined. To
date, the applicability of this ‘dose ratio’ technique has only been investigated
on the distal side of the lower energy Bragg peak due to the sharp fall-off.
An investigation is therefore made into the use of proximal side, which has
the potential to allow for a much wider range of water-equivalent thicknesses
(WETs) to be imaged. Comparisons are made with use of the distal side.
The theoretical approach - using an analytical approximation for the Bragg
peak to generate theoretical dose ratio curves - was validated using measure-
ments of a sapphire sphere with a complementary metal oxide semiconductor
active pixel sensor (CMOS APS). In the theoretical investigation it was found
that, provided the noise level in the dose ratio image was less than 2%, a
larger spread of WETs could be imaged using the proximal side of the Bragg
peak (max 5.31 cm) compared to the distal side (max 2.42 cm). A square field
equivalent size of 7.6 cm2 could be imaged in a paediatric brain for a required
accuracy in the WET of 3mm and a 1% noise level in the dose ratio image,
but otherwise the technique was found to have limited applicability to different
patient sites.
• After demonstrating the limited applicability of proton radiography as a single
solution in the previous chapter, it is shown that it can be combined with X-ray
CT to generate patient-specific calibration curves. Assuming the information
in the proton radiograph to be correct, the calibration curve can be optimised
by comparison with a digitally reconstructed radiograph water-equivalent path
length (DRRWEPL) map through the high resolution X-ray CT. The function of
this optimiser is validated on synthetic datasets, with reductions in the root-
mean-square difference between the DRRWEPL and a known WEPL, before
and after optimisation, of 87-100%. Its application is demonstrated with real
measurements on plastic and real tissue phantoms, using the established ‘time-
resolved’ method of single-detector proton radiography. The mean error in
the WEPL for the generic/optimised calibration curves was 1.8/0.4% for the
plastic phantom and -2.1/-0.2% for the real tissue phantom. The technique
was also shown to offer an improvement in the prediction at the therapeutic
depth.
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Chapter 2
Proton treatment planning system
comparison
Work in this chapter can be found in the following journal article and was presented
at the following meetings:
• (Accepted) Doolan P, Alshaikhi J, Rosenberg I, Ainsley C G, Gibson A,
D’Souza D, Bentefour E H, Royle G 2014 A comparison of the dose distribu-
tions from three proton treatment planning systems in the planning of menin-
gioma patients with single-field uniform dose pencil beam scanning Journal of
Applied Clinical Medical Physics
• Alshaikhi J, Amos R, Doolan P, D’Souza D, Royle G, Rosenberg I 2014
Comparison of proton treatment planning systems International Conference
on Radiation Medicine (ICRM), Riyadh, Saudi Arabia, P48 (Poster)
• Doolan P, Rosenberg I, Ainsley C, Gibson A, Royle G 2013 A comparison of
the beam configuration modules of two proton treatment planning systems Eu-
ropean Society of Therapeutic Radiology and Oncology (ESTRO) 2nd Forum,
Geneva, Switzerland, PD-570 (Oral presentation)
As can be seen, there were many contributors to this work. J Alshaikhi produced the
plans on XiO, under strict guidelines from myself. C G Ainsley and the physics team
at UPenn acquired the integrated depth doses and spot profiles and helped with the
commissioning of each system. All other work in this chapter was conducted by
myself.
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2. Proton treatment planning system comparison
2.1 Background
2.1.1 The systems
This work was conducted as part of the procurement process for the new proton cen-
tre at University College London Hospital (UCLH). The TPSs under consideration
include: Eclipse (Varian Medical Systems), Pinnacle3 (Philips Radiation Oncology
Systems), RayStation (RaySearch) and XiO (Elekta). In this work the Eclipse,
Pinnacle3 and XiO systems (summarised in table 2.1) were assessed by planning a
number of different patient cases on each system.
It should be noted that, at the time of the study, Pinnacle3 was a non-clinical
research system. Philips had not yet received regulatory clearance and it was still un-
der development. During the course of the study five different versions of Pinnacle3
were released, so different parts of the study were completed under different versions.
As such, some results found in older versions may improve in later versions.
2.1.2 Previous treatment planning system comparisons
There have been many publications of treatment planning comparisons between pho-
tons and protons (a selection: (Cozzi et al. [2001]; St Clair et al. [2004]; Stuschke
et al. [2012]; Trofimov et al. [2007]; Yoon et al. [2011]), specifically for meningiomas:
(Arvold et al. [2012]; Combs et al. [2012])) and for different proton therapy tech-
niques (Arjomandy et al. [2012]; Noa et al. [2012]; Tang et al. [2013]; Yeung et al.
[2014]). A number of publications exist on the theory and accuracy of the dose
calculation algorithms for two of the systems (Eclipse (Schaffner [2008]; Schaffner
et al. [1999]; Ulmer and Matsinos [2011]; Ulmer and Schaffner [2011]; Zhu et al.
[2013]) and XiO (Rana et al. [2013]; Soukup et al. [2005])). For Pinnacle3, only the
theoretical basis is available (Bortfeld [1997]; Gottschalk et al. [1993]; Kooy et al.
[2010]; Lynch et al. [1991]; Soukup et al. [2005]), because at the time of the study
Philips had yet to receive regulatory clearance for the software. While there have
been numerous comparisons of commercial photon TPSs (Ayyangar et al. [2005];
Eldesoky et al. [2012]; Fogliata et al. [2003, 2005, 2007]), we are not aware of any
publications comparing different commercial proton TPSs. This is largely because
Manufacturer System Version
Varian Eclipse 10.0.39
Philips Pinnacle3 9.100.0
RaySearch RayStation 3.4.9
Elekta XiO 4.7.00
Table 2.1: Details of proton TPSs under consideration at UCLH.
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proton TPSs were typically built in-house, but the rapid expansion of proton therapy
has led the major photon TPS vendors to develop or purchase their own modules.
This study compares the plans produced by three proton TPSs, Eclipse (Varian),
Pinnacle3 (Philips) and XiO (Elekta), for a set of ten meningioma patients in which
as many variables as possible were kept consistent. It is the hoped that such an
assessment will provide additional information to the procurement process for new
proton centres and will encourage further proton TPS development.
2.1.3 Delivery modes
Proton treatments currently fall into two modes: scattering or scanning. Passive
scattering, the most common current treatment, consists of a beam of fixed energy
intercepted by various beam modifiers. After initial beam energy modification up-
stream, the energy is refined by placing material in the path (variable range shifter,
range modulator wheel or ridge filter). The initial pencil-shaped beam is laterally
spread to a more useful, larger Gaussian profile using one or two scattering foils
(double scattering is more common). The lateral shape of the beam is made to
match the lateral shape of the tumour (plus any margin) using a custom (field-
and patient-specific) brass aperture. Dose conformation in the depth direction is
achieved using custom (field- and patient-specific) compensators of lucite or wax.
Scanning treatments are far more convenient, but until recently have not been
used routinely because the technology was not commercially available and/or centres
lacked experience. In scanning the beam energy is refined before the nozzle, using
range shifters. The pristine pencil beam is deflected using magnetic dipoles to scan
the beam across the patient. Beam energy corresponds to a given depth in tissue, so
once the cross-section of a tumour has been scanned the energy is altered (usually
lowered) and the next cross-section is scanned. Scanning has an advantage over
scattering techniques as it allows for more conformal treatment plans, particularly
at the proximal tumour edge (which cannot be conformed to with conventional
scattering techniques). In addition, apertures and compensators are not required
for every patient field, saving both time and money. There are worries over delivery
times and interplay with patient motion (Grassberger et al. [2013]), but the general
trend is for new centres to open with scanning techniques.
2.1.3.1 Modes of scanning
Scanning can either be delivered discretely on a spot-by-spot basis (known as spot
scanning) or in a continuous mode (also known as PBS). In either of these modes the
fluence at each position can be constant (known as uniform scanning) or modulated
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Figure 2.1: Classification of the techniques possible in proton therapy. Abbreviations are
given in the text.
(active scanning). In uniform scanning it is possible to have different spot weights
using a compensator, as with passive scattering.
In active scanning there are two common techniques: (i) single field uniform
dose (SFUD), where each field is individually optimised to deliver a uniform dose
distribution to the target; and (ii) intensity modulated proton therapy (IMPT),
where the final dose distribution is the result of contributions from multiple fields,
each of whose individual contribution to the target dose distribution is non-uniform
(Lomax [1999]). In addition, there are two different ‘flavours’ of IMPT: (i) 3D
IMPT, where Bragg peaks from all beams are placed throughout the volume and
their weights are optimally adjusted; and (ii) distal edge tracking (DET), in which
Bragg peaks are placed only on the distal edge of the target (McGowan et al. [2013]).
Liu et al. [2012b] showed that the latter requires many fields and is less robust to
uncertainties, but Oelfke and Bortfeld [2000] demonstrated that it offers reduced
integral dose, improved lateral fall-off and reduced dynamic range of Bragg peak
weights. The classification of all these techniques can be seen in figure 2.1.
2.1.4 Optimisation
Treatment planning is a procedure that takes as its input a model of the radia-
tion beam and patient anatomy and produces two outputs: (i) instructions to the
machine to deliver the treatment; and (ii) the expected distribution in the patient.
Dedicated TPSs are used for this process.
Active scanning has a large number of degrees of freedom, with the planner being
able to control the position, energy and intensity of every pencil beam (which can
have a standard deviation (Gaussian in shape) as small as 3mm in air). Assuming
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the spots are spread uniformly across the tumour and the number of energy layers
are fixed, the intensity (weight) of each pencil beam must be optimised to achieve
the best possible coverage of tumour and sparing of normal tissue. Typically there
can be of the order of 103 pencil beams per treatment, so this must be an inverse
planning process performed by a dedicated TPS.
Inverse optimisation involves the minimisation of a function that quantifies as-
pects of the dose distribution and specifies trade-offs between target volume coverage
and organ at risk (OAR) sparing (Schwarz [2011]). The routine to minimise this cost
function is similar between all systems and is thus unlikely to cause differences be-
tween plans in itself. However, each software has a different method of pre-weighting
and positioning spots prior to the minimisation step, which is likely to affect the
final plan quality.
At the time of this work, to the best of the author’s knowledge, there have been
no publications investigating the performance of proton optimisation algorithms in
current commercial TPSs, most likely because there previously was little choice. As
recently as 10 years ago most proton TPSs were built in-house. The rapid expansion
of proton therapy has however led to the major photon TPS vendors to produce or
purchase their own system. For instance the planning system developed at the Paul
Scherrer Institute (PSI) forms the basis of the Varian Eclipse proton TPS; the system
developed at MGH and Harvard Cyclotron Laboratory has been adapted by Elekta
(previously CMS) to form the basis of the proton planning in XiO; and the system
built by the University of Florida is currently being adapted by Philips to form
their proton module within Pinnacle3 (Yeung [2009]). With many new centres due
to open in the next 5-10 years there is demand for an evaluation of these commercial
systems.
2.1.5 Meningioma
One method of comparing TPSs is to plan the same patient on each system. The
multitude of settings available in each system makes this a difficult process, but it
is possible to isolate some conditions for testing. It is important that the patients
selected are suitable for scanning proton therapy and provide a difficult test to each
system, so that differences can be observed. In an ideal case many different treatment
sites would be tested, however this was not possible due to time constraints. It was
concluded, in consultation with an experienced medical physicist, that meningiomas
would be appropriate for this purpose.
Meningiomas account for 13-26% of all primary intracranial tumours (Kleihues
et al. [2002]). A number of treatment planning intercomparisons have shown that
proton beam therapy can substantially decrease the dose to OARs in the brain
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Figure 2.2: Meningioma patient to be used in the TPS comparison. Slices have been
selected to best demonstrate the difficulty of the case in the (left) transverse, (top right)
coronal and (bottom right) sagittal directions. Organs outlined: light pink = clinical target
volume; dark pink = right optic nerve + 3mm; dark brown = left optic nerve + 3mm;
orange = right orbit + 3mm; green = left orbit + 3mm; blue = brain.
(Baumert et al. [2001]; Lin et al. [2000]) and Weber et al. [2004a] confirmed this
specifically in meningioma patients. This advantage of proton therapy, together with
the difficulty of treating a volume that has a number of overlapping or surrounding
critical structures, make these suitable cases on which to conduct a dose distribution
comparison of different systems.
An example of one of the patients used in the comparison is shown in figure
2.2. The clinical target volume (CTV) encompasses the visible tumour, with an
extension to areas likely to have microscopic spread. The difficulty in this case
is that the right optic nerve overlaps with the target volume, a problem that was
typical of the ten patients selected. Here the sharp dose fall off of the proton depth
dose curve could be used in a superior or superior oblique beam, sparing many of the
organs at risk. In photon plans such an arrangement would be ill-advised because
the X-rays would continue through the rest of the patient’s body, depositing dose
along critical structures such as the spine.
2.1.6 Proton beam commissioning
A fair comparison requires all systems to have the same beam data. Therefore,
raw PBS beam data from UPenn’s horizontal fixed beam line, an IBA machine (Ion
Beam Applications, SA, Louvain-La-Neuve, Belgium), were added to each system
and commissioned according to the requirements and tools of each TPS.
Most modern TPSs are based on models rather than measurements, i.e. they
do not use this measured beam data directly but instead fit a model to the data
and perform all calculations using the model. It is possible to create a dose model
that accurately characterises the output of a given machine by iteratively adjusting
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the dose model parameters and evaluating the quality of the match between the
measured and computed data. Even after this manual adjustment the model in
each system will be different, so it is important to commission the beam so that any
limitations are highlighted. Such commissioning must be completed for all beam
data that will be used for subsequent treatment planning. In this comparison study,
any differences between the beam model in different systems may lead to different
results. As such, it is important any differences at this level are known and well-
documented.
Proton beam commissioning is simpler than photon beam commissioning, as far
fewer measurements are required:
1. Integrated depth dose (IDD) curves: pristine (not modified by scattering plates)
Bragg peaks from single, unscanned spots are measured at a range of depths in
water for a number of discrete energies. It is important the ionisation chamber
is large enough to collect the entire charge from the spot. To avoid inaccuracy
in such modelling most systems recommend using curves every 1-2 g/cm2 (i.e.
every 1-2 cm in water), which corresponds to energies approximately every
5-10MeV.
2. In-air spot profiles: lateral profiles (in x- and y-directions) of the spot are
measured at a range of positions from the source, for as many energies as
available.
3. General machine parameters: numerous properties of the machine must be
entered into the system.
2.1.6.1 Integrated depth doses
Each system uses different models to calculate the proton dose in a patient or phan-
tom. These are the same models that are used in beam configuration to model the
measured depth dose curves input by the user and thus it is important to understand
the differences. These models are often a compromise between speed and accuracy.
2.1.6.1.1 Pinnacle3 (the Bortfeld model)
The analytical model proposed by Bortfeld [1997] is used to approximate the depth
dose distribution for protons within Pinnacle3. The dose D as a function of depth
z can be parameterised according to the following equation:
D(z) = Φ0
e−ξ
2/4σ1/pΓ(1/p)√
2piρpα1/p(1 + βR0)
[
1
σ
L−1/p +
(
β
p
+ γβ +

R0
)
L−(1+p)/p(−ξ)
]
(2.1)
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Figure 2.3: Normalised depth dose curves for 150MeV protons in water, for the three
Bortfeld equations.
where Φ0 is the primary fluence; ξ = (R0−z)/σ, where R0 is the range of the proton
beam (distal 90%), z is the depth along the beam direction and σ is the width of the
Gaussian range straggling; Γ is the gamma function; ρ is the density of the medium;
and L is a parabolic cylinder function. The other parameters are constants and their
values for protons in water are given in table 2.2.
Equation 2.1 takes account of (i) range straggling, a phenomenon in which dif-
ferent protons lose different amounts of energy; and (ii) the energy spectrum of the
initial proton beam (assumed to consist of two parts: a peak, approximated by a
Gaussian; and a small ‘tail’ extending toward low energies). There are other Bort-
feld equations that do not take account of one or both of these and their different
depth doses are shown in figure 2.3. It can be seen that consideration of these two
factors not only has a distinct effect on the shape of the Bragg peak, but also its
position.
Parameter Description Value Unit
p Exponent of range-energy relation 1.77 -
α Proportionality factor 0.0022 cm MeV−p
β Slope parameter of fluence reduction rela-
tion
0.012 cm−1
γ Fraction of locally absorbed energy re-
leased in non-elastic nuclear interactions
0.6 -
 Fraction of primary fluence contributing to
the tail of the energy spectrum
≈ 0.0− 0.2 -
Table 2.2: Summary of constants and parameters used in the theoretical model proposed
by Bortfeld [1997]. The values are for protons in water. The last value is machine specific.
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Figure 2.4: Contribution of components to the total depth dose, for a 250MeV proton
beam in water, using the beamlet model. Varian [2011]
Pinnacle3 uses the distribution that takes account of both factors, as described by
equation 2.1. A problem with this model is that it does not account for dose build-
up at the entrance (for high energy proton beams) or the transport of secondary
protons. Eclipse therefore uses a different model that does take account of the
build-up, details of which are provided in section 2.1.6.1.2.
2.1.6.1.2 Eclipse (the Beamlet model)
The dose calculation model, known as ‘Proton Convolution Superposition’ in Eclipse,
is based on the model of proton beamlets in water by Ulmer and Schaffner [2011].
The beamlet is separately modelled in depth and perpendicular to the beam direc-
tion.
The depth dose curve is modelled as an infinitely broad, non-divergent beam
impinging orthogonally to the surface, so the beamlet dose deposition only depends
on the incoming energy spectrum. The dose curve is divided into contributions
from primary protons, secondary protons and recoil particles. The lateral dose
distribution is modelled by a 2D Gaussian distribution. The 3D dose distribution of
a single beamlet can be found by multiplying the number of protons, the normalised
lateral distribution and the maximum (central axis) dose on a given plane. The dose
from a real proton beam line is composed of a continuum of beamlets with spatially
varying intensities in the plane perpendicular to the beam axis. A summary of
the contribution of primary, secondary and recoil particles to the total depth dose is
shown in figure 2.4, for an incident energy E0 = 250MeV and a straggling parameter
(accounting for the finite energy spread of the incident protons and range straggling)
τincident = 0.2 cm.
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2.1.6.2 In-air spot profiles
When protons pass through material they interact with the Coulomb and hadronic
field of its nuclei, resulting in a small energy loss and a small angle deflection. While
the deflection is small, because of the large number of interactions the effect becomes
considerable. This process is known as multiple Coulomb scattering (MCS) and the
theory was first derived by Molière [1948] and developed by Bethe and Ashkin [1953].
These deflections are random but their cumulative effect can be modelled using a
Gaussian angular distribution when viewed on a macroscopic scale. As such, both
systems model the lateral source size at any distance from the machine head by a
two-dimensional Gaussian distribution.
2.2 Aim
The aim of this part of the thesis was to compare the performance of three proton
TPSs, to inform the procurement process for the new UCLH proton centre. This
was conducted through the planning of ten meningioma patients on all systems.
A full comparison of the entire TPS of each system would be impractical, due
to the size, complexity and number of so many different features on each system.
Rather than attempt such a task, that would quickly become out of date as the TPS
evolves, our preliminary work focused on a very specific case (SFUD for meningioma
patients). Even then, there were restrictions to the approach that could be taken.
Firstly, the vendors have proprietary rights to their software and so it was not pos-
sible to know the internal details of the algorithms. Secondly, the complexity of the
systems makes it very difficult to single out a specific component for testing. As such
we took a pragmatic approach of comparing the best plan that each system could
produce, with the same clinical constraints. Such an approach has both advantages
(e.g. it allows the use of options offered by each TPS) and disadvantages (e.g. there
are different implementations between TPSs and planners). The accuracy of each
dose calculation algorithm is an important topic, but it is something that we decided
not to investigate in this work due to the scale and depth required by the task. Also,
phantom studies are not purely a reflection of the inherent accuracies of the dose
calculation algorithms themselves, but also of how well the respective beam mod-
els have been configured; and the latter can be improved with experience. Given
our relative inexperience with each system, we decided to avoid this ambiguity and
simply assessed the beam models by their abilities to reproduce the measured in-
put data; all TPSs were found to be capable of doing this within clinical tolerances
(Doolan et al. [2013]).
The comparison was formed of two main analyses of 10 patient plans for each
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system: (i) the DVH metrics for the target and OARs; and (ii) an assessment of
the uniformity and distribution of spot weights. No qualitative features (ease of
use, visualisation features etc.) were compared to avoid the possibility of subjec-
tivity. Although there are numerous ways to compare different TPSs, we believe
that this is the first study, albeit a preliminary one, to explicitly compare clinical
implementations of different TPSs for proton therapy.
2.2.1 Objectives
In order to be able to compare different optimisation algorithms the same patient
was planned on each system. To achieve this aim, there were a number of objectives
that must be fulfilled:
1. The image data and the outlines of target and organs at risk must be consistent
on each system.
2. Protons and X-rays interact differently in tissue and so the HUs from the X-
ray planning CT must be converted to RSPs. This requires the production
of a calibration curve, which must be made consistent between systems. An
investigation into the uncertainties introduced by the use of this single curve,
together with efforts to reduce them, form chapters 3, 4 and 5 of this thesis.
3. In a comparison the beam data needs to be consistent between TPSs. It is
therefore necessary to acquire beam data from a clinical proton machine, load
the data into each system and model the beam.
4. After the most appropriate beam geometry has been determined, the menin-
gioma patients must be planned on each system and compared.
2.3 Materials and methods
This intercomparison study was conducted at a dose planning level (plans were made
on the TPS, without measurement validation). SFUD plans, using a horizontal fixed
beam geometry, were produced for three TPSs available to us:
1. Pinnacle3, Philips Radiation Oncology Systems (Fitchburg), version 9.1.00.
This was a non-clinical research system, as Philips had not yet received regu-
latory clearance for this software;
2. Eclipse, Varian Medical Systems, version 10.0.39;
3. XiO, Elekta, version 4.70.00.
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Fixed horizontal SFUD fields were employed in the study because, at the time
of writing, they are probably the most common implementation of spot scanning
proton beams due to their relative robustness over IMPT fields to range uncertainties
(Lomax [2008]; Weber et al. [2004b]). Although we allowed couch rotations, by
removing the additional degrees of freedom provided by IMPT plans, differences
between systems could be more easily identifiable.
2.3.1 Proton beam commissioning
A fair comparison requires all systems to have the same beam data. Therefore,
the raw PBS beam data from UPenn’s horizontal fixed beam line, an IBA ma-
chine, were added to each system (my work involved the commissioning of Eclipse
and Pinnacle3 only, so only these systems are described in this thesis). The beam
models were tuned within each system until the differences from the input data
were within clinical tolerances (Doolan et al. [2013]). A consistent minimum spot
monitor unit (MU) of 0.021 MU was enforced on all systems to ensure the plans
were deliverable (so that the statistical error on the spot dose, as dictated by the
charge measurement resolution of the monitor chambers in the nozzle, is within
1%). These MU constraints are dealt with during post-processing, with all systems
rounding equivalently, the impact of which is discussed in depth by Zhu et al. [2010].
The HU to RSP calibration curve was determined using a stoichiometric calibration
(Schneider et al. [1996]) and was identical between all three systems. Many more
details on this stoichiometric procedure can be found in the chapters 3, 4 and 5 of
the thesis. As one patient had titanium clips inside the target, the HU had to be
overridden in contouring because of saturation in the image.
2.3.1.1 Integrated depth doses
At UPenn, proton IDDs were acquired using a fixed horizontal beamline (i.e. the
gantry cannot be rotated around the patient) directed through the side of a water
tank. The WET of the side of the tank (18mm WET), an offset from the surface
(20mm - this is required as it is difficult to position the chamber precisely at the sur-
face) and the detector WET (4mm) meant that 42mm was the shallowest effective
water-equivalent depth that the detector could be placed. All measurements there-
fore have no values below 42mm. The lack of data in this build-up region proved
to be problematic for one of the planning systems, as discussed in section 2.5.1.1.1.
Measurement step sizes were not equidistant and were adapted for different energies:
0.5-1.0mm in the area of the Bragg peak and 3mm elsewhere.
The detector used was a parallel plate PTW 34070 Bragg peak chamber, as
shown in figure 2.5 (parallel plate chambers are recommended as they have a small
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dimension in the depth direction). It has a sensitive volume of 10.5 cm3, with a ref-
erence point 3.47mm below the chamber surface (which contributes to the detector
4mm WET mentioned above). In depth doses measurements with spot scanning
the dose from a single spot is measured, so it is important that the chamber is large
enough so that the whole beam spot is captured in the chamber. To achieve this,
Eclipse recommends (Varian [2011]) using a chamber with a radius Rmin of at least
3 x σs, where
σs =
√
σ2 + 2× (0.0307×R0)2. (2.2)
The factor ‘3’ originates from 3 x standard deviations covering approximately 99% of
a Gaussian distribution; σ is the standard deviation of the Gaussian-modelled spot;
the factor ‘2’ accounts for the lateral distribution of large angle scattered protons and
protons from nuclear interactions, which is approximately twice the size of primary
protons; the factor ‘0.0307’ is an empirical factor for the spot size at the peak as a
function of the beam range; and R0 is the beam range.
The largest spots in air are found for the lowest energy beams at the greatest
distance from the nozzle. In water, however, the highest energies penetrate to deeper
ranges, undergo more scattering and thus have larger spots. Equation 2.2 takes
account of this effect. It is therefore necessary to assess all of the input lateral
profiles in the x- and y-directions to determine the Rmin required; the result of
which is shown in figure 2.6 (for the x-direction only, a similar result was found for
the y-direction). It can be seen that the radius of the chamber is not large enough
to acquire spots with the highest energies E ≥ 218MeV, as it only has a radius of
40.8mm. For these higher energies, parts of the spot tails will not be acquired. The
radius is up to 6% too small, resulting in dose not being collected on the order of
∼ 1%. The systems assume a Gaussian profile that extends to infinity, which will
affect the fitting (discussed in section 2.5.1.2). The required radius of the detector
is > 43.4mm and > 42.8mm in the x- and y-directions respectively, for the highest
energy (226.7MeV).
2.3.1.1.1 Pinnacle3
The depth dose fitting process in Pinnacle3 was fully automated, with little input
required by the user. After loading in the data in OmniPro-Accept RFA-300 ASCII
Figure 2.5: PTW 34070 Bragg peak chamber used for IDD measurements. PTW [2013]
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Figure 2.6: Minimum radii required in the x-direction to ensure whole spot is captured
in depth dose measurements at various distances from the nozzle. The solid black line at
40.8mm illustrates the radius of the detector used.
format and entering the possible range bands, Pinnacle3 fitted all profile parameters
to the Bortfeld function that considers both the initial energy spread and range
straggling (section 2.1.6.1.1). Fitted values were generated for R0, σ, σ1 (a correction
term to better fit the proximal tails of the peaks, especially at higher energies) and
. In the automated beam modelling process it was possible to reach a minimum
whereby the result is not accurate, but this was remedied by altering the initial
value.
In addition to the automated fitting process it was necessary to enter a number
of parameters manually. These include: (i) the z offset [g/cm2]. This is the distance
that the IDD is shifted due to measurement conditions, such as the chamber wall
thickness. In our case z= 4.2 g/cm2. (ii) R90 [g/cm2] (depth of the distal 90% of
the Bragg peak) for each energy in water. This is the depth in water that the curve
nominally reaches without the measurement device wall thickness. (iii) The max
Dose/MU [cGy/MU]. This is dose rate at the peak of the Bragg curve, which is used
to scale the IDD curve into absolute units.
2.3.1.1.2 Eclipse
The modelling process in Eclipse was also completely automated. The only free
parameters for the user are the initial energy, E0, the straggling caused by the initial
energy spread, τincident and (optionally) a coefficient called ILan1 . The first two of
these were included in the input data. It was found, however, that another term
ILan2 had the greatest effect on the entrance dose, but this could not be controlled by
the user (in the version evaluated, v10.0.39). This proved problematic, as discussed
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in section 2.5.1.1.1.
2.3.1.1.3 Evaluation
Typically the quality of a model’s fit to data would be assessed using the chi-squared
test, but such a metric would be inappropriate for assessing the fit of proton depth
doses as it places too much weighting on the fitting to the Bragg peak. It could be
argued that such weighting is a good thing, because the large dose deposition and
sharp distal fall off of the Bragg peak makes it the most important part of the depth
dose curve. However, a more complete assessment of the fitting was performed using
gamma analysis. More details of this process can be found in appendix A. In quality
assurance tests a 3%/3mm stipulation is typically applied as the pass/fail criterion
(Low et al. [1998]). In this analysis a tighter 2%/2mm criterion was used in an
attempt to reveal differences between the fitting.
2.3.1.2 In-Air Spot Profiles
Proton spot profile measurements were acquired in air using IBA’s scintillator/CCD
camera system, ‘Lynx’, shown in figure 2.7a. Two-dimensional fluence arrays were
acquired in air for planes perpendicular to the beam direction, as shown schemati-
cally in figure 2.7b.
(a) Lynx system (b) In-air spot profile measurement set up
Figure 2.7: (a) Proton spot profile measurement device. (b) Measurement positions in
air. The proton beam is directed horizontally and measurements of the spot profile (orange
Gaussian profiles) are made at a range of positions in air using ionisation chambers.
Measurements were made at positions from the nozzle of 390, 330, 200, 100, 0
(isocentre), -100, -170 and -300 (all mm) (negative numbers indicating distances fur-
ther from the nozzle). Example spot profiles (in the x-direction) are shown in figure
2.8, demonstrating the expected decrease in profile size closer to the nozzle (higher
positive numbers) and with increasing energy. Based on the 8 input measurements
in air, the beam divergence and thus the initial source size was modelled, for the 27
energies available and in both the x- and y-directions.
29
2. Proton treatment planning system comparison
−20 −10 0 10 200
20
40
60
80
100
Distance / mm
D
os
e 
/ %
 
 
390 mm
330 mm
200 mm
100 mm
0 mm
−100 mm
−170 mm
−300 mm
(a)
−20 −10 0 10 200
20
40
60
80
100
Distance / mm
D
os
e 
/ %
 
 
390 mm
330 mm
200 mm
100 mm
0 mm
−100 mm
−170 mm
−300 mm
(b)
−20 −10 0 10 200
20
40
60
80
100
Distance / mm
D
os
e 
/ %
 
 
390 mm
330 mm
200 mm
100 mm
0 mm
−100 mm
−170 mm
−300 mm
(c)
Figure 2.8: Spot profiles in the x-direction acquired at a range of distances from the
nozzle for (a) 100MeV, (b) 150MeV and (c) 220MeV.
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Figure 2.9: Spot sizes (FWHM) in the x- and y-directions (left and right respectively),
for a range of energies and measurement positions.
Assuming a Gaussian shape, the spot width (full-width at half-maximum, FWHM)
was determined. The variations of x- and y-FWHMs with energy and measurement
position for the 512 measured profiles (8 measurement positions x 27 energies x 2
directions (x/y)) can be seen in figure 2.9. The spot size is dependent on the collima-
tor slit settings at the energy selector system and on the tuning of the quadrupoles
in the nozzle, both of which depend on energy. The general decrease with increas-
ing energy is to be expected as higher energy beams undergo less scattering in air
than lower energy beams, however the increase in spot size towards the highest en-
ergies suggests a different set of collimator/energy selector settings are used above
210MeV. Additionally it can be seen that the profiles are much more divergent in the
x-direction than the y-direction (different measurement positions are more spread
out). This is because the horizontal quadrupole (x-direction) is further upstream
than the vertical quadrupole (y-direction).
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Figure 2.10: Pinnacle3 user entry screen for fitting lateral profiles.
2.3.1.2.1 Pinnacle3
Similar to depth doses, the fitting process for lateral profiles was fully automated
in Pinnacle3, with the user screen shown in figure 2.10. Two-dimensional Gaussian
functions are fitted to OmniPro-Accept RFA-300 ASCII format profiles (same format
as IDD curves). Values are fitted for the centre, σ and the normalisation factor for
all measurements at different z positions.
After entering the R90 and with the profile shapes and range known, Pinnacle3
modelled the source size as a function of distance for each energy using a hyperbolic
equation. If the data is too sparse the result will be less accurate and so it was
recommended that the user imports sets of profiles in X and Y every 1-2 g/cm2
(≈ 5-10MeV), which was satisfied as energy measurements were made every 5MeV.
The research version analysed (April 2012) modelled the source as a two-dimensional
Gaussian. Later versions (February 2013, not assessed in this work) used a double
Gaussian model to better account for large non-Gaussian tails at wide angles. This
caused a problem with the depth doses, as detailed in section 2.5.1.1, and it would
be of interest to determine the accuracy of the improved profile modelling in the
later versions.
2.3.1.2.2 Eclipse
The fitting process for lateral profiles was also fully automated in Eclipse, requiring
the measurement of at least 3 profiles at different positions per energy. Using these
profiles the angular divergence was calculated and the source position was modelled
by projecting back to a zero field size.
2.3.1.2.3 Evaluation
The fitting of each system to these profiles was analysed using gamma analysis, in
the same approach as for depth doses (section 2.3.1.1.3). The gamma index is a com-
31
2. Proton treatment planning system comparison
bination of the dose difference (DD) and the distance-to-agreement (DTA) between
two points, but the 2%/2mm criteria used for the IDD analysis was not suitable for
spot profiles because of the small dimensions. It was therefore necessary to impose a
much tighter restriction on the DTA of 0.05mm. Prior to any gamma analysis both
the measured and fitted profiles were resampled to a very high resolution (every
0.01mm).
2.3.1.3 General Machine Parameters
The attributes of the machine were also defined during beam commissioning. For
instance, the range of gantry rotation determines the angles beams can be directed
from. Other information entered included: range of couch angles; nozzle compo-
nents; source-to-axis distance; magnet-to-axis distance; possible range shifters and
the range of snout sizes.
As stated previously, a consistent minimum spot MU limitation (0.021MU) was
enforced on all systems to ensure the plans were deliverable. If this practical lim-
itation were to be removed, the plans would look better but they would have no
practical consequence.
2.3.2 Treatment Approach
Fixed horizontal SFUD fields were employed in the study because, at the time
of writing, they were probably the most common implementation of spot scanning
proton beams due to their relative robustness over IMPT fields to range uncertainties
(Trofimov et al. [2007]). Using a fixed horizontal beam line reduces the flexibility of
angles available to the planner, but this could be seen as an advantage as there is
less choice and therefore a greater possibility of the optimum angle being selected.
Additionally, SFUD plans are easier to plan than IMPT plans, which is advantageous
due to the planner’s inexperience. Also, by removing the additional degrees of
freedom provided by IMPT plans, it was hoped differences between systems could
be more easily identified.
2.3.3 Patients
Ten meningioma patients, treated at our institution using a RapidArc X-ray ra-
diotherapy treatment, were selected for the comparison. The case load included
tumours, with and without overlapping structures, of different sizes (target struc-
tures ranged from 45.5 to 248.4 cm3) and grades. Full details can be found in table
2.3.
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Patient Age [yrs] Grade† Details Beam direction(s)
1 57 2 Parafalcine LSO, RSO
2 67 2 Frontal Vertex
3 40 - Cavernous sinus LLat, LSO
4 67 1 Cavernous sinus LLat, LSO
5 40 1 Sphenoid wing RLat, RSO
6 31 2 Cavernous sinus LLat, LSO
7 19 2 Sphenoid wing (brain invasion) LLat, LSO
8 40 - Cerebellopontine angle RLat, RSO
9 55 - Left orbital apex / sphenoid LLat, LSO
10 62 - Cavernous sinus LLat, LSO
Table 2.3: Patient and tumour characteristics. †Grade only measured for patients in
which a biopsy was practically possible. Beam direction abbreviations: L=left; R=right;
S=superior; O=oblique; Lat=lateral.
2.3.4 Target volumes and OARs
The gross tumour volume (GTV) and clinical target volume (CTV) were outlined
according to departmental protocol. Each CTV was expanded by 5mm to a pen-
cil beam scanning target volume (PBSTV). This expansion, which is 2mm larger
than that employed to construct the departmental PTV used for X-ray radiotherapy
planning, is to make the plans sufficiently robust to range uncertainties. Conven-
tionally, margins associated with range uncertainties should only be applied in the
proton field direction, but none of the systems allowed for the production of beam-
specific PTVs. Additionally, it was much more convenient to work with a single
target volume. The use of a consistent margin was appropriate for all patients as
the distances to the target distal edge were approximately similar (9.9-13.9 cm) and
thus the range uncertainties (a prescription of 3.5% × range + 1mm is employed at
UPenn for PBS treatments) did not vary much (4.5-5.9mm).
The dose prescription was 50.4Gy in 28 fractions. The dose-volume constraints
for the coverage of the PBSTV, together with the OAR constraints, are detailed in
table 2.5. All OAR constraints apply to the planning risk volumes (PRVs), formed by
3mm expansions from the corresponding structures to account for patient motion.
Although no specific constraints were applied, attempts were made to keep the brain
dose as low as possible without sacrificing target coverage and the mean dose to the
healthy brain was assessed.
2.3.5 Planning strategy
The study objective was to compare clinically-equivalent plans between TPSs, in-
dividually optimised for each system. The decision was therefore made to try to
give the planners the freedom they would have were they to use each TPS for real
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planning (i.e. allow choice of objectives and priorities), but with some artificial con-
straints imposed to keep the test fair. Similar approaches have been used by other
authors conducting TPS comparison studies (Fogliata et al. [2003, 2005]).
Beam geometries, patient isocentres and outlined structures were made consis-
tent between all systems. The beam arrangements used are detailed in table 2.3.
The same clinical constraints (table 2.5) were used for all patients, however the
choice of numerical objectives that achieves these goals differs between systems and
so was not fixed.
2.3.6 Layer spacing, spot spacing and spot positions
It was not possible to define the layer spacing in an identical fashion in each system,
although Pinnacle3 and XiO have similar approaches. For Pinnacle3, the layer spac-
ing is variable and dependent on the Bragg peak width. The system places layers
such that the distal 80% of the shallower layer matches the proximal 80% of the next
deepest layer (in later versions the user can alter the distal percentage value to alter
the spacing, but this was not possible in the version we tested). In XiO, the spacing
is also variable and equal to the Bragg peak width (defined in commissioning, with a
definition of the user’s choosing) times by a peak width multiplier (an integer value
selected by the user during planning). To ensure consistency with Pinnacle3, we set
the Bragg peak widths in commissioning as the 80-80% width of each pristine Bragg
peak, and used a peak width multiplier of 1. For Eclipse, the layer spacing cannot be
defined in the same way, but it can be configured with the following options during
commissioning: fixed distance (in mm) available throughout the energy range; fixed
change in energy (in MeV); fixed distance (in mm), determined based on the range
sigma of the highest or lowest energy per field; or variable distance, equal to the
range sigma of the next highest energy layer multiplied by a user-defined multiplica-
tion factor. In our study, the variable distance option was selected in an attempt to
maintain consistency with Pinnacle3 and XiO. The range sigma used in Eclipse only
accounts for the energy spread of the initial beam, whereas the Bragg peak width
used in Pinnacle3 and XiO also accounts for the range straggling. To determine what
multiplication factor should be used we experimented with beams of different range
and modulation, both with and without a range shifter. The further the layers were
spaced apart, the larger were the dose ripples along the beam direction. The closer
they were together, the more layers there were (hence longer delivery time) and
the greater becomes the sensitivity to the minimum spot MU problem (more layers
mean fewer MUs per layer and, hence, per spot). This led to spikes and troughs
as spots below the minimum MU threshold are either rounded up to the minimum
MU or rounded down to zero. The dominating phenomenon depends on the range
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and modulation. However, because Eclipse’s beam configuration only allowed for
the choice of a global value, it was found that using 4 × the range sigma was a good
compromise between these competing factors across all the beams studied.
Symmetric lateral spot spacings were defined according to the spot size at the
most distal layer of the target, such that there was sufficient overlap between neigh-
bours to avoid appreciable dose ripples. Lateral margins were then set to be equal
to this spacing to ensure at least one additional ring of spots was located outside the
PBSTV, reducing the possibility of highly weighted spots close to the target edge.
For Eclipse and XiO the available spot positions are defined by a 3D rectangular
grid passing through the isocentre, within the target boundaries (and margins).
Pinnacle3 defines 2D square grids for each layer, starting from the left hand side of
the target (in the beam’s eye view), such that the available positions of successive
layers are often offset.
An attempt was made to minimise any variation in planners’ ability with each
system by asking for feedback on the plan quality from the individual vendors.
2.3.7 Optimisation options and dose calculation parameters
Optimisation involves minimising some variable that quantifies target volume cov-
erage and OAR sparing. During this optimisation process, the stopping tolerance
was set to a suitably small value relevant to each system (0.001 in Eclipse, 10−5 in
Pinnacle3 and 0.0001% in XiO), so that an optimal dose distribution was ensured
but also that the optimisation did not take longer than 30 minutes (the maximum
number of iterations was never reached). Although an important factor in optimisa-
tion processes, differences between computing powers of the individual workstations
made timing comparisons infeasible.
Each system has different optimisers and/or options available, as summarised in
table 2.4. In this study the plans were quantified through dose volume histogram
(DVH) metrics, so for systems in which there is a choice we selected the optimiser
that gave the best dosimetric plan. No robustness options and/or features were
tested. Eclipse has two available optimisers: (i) the simultaneous spot optimisa-
tion (SSO) algorithm, which is based on a scanning optimisation algorithm (Lomax
et al. [1996]); and (ii) the conjugate gradient (CG) algorithm. Both optimisers can
produce SFUD and IMPT plans, but only SSO was used in this study as it gives
better DVHs (Varian [2011]). Pinnacle3’s optimiser, IMPT, allows for the produc-
tion of either SFUD or IMPT plans (only the former was tested in this study). A
robustness option and the creation of erroneous patient setup scenarios was also
available, but was not tested in this study. XiO has three options when optimising:
(i) beamwise optimisation of fluence, which produces SFUD plans; (ii) full intensity
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System Optimiser Comments Used in study
Eclipse Simultaneous spot opti-
misation (SSO)
Better DVH X
Eclipse Conjugate gradient
(CG)
Smoother distributions ×
Pinnacle3 IMPT Can produce IMPT and
SFUD plans
X
XiO Beamwise optimisation
of fluence
SFUD plans only X
XiO Full intensity modu-
lated proton therapy
IMPT plans only ×
XiO Sequel beamwise opti-
misation
Compromise between
SFUD robustness and
IMPT coverage
×
Table 2.4: Optimisers available in each proton TPS.
modulated proton therapy, which produces IMPT plans; and (iii) sequel beamwise
optimisation, which provides a compromise between the robustness of SFUD plans
and the coverage of IMPT plans. In this study only the first option was utilised
as only SFUD plans were produced. A smoothing option was available during the
optimisation, but was not employed.
Dose was calculated on all systems with a grid size of 2.5mm, using each system’s
most accurate dose calculation algorithm (for Eclipse this is ‘Proton Convolution
Superposition’, for Pinnacle3 ‘Proton PBS’, for XiO ‘Pencil Beam Algorithm’). All
three systems account for heterogeneities and model nuclear interactions. As the
accuracy of each dose calculation algorithm was not assessed, full details of the
different algorithms can be found in the relevant literature (Philips Medical Systems
[2013]; Soukup et al. [2005]; Varian [2011]).
The MUs of each system were normalised to be identical for a uniformly-irradiated
5 cm × 5 cm × 5 cm cube, 5 cm deep within a water phantom. The MUs needed to
be comparable between systems because the uniformity of spot weights was to be
assessed (see section 2.3.8 below). The 5 cm depth was chosen to ensure that the
available 74mm (water-equivalent) thick range shifter was included, as the targets
in all patients extend more proximally than the range of the lowest available energy
and thus required the use of this device.
2.3.8 Evaluation
To avoid discrepancies in the final volume building of DVHs, datasets were exported
with consistent dose bin widths (0.1Gy) and analysed independently using CERR,
the Computational Environment for Radiotherapy Research (Deasy et al. [2003]).
For each patient a set of parameters was computed from the DVHs, as detailed in
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table 2.5.
The uniformity and distribution of spot weights from each field was also analysed
using 3D spot maps. The spot MUs were determined by multiplying the spot weight
by the calibrated MUs for the given field. A parameter, C, was defined to allow
quantitative comparisons between systems:
C =
∑N
i=1 (w(i)× d(i))∑N
i=1w(i)
(2.3)
where w is the weight and d the distance from the isocentre for a spot i. The total
number of spots is N . The distance is calculated using the x- and y-co-ordinates
and energy (converted to a water-equivalent Bragg-Peak depth) for each spot.
2.4 Results
2.4.1 Proton beam commissioning
2.4.1.1 Integrated depth doses
For clarity it is easiest to assess the fitting by splitting the energies up into ranges. At
low and mid-range energies (100-160MeV) Pinnacle3 fits well on the proximal slope
of the Bragg peak, but overestimates the dose on the distal slope. Figure 2.11 shows
an example set of fits at 110MeV, with the gamma analysis statistics for these fits
in figure 2.12. In figure 2.12a there are four plots illustrating the breakdown of the
gamma analysis: (top left) the distance-to-agreement and (top right) dose difference
along the depth of the Bragg peak; (bottom left) the agreement and (bottom right)
absolute agreement (whereby the origin represents perfect agreement). Figure 2.12b
shows the composite of the distance-to-agreement and dose difference along the
Bragg peak, known as the gamma index. Pinnacle3’s overestimation of the Bragg
peak position (figure 2.11, at 9-9.5 cm) is reflected by an increase in the gamma
index at these depths (figure 2.12b). It is important the system models the position
and dose around the Bragg peak well as one of the advantages of proton therapy is
the ability to treat tumours very close to critical structures. While underestimating
the Bragg peak depth could have very damaging results (a deeper actual depth could
irradiate distally-adjacent critical structures), overestimating will have a similarly
poor result of underdosing the target. In this energy range (100-160MeV) the fitting
of Eclipse is much better, as demonstrated by the greater density of points at the
origin in the lower left plot of figure 2.12a. Its fitting to the distal slope is much
better, but sometimes there is a slight overestimation of the plateau dose, as can be
seen in figure 2.11 (≈ 5.5 cm), with an increase in the gamma index in figure 2.12b
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Figure 2.11: Integrated depth dose curves for a 110MeV proton beam in water.
at this depth.
At higher energies (165-226.7MeV), Pinnacle3 still suffers from an overestima-
tion of the distal dose (figure 2.13). Eclipse slightly overestimates the plateau dose,
but also overestimates the effect of build-up. As detailed in section 2.1.6.1.2, one
of the benefits of using the beamlet model is that build-up is incorporated into
the depth dose, unlike the Bortfeld model (section 2.1.6.1.1). However, there is an
underestimation of dose at the shallowest depths that gets larger (reflected by an
increase in the gamma index at shallow depths in figure 2.14b) until about 200MeV,
where it reaches 2.5%. It remains at this value for the higher energies.
Figure 2.15 shows the variation of gamma index with energy. It can be seen that,
for both systems, the fitting worsens with increasing energy. Pinnacle3 suffers from
the biggest single errors, but Eclipse suffers more often at higher energies because
of the poorly modelled build-up.
2.4.1.2 In-air spot profiles
A representative example of the fitting of each system to the measured y-profile
data can be seen in figure 2.16a, for 145MeV. It can be seen that, in general, both
systems do not fit well to the tails. In the same format as the depth dose analysis,
the statistics and variation of gamma index with position can be seen in figure 2.17.
The fitting of each system to the x-profile is generally better, as shown in figure
2.16b.
The mean/max gamma index for different energies is shown in figure 2.18. The
mean gamma for each energy versus the measurement position can be seen in figure
2.19 (where negative values are further from the nozzle). There appears to be little
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Figure 2.12: Gamma index analysis for the 110MeV proton IDD.
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Figure 2.13: Integrated depth dose curves for a 175MeV proton beam in water.
correlation with position.
2.4.1.2.1 Summary
In summary, both systems fit to the measured data within clinical tolerances. For
the integrated depth dose curves, Pinnacle3 has a tendency to overestimate the distal
Bragg peak depth while Eclipse overestimates the effect of build up at high energies.
Both systems generally fit well to the spot profiles, although neither are able to
model the tails in the y-direction.
2.4.2 Treatment planning comparison
Table 2.5 details the mean target coverage and OAR sparing for the three systems,
for a variety of parameters typically assessed during treatment planning. A mean
value for each statistic is given in units of Gy, with an error defined by the standard
error on the distribution across the ten patients. Although the errors are larger for
the OARs because each case requires different organs to be spared, the values are
still useful for comparison between systems because each system had the same range
of cases. The bracketed values in the constraint column are the percentages of the
prescribed dose (50.4Gy), while the bracketed values in the other columns are the
numbers of patients (out of ten) that fail to meet the higher/lower constraints. One-
way analyses of variances (ANOVAs) were calculated between the three systems for
each metric, with p-values shown in the far right column.
Figures 2.20 and 2.21 provide a graphical representation of these metrics, with
the boxplot showing the distribution of results across the ten patients. The edges of
each box are formed by the 75th (q3) and 25th (q1) percentiles; the whiskers extend
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Figure 2.14: Gamma index analysis for the 175MeV proton IDD.
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Figure 2.15: Variation of mean (line) and max (open circles) gamma index with energy
for depth doses. Error bars are formed by the standard deviations of gamma index values
across all measurement positions.
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Figure 2.16: (a) Y profiles at 145MeV. (b) X profiles at 135MeV.
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Figure 2.17: Gamma index analysis for the 145MeV y-profile. The solid black lines
indicate the pass/fail criteria.
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Figure 2.18: Variation of mean (line) and max (open circles) gamma index with energy
for spot profiles in the y- (a) and x-direction (b).
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Figure 2.19: Variation of mean gamma index with position for spot profiles in the y- (a)
and x-direction (b).
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Structure Metric Constraint Eclipse Pinnacle
3 XiO p/ Gy / Gy / Gy / Gy
PBSTV D2 (107%) < 53.9 52.4±0.1 (0) 51.4±0.3 (0) 51.0±0.1 (0) 1.7x10−4*
D5 (105%) < 52.9 52.0±0.1 (0) 50.9±0.2 (0) 50.7±0.1 (0) 5.6x10−7*
D95 (95%) > 47.9 46.5±0.8 (7) 48.0±0.6 (2) 48.0±0.6 (1) 0.21
D99 (90%) > 45.4 43.2±1.6 (6) 43.1±1.9 (3) 43.7±2.1 (4) 0.97
V95 - 91.3±1.9% 95.8±1.4% 95.6±1.0% 0.041
BStem Max < 55 41.5±6.8 (0) 41.7±6.5 (0) 41.0±6.5 (0) 1.00
Mean 20.0±4.0 14.7±3.1 21.2±4.0 0.43
R Glo Max < 45 22.0±4.5 (0) 14.9±4.8 (0) 18.6±4.9 (0) 0.58
Mean 6.1±2.7 3.6±2.5 4.7±3.0 0.81
L Glo Max < 45 33.8±4.8 (1) 31.7±5.5 (1) 31.6±4.9 (0) 0.94
Mean 12.4±2.9 8.8±2.8 7.0±1.7 0.31
R ON Max < 50 31.8±5.7 (1) 27.4±6.0 (0) 33.1±5.3 (1) 0.76
Mean 15.5±3.8 10.3±3.3 13.9±3.6 0.58
L ON Max < 50 42.8±4.9 (2) 41.9±5.2 (2) 43.5±4.6 (3) 0.98
Mean 34.3±5.4 32.8±5.8 32.0±5.1 0.95
O Chi Max < 50 44.2±4.9 (0) 44.6±4.9 (1) 45.9±4.1 (2) 0.97
Mean 38.1±5.5 37.3±5.6 39.7±4.9 0.95
R Lens Max < 6 6.7±2.3 (5) 1.7±1.0 (1) 1.2±0.4 (1) 0.024*
Mean 2.7±1.4 0.5±0.3 0.3±0.1 0.094
L Lens Max < 6 11.9±3.3 (6) 6.2±3.2 (4) 2.6±0.6 (5) 0.063
Mean 6.6±2.2 3.0±2.1 1.0±0.3 0.092
Brain Mean 8.2±0.6 6.5±0.6 8.9±0.6 0.022*
Table 2.5: Dose-volume constraints and coverage statistics. All OARs refer to PRVs.
The bracketed values in the constraint column are the percentages of the prescribed dose
(50.4Gy). The bracketed values in the Eclipse, Pinnacle3 and XiO columns are the number
of patients that failed to meet the criteria. Abbreviations: PBSTV = pencil beam scanning
target volume; BStem = brainstem; R/L Glo = right/left globe; R/L ON = right/left
optic nerve; O Chi = optic chiasm; R/L Lens = right/left lens; Brain = healthy brain.
*Significant.
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Figure 2.20: Target coverage statistics for the ten patients, for each system. Boxplots
are as described in the text, with the upper/lower constraints of each statistic (from table
2.5) shown by the solid/dashed black lines, respectively.
to the most extreme value that is not an outlier; points are considered outliers if
their results are greater than q3 +w(q3−q1) or smaller than q1 +w(q3−q1) (where w
is set to 1.5) and are shown by crosses; and the median is shown by the black circle
within the box. As an illustration, figure 2.22 shows dose distributions for patient
8 planned on all three systems.
To assess the uniformity and distribution of spot weights of the plans produced
by each system, the weight of each spot (normalised to each system’s mean) was
plotted against its absolute distance from the isocentre. This is shown in figure
2.23(a), together with the calculated values for C (equation 2.3), for all patients
and all fields. The mean weight of all spots at every 1mm, is shown in figure
2.23(b) for all systems.
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Figure 2.22: Dose distributions for patient 8. Structure abbreviations can be found in
table 2.5.
Figure 2.23: (a) Relationship between the normalised spot MUs and distance from the
isocentre, for all patients, for Eclipse (red squares), Pinnacle3 (blue triangles) and XiO
(green circles). The calculated values for C (equation 2.3) are displayed on the figure for
Eclipse (Ce), Pinnacle3 (Cp) and XiO (Cx). (b) The mean weight of all spots at every
1mm, for each system (same colour scheme).
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2.5 Discussion
2.5.1 Proton beam commissioning
2.5.1.1 Integrated depth doses
In general the fitting of both systems was good, with both models within accepted
clinical tolerances. There were a number of areas of concern, however.
2.5.1.1.1 Build-up
If the Bragg peak is measured with little or no solid material before the water (no
tank wall and very thin dosimeter wall) the depth dose curve should demonstrate
electron and nuclear build-up in the entrance region (Gottschalk [2004]). Electrons
generated by electromagnetic interactions build-up to equilibrium very quickly in
proton beams (≈ 1mm), which is one of the disadvantages of protons over photon
beams (little or no skin sparing). Nuclear build-up occurs over a larger distance
(≈ 1−2 cm in water), but it is smaller because nuclear secondaries account for only a
small fraction of the absorbed dose. To date there have been very few measurements
of nuclear build-up. Carlsson and Carlsson [1977] used a 185MeV proton beam
incident on a stack of (C2F4)n sheets interleaved with thermoluminescent detectors.
They observed a nuclear build-up of 7% over a characteristic length of 2 g/cm2 (i.e.
2 cm in water).
The measured data acquired at UPenn does not demonstrate any build-up be-
cause the measurements do not go below 4.2 cm (water tank wall thickness + sur-
face offset + chamber entrance window thickness), at which point the build-up
has reached equilibrium. The Bortfeld model does not account for any build-up of
dose, so the model (somewhat fortuitously) fits well. One of the major failings in
the Eclipse modelling was an overestimation of the build-up, as detailed in section
2.4.1.1. For energies E ≥ 175MeV the Eclipse model introduces a build-up of 2-3%
up to a depth of ≈ 7 cm, as shown in figure 2.24.
A summary of the contributions of the six main components to the primary
proton depth dose model of Eclipse is shown in figure 2.25. It can be seen that the
ILan2 term takes account of the build-up at higher energies, but as stated in section
2.3.1.1.2, this term could not be controlled by the user. From our results it is clear
that the Eclipse model has not been benchmarked against datasets for which you
do not expect to see build-up. This issue was relayed to Varian and the ILan2 term
became controllable in later versions of the software.
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Figure 2.24: Eclipse calculated depth dose curves for UPenn measured data (100-
226.7MeV), demonstrating an erroneous build-up region up to 70mm for the highest en-
ergies.
Figure 2.25: Contribution of components to the total dose deposited by primary protons,
for a 250MeV proton beam in water, using the beamlet model. Definitions of the individual
components can be found in the Varian [2011] user manual.
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Figure 2.26: Pinnacle3 fitting for 130MeV integrated depth dose using (a) Feb 2012
version and (b) July 2012 version.
2.5.1.1.2 Bragg peak depth
Pinnacle3 consistently overestimated the distal Bragg peak depth, with a mean/max
distal R50 error of 0.3mm/0.5mm over the 27 energies. These errors are small but
noticeable, an example of which can be seen in figure 2.13. The fitting is otherwise
good. It can be seen in figure 2.15 that the fitting fails (gamma index > 1) for 5/27
energies: 110, 130, 175, 215 and 220MeV.
A possible reason for the overestimation in Bragg peak depth could be due to an
underestimation of the spread of initial energies. Extreme cases of this are shown in
figure 2.3, where different forms of the Bortfeld equation do not take account of the
initial spread or range straggling at all, and it is clear that this affects the Bragg
peak depth. The level of range straggling is mathematically defined, but the initial
energy spread can be input manually into the model. It seems plausible that this
could result in an overestimation of the Bragg peak depth, but it does not explain
why it only happens at particular energies. The results have been reported to Philips
and are currently under investigation.
2.5.1.1.3 Future versions
In Pinnacle3’s July 2012 update, it was possible to place an increased weighting on
the distal edge during the fitting process. This option was tested and an example
of the fitting improvement of the distal part of the Bragg peak can be seen in figure
2.26. The compromise is that there is a slight underestimation of proximal dose,
between 11.5-12.0 cm. The effect of this on the mean and max gamma with each
energy is shown in figure 2.27. When comparing the two fittings (Feb fitting = black,
July fitting = magenta) the mean gamma is almost unaffected, but the maxima are
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Figure 2.27: Variation of mean (line) and max (open circles) gamma index with energy,
for February 2012 (black) and July 2012 (magenta) Pinnacle3 versions.
significantly reduced for the previously affected energies (110, 130, 175, 215 and
220MeV). By placing greater weight on the distal edge fitting the mean/max distal
R50 errors were reduced from 0.3mm/0.5mm to 0.03mm/0.1mm.
As detailed in section 2.1.6.1.1 the Bortfeld model does not incorporate build-
up. This did not impact on Pinnacle3’s fitting of our data because it did not go
to depths low enough where build-up would be seen, but a more recent version of
Pinnacle3 (Feb 2013) includes a correction factor to model build-up, whilst still using
the Bortfeld model. It would be of interest to see how this performs compared to
the Eclipse beamlet model for data that extends to the shallowest 1-2 g/cm2 depths.
As discussed in section 2.5.1.1, Eclipse’s main failing was an underestimation
of the entrance dose. This was attributed to the term ILan2 , which could not be
controlled by the user. In version 11 (the version being tested in our work was
10.0.39), an additional correction curve can be used to control possible build-up
artefacts. An example is shown in figure 2.28.
2.5.1.1.4 Impact
The impact of Eclipse incorrectly modelling the build-up is likely to have a small
effect in proton therapy planning. As discussed in section 2.5.1.1.1, the nuclear
build-up is estimated to be around 7% over the first 2 cm in water, which is a small
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Figure 2.28: An additional curve is available in Eclipse version 11 to correct for build-up
artefacts. The entrance dose can thus be correctly modelled by the user.
contribution to the total dose. Although small, this build-up is measurable and it is
likely to be detected during patient quality assurance (QA). It is also possible that
incorrect modelling could lead to unexpected skin side effects.
The marginally-incorrect modelling of the Bragg peak depth by Pinnacle3 is
likely to have a bigger impact on patient dose. An underestimation of the depth
would lead to under dosing at the distal edge of the target, while an overestimation
would lead to irradiation of normal tissues distal to the target.
2.5.1.2 In-air spot profiles
2.5.1.2.1 General
As detailed in section 2.4.1.2, the spot profile fitting of each system is good, but
not perfect. For the y-profiles both systems have problems fitting to the tails,
but the fitting for the x-profiles is good. This is suggestive that the spots do not
demonstrate a two-dimensional Gaussian shape. Upon closer inspection, it appears
the measurements demonstrate a deviation from the Gaussian shape at the highest
energies (E ≥ 215MeV) in the y-direction, although the reason for this is unclear.
At other energies however the profile shape remains Gaussian.
From figure 2.19 there also appears to be little to no dependence on the profile
measurement position, which is surprising. Further from the nozzle it is expected
the spot profile would be more Gaussian-like in shape (following more scattering)
and thus the systems would find it easier to fit to.
Both systems modelled the FWHMwell. The spot width (defined by the FWHM)
is used in dose calculations and it is possible that the system places a greater em-
phasis on ensuring this is correct (possibly at the sacrifice of the tail modelling).
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2.5.1.2.2 Input data
An issue affecting both systems is the radius of the chamber, which was smaller than
the spot size for the highest energies and deepest depths, as detailed at the start
of section 2.3.1.1. If this was the only problem, however, the small spot fraction
not being collected (of the order of ∼ 1%), would translate into insignificant clinical
consequences. A bigger problem is that the spots have since been found by UPenn
to have long, non-Gaussian tails, caused by large angle scattering and/or nuclear
interactions in the monitor chambers. These events affect all energies and all depths
and could result in a few per cent of the signal being lost even for low-energy beams
at shallow depths. In the versions analysed (Pinnacle3, Feb 2012; Eclipse, 10.0.39)
fitting of the in-air spot profiles was restricted to a two-dimensional Gaussian fit, so
these non-Gaussian tails would not be modelled.
2.5.1.2.3 Impact
A good model of the tails is very important if one wants to deliver IMPT (or even
widely-varying field sizes) accurately. At the time of the work the fixed beam line at
UPenn was mostly used for treating prostate cancer patients, whose field sizes are
fairly standard and whose spot intensities did not vary much. Provided this is the
case, the models commissioned on the assumption that the spots do not have long
tails is acceptable. However, upon the treatment of more complicated sites it was
found that discrepancies between the calculated and measured doses appeared, the
origin of which was attributed to the low-level tails not being modelled. UPenn are
currently acquiring additional data to refine their Eclipse model for such treatments
in the future.
2.5.2 Treatment planning comparison
2.5.2.1 Overall performance
The aim of the study was to compare the dose distributions produced by three pro-
ton TPSs, Eclipse, Pinnacle3 and XiO, with a common set of planning guidelines,
specifically for meningioma patients. The use of spot scanning protons for menin-
giomas has been shown to be beneficial (Weber et al. [2004b]), and the cases selected
challenged each system as there were often many overlapping structures. Plan dif-
ferences could be attributed to system differences, which would both inform new
proton centers deciding which TPS to purchase and encourage further development
of proton TPSs.
With a consistent planning strategy, all systems showed a good capacity to pro-
duce satisfactory plans that sufficiently respected the constraints for both the target
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Figure 2.29: Beam’s eye views of the spot distributions, with the spots in all layers
overlaid for (a) Eclipse, (b) Pinnacle3 and (c) XiO, for a particular patient and field. Each
spot map has been normalised to its own mean, with spot colour and size proportional to
the spot weight. The colour scale range differs between figures.
and OARs, despite difficult and conflicting objectives, with large overlapping re-
gions. The operation of these different systems and the options available to the
planner do differ, but the final results were similar.
Statistically significant differences were found for the high target doses, D2
(p=1.7x10−4) and D5 (p=5.6x10−7), the maximum dose for one of the lenses (p=0.024)
and the mean brain dose (p=0.022). Although not significant, there was a gen-
eral tendency for Pinnacle3 to deliver lower OAR doses (as can be seen in figure
2.21). Mean integral doses outside the PBSTV, across all patients, were found to be
4.4± 1.5Gy in Pinnacle3 (mean ± standard deviation), compared to 6.0± 2.2Gy in
Eclipse and 6.3±2.3Gy in XiO. This can also be seen in figure 2.22, with Pinnacle3’s
dose distribution showing marginally better conformality to the tumour than those
of Eclipse and XiO. A possible reason for this is the flexibility of available spot
positions, which are more staggered than the fixed 3D grids available in Eclipse and
XiO, as explained in section 2.3.6. An illustration of the effect of this is shown in
figure 2.29. Other possible reasons, such as different energy layer spacings and other
system differences, are detailed below.
2.5.2.2 Energy layers
As stated in section 2.3.6, the layer spacing could not be defined in a consistent
manner for all systems. Attempts were made to make the resultant layer spacing
of each system consistent, however this proved difficult. It was found (by analysing
mean ± standard error across all patients) that Pinnacle3 (21±2) used fewer energy
layers than XiO (31 ± 2). A variable spacing of 4 times the range sigma was used
by Eclipse, but this was perhaps not high enough as the average number of layers
(17 ± 1) was lower than both Pinnacle3 and XiO. This was a potential source of
disadvantage to Eclipse. In the plans produced, the number of spots per layer was
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similar: Eclipse (68± 9), Pinnacle3 (86± 12) and XiO (79± 11) (mean ± standard
error across all patients).
2.5.2.3 System differences
Eclipse and Pinnacle3 allow multiple fields to be simultaneously optimised as sepa-
rate SFUD fields, whereas XiO requires separate optimisation of each field, with half
the prescription dose and half the tolerance doses to the OARs, followed by sum-
ming of the different field doses at the end. This effectively doubles the optimisation
computational time.
Pinnacle3 is the only system that has an option to allow the relative weighting
of the two fields to be adjusted by the optimiser. As sometimes one field can better
spare an OAR while delivering more dose to the target than another, this option
could be useful and is a potential explanation for the generally lower OAR doses
discussed in section 2.5.2.1.
It is known that, for this version of Eclipse, the optimiser has a tendency to form
one or two highly weighted spots. Ordinarily, the planner would assess the effect of
removing these, but no post-processing of spot weights was completed in this study
in order to specifically test the algorithms. This was less common for Pinnacle3 and
XiO.
2.5.2.4 Spot uniformity and distribution
An assessment was made of the uniformity and distribution of spot weights between
TPSs. A parameter, C, was defined to quantify this difference, which involves
analysing the spot weight as a function of the distance from the isocentre (equation
2.3). In figure 2.23(b) it can be seen that Pinnacle3 has a more uniform distribution
of spot weights than Eclipse and XiO. This is backed up by the values of C, in which
Pinnacle3 has a lower value (38.3 ± 2.0mm) than for both Eclipse (41.2 ± 2.5mm)
and XiO (44.9±2.6mm). Although not verified in this work, it is hypothesised that
such a metric could be used as a heuristic measure of field robustness. For a field
to be robust, the highly weighted spots should generally be located further from
the edge of the target (and thus closer to the isocentre), so that changes in patient
position and range uncertainty within a given field are then less critical to the target
coverage and dose to the surrounding OARs. This would lead to a lower value of C.
Verification of this hypothesis, however, and the determination of a threshold value
for C, were beyond the scope of our work.
It should be added that this measure of robustness is only really applicable to
SFUD plans and is in contrast with the desire for an optimal plan. The larger
number of degrees of freedom in IMPT plans allow for generally better coverage
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and OAR sparing (Yeung et al. [2014]), but it has also been shown that IMPT
techniques such as distal edge tracking (in which the intention is to deliver highly
weighted spots to the distal edge of the target) are less robust to uncertainties (Liu
et al. [2012a]; Lomax [2008]). A variety of methods to handle such uncertainties
have been suggested (Chen et al. [2012]; Fredriksson et al. [2011]; Meyer et al.
[2010]; Pflugfelder et al. [2008]; Unkelbach et al. [2009]; Zhang [2012]), including the
reduction of the intensity of spots close to tissue heterogeneities (Pflugfelder et al.
[2007]), which is along similar lines to our hypothesis.
2.5.2.5 Study limitations and future work
As stated previously, comparing different TPSs is a very difficult task due to the
many variables. Any study trying to perform such a task will have limitations and
care should be taken to rank systems based on these preliminary results.
In an ideal study, the dose calculation would be performed in a single or inde-
pendent engine, to allow testing of the optimiser alone. This is difficult to achieve in
practice, however, as dose calculation is a necessary part of the optimisation process
and the two cannot be easily disentangled. As mentioned in the methods, the dose
calculation algorithm differs between systems and it is inevitable this will impact
on the plans. For instance, it may be possible to attribute the higher OAR doses
in Eclipse and XiO to deficiencies in their dose calculation algorithms leading to
an overestimation of the lateral penumbra, as has been reported to be the case for
uniform scanning proton therapy (Rana et al. [2013]). This would lead to OARs
lateral to the beam direction receiving a higher dose in the plan. Without verifica-
tion of the dose calculation algorithm, it is possible Pinnacle3 may suffer from the
opposite problem (i.e. the dose calculation algorithm may underestimate the lateral
penumbra, leading to reduced OAR doses). The aim and scope of our work was
to compare the dose distributions produced by three proton TPSs using equivalent
beam data and (as best as possible) matched configuration settings. A thorough, de-
tailed assessment of the dose calculation algorithms of each system is thus necessary
to validate our findings.
As stated in the methods, time is an important factor in the optimisation process,
but this could not be assessed due to the hardware differences between systems. Also,
the layer spacing could not be controlled in a consistent way for each system, and
the resulting number of layers available to each optimiser differed.
To calculate the distance for the quantitative metric C (equation 2.3) it was
necessary to convert the spot energy to a water-equivalent range, which does not
necessarily correspond to the physical co-ordinate of the pristine peak in the patient
relative to the isocentre. It should also be noted that each system has different
options available during optimisation, stated in the methods, which may improve
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the result of C. Eclipse offers the use of the CG optimisation algorithm, Pinnacle3
has a ‘robustness’ option and XiO has a ‘smoothing’ function, but none of these
were tested. It was not possible in this work to test the validity of this metric C as a
measure of robustness, but it could be incorporated into future work by introducing
shifts in the patient position.
The plans were made robust to range uncertainties using a uniform 5mm expan-
sion from the CTV, however a full assessment of robustness requires shifts in the
patient position, and systematic and statistical variations in the patient density and
chemical composition. Such assessments could not be carried out within all TPSs
tested, and it is a procedure that we would like to carefully control in an independent
scheme. This is an area of future work.
The study only looked at meningioma brain treatments using fixed horizontal
SFUD fields. It is anticipated there would be bigger differences in the performance
of each system when producing full-gantry IMPT plans, and this is also suggested
as an area of future work. How systems cope with different treatment sites will
be of interest because of the different OARs and heterogeneity issues that must be
considered. Also, as with any TPS comparison study, comparison results age quickly
because of the continual evolution of each system.
2.5.2.6 Impact on the proton physics community
In this dose comparison study it has been shown that there are clear differences
between the three TPSs and a new proton centre should take these into consideration
during the procurement process. For instance, each system has different options to
control the layer spacing and it may be the preference of the centre that this can
be varied during planning, particularly if the caseload is widely varying. This is not
possible in the version of Eclipse tested. Another clear difference was the staggering
of spot positions layer-by-layer. In Eclipse and XiO each layer exactly overlaid
the layer below, while in Pinnacle3 the layers could be offset. Although the lower
OAR doses in Pinnacle3 were attributed to this offsetting feature, the implications
of this on performing patient QA and (potentially) on delivery times should also
be considered by new proton centres. It is hoped that highlighting these differences
will generate interest and further work in proton TPS production. It is possible
that these system differences could impact on multi-institutional studies if different
TPSs are used. Care should therefore be taken to ensure that any TPS differences
are documented at the outset of the study, as these may account for different results
(as was seen in this work) between centres.
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2.6 Conclusions
2.6.1 Proton beam commissioning
The two systems involved in the commissioning (Eclipse and Pinnacle3) demon-
strated a good capability to produce beam models within clinically-accepted tol-
erances. However, the differences in algorithms lead to minor fitting differences.
Perhaps the most important differences are Eclipse’s overestimation of the build-up
at high energies and Pinnacle3’s consistent overestimation of the Bragg peak position
(mean/max 0.3/0.5mm), for the depth dose curves. The spot profiles were generally
modelled well, although additional measurements must be acquired so that the long,
non-Gaussian tails can be modelled. Both systems modelled the FWHM well.
2.6.2 Treatment planning comparison
The study compared the plans produced by three proton TPSs, Eclipse, Pinnacle3
and XiO, for the treatment of meningiomas with an SFUD horizontal fixed beam
arrangement. Few statistically significant differences were found, but Pinnacle3
generally gave lower OAR doses, with an integral dose outside the target 27% lower
than Eclipse and 30% lower than XiO on average, across all patients. Possible
reasons for this are the flexibility of available spot positions and the option that
the optimiser can adjust the relative weighting of the two fields, however the dose
calculation algorithms of each system must be assessed in future works to validate
our findings. Pinnacle3 was found to distribute its spots more uniformly than Eclipse
and XiO, although the effect of this on any possible robustness has not been explored.
In highlighting the differences between the systems we believe the study will prove to
be useful both to new proton centers and to the improvement of the TPSs themselves.
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Chapter 3
Uncertainties in computing the
relative stopping power
Work in this chapter can be found in the following journal article and was presented
at the following meetings:
• (Under review) Doolan P, Collins-Fekete C-A, Dias M, Royle G, Seco J 2014
Range effects in proton therapy caused by systematic errors in the stoichio-
metric calibration procedure Physics in Medicine and Biology
• Doolan P, Dias M, Collins-Fekete C-A, Seco J 2014 Range effects in proton
therapy caused by systematic errors in the stoichiometric calibration American
Association of Physics in Medicine 56th Meeting, Austin, TX, USA (Poster)
• Collins-Fekete C, Dias M, Doolan P, Hansen D, Beaulieu L, Seco J 2014
Combining proton radiography and X-ray CT information to better estimate
relative proton stopping power in a clinical environment American Association
of Physics in Medicine 56th Meeting, Austin, TX, USA (Poster)
• Dias M, Collins-Fekete C, Riboldi M, Doolan P, Hansen D, Baroni G, Seco
J 2014 Ion imaging to better estimate in-vivo relative stopping powers using
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3.1 Background
As stated in the introduction, the principal benefit of proton therapy derives from
one of the physical characteristics of the depth dose curve: the dose peak at a
well-defined depth in tissue. The position of this ‘Bragg peak’ and the range that
protons reach in tissue is controlled by their initial energy and by the integrated
stopping power of the tissues along the beam path. Provided the initial proton
energy is known, to predict the range of protons in tissue it is necessary to measure
the tissue stopping power. An ideal procedure to do this would consist of a direct
measurement using a proton beam. Currently this can only be conducted in 2D,
using proton radiographs, as proton CT is not currently available. However, this
is not useful for treatment planning as 3D datasets are required. A more detailed
review of proton radiography can be found in section 4.1.
As such, the current approach is to acquire a conventional X-ray CT image,
which is a dataset of photon attenuation. To perform any proton dose calculations
this dataset (in HU) has to be converted into a dataset of proton energy loss, which
is described by the RSP. The single calibration curve used to do this will henceforth
be referred to as the ‘HU-RSP calibration curve’. The quality of the calibration
curve directly affects the accuracy of determining the RSP values in the patient’s
body, thus affecting the accuracy of dose calculations and the accuracy of the proton
range prediction. This area of research is therefore of great importance.
3.1.1 Producing the calibration curve
The ambiguity in transferring from CT numbers to RSPs arises because the CT
number is related to the X-ray absorption coefficients, while the RSP is dependent
primarily on the relative electron density (Shinoda et al. [2006]). This conversion
results in a uncertainty of where the protons will stop in the patient, known as
‘range uncertainty’. As discussed in the introduction, in clinical practice a 3.5%
margin is added to account for the proton beam range uncertainty, with this HU-RSP
conversion process contributing ≈ 0.5% to the uncertainty (Paganetti [2012]), or up
to 1.8% if the uncertainty in the mean ionisation energy of the tissue (henceforth
referred to as ‘I-value’) is also considered (Schaffner and Pedroni [1998]).
There are a number of different methods to produce the HU-RSP calibration
curve, with different levels of complexity and effort required by the user. An overview
of these techniques is described here.
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3.1.1.1 Stoichiometric calibration
The stoichiometric approach, first proposed by Schneider et al. [1996], is widely
accepted as the most accurate method for producing the calibration curve for this
conversion (Yang et al. [2012]). The process consists of four main steps:
1. Image tissue-substitute materials with known chemical composition.
2. Parameterise the response of the CT as a function of chemical composition,
using the equation,
HU = ρrele
(
AZ3.62 +BZ1.86 + C
)
(3.1)
where ρrele is the volumetric electron density relative to water; Z is the effec-
tive atomic number (calculated using the fraction by weight of the individual
elements for compounds); and A, B and C are constants that characterise the
contributions of photo-electric, Rayleigh scattering and Compton scattering
to the total attenuation, respectively.
These constants, that parameterise the response of the CT system, depend on
the X-ray energy spectrum and are determined by fitting equation 3.1 to a plot
of measured HU values of the tissue-substitute samples (Schaffner and Pedroni
[1998]). Example values, from Schneider et al. [1996], for these constants are
A = 1.227 × 10−5, B = 4.285 × 10−4 and C = 0.5. These approximately
agree with the relative contributions of photo-electric, coherent scattering and
Compton scattering to the total attenuation shown in figure 3.1.
3. Calculate the CT numbers of human biological tissues. In an ideal scenario
these would be measured directly in the CT scanner, but this is rarely practical.
Even if real tissues could be readily handled, it would still require the separate
scanning of individual tissues (to avoid problems such as beam hardening).
Therefore, the CT numbers for real biological tissues are theoretically predicted
using equation 3.1, together with the fitted constants. Chemical compositions
and effective densities are taken from literature such as Woodard and White
[1986], White et al. [1987] and ICRU [1989].
4. Calculate the RSPs of human biological tissues. As with step 3, ideally these
would be measured directly with a proton beam, but again this is not practi-
cal. Therefore, these values have to be theoretically calculated using the same
chemical compositions from literature (Woodard and White [1986], White
et al. [1987] and ICRU [1989]). The absolute stopping power depends on
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Figure 3.1: Contributions to the mass attenuation coefficient of water, produced using
Nowotny [1998] with data from Boone and Chavez [1997]. The diagnostic energy range is
highlighted by the black box.
the energy of the particle, but it has been shown that the RSP is almost in-
dependent of β (particle velocity as a fraction of the velocity of light) for the
range of particle energies relevant to radiation therapy, as shown in figure 3.2.
As such, the RSP is a much more useful quantity for proton therapy treatment
planning, where the beam energy varies with depth in the patient. A few
different formulae currently exist in literature for this calculation.
(a) The first proposal was given by Bichsel [1972], with the absolute stopping
power SB given by:
SB = ρ
4pie4
mec2uβ2
z2
Z
A
{
ln
[
2mec
2β2
(1− β2)
]
− β2 − ln I t − C
Z
− δ
2
}
(3.2)
where ρ is the mass density; e is the electron charge; mec2 is the rest
mass energy of the electron; u is the atomic mass unit; z is the charge
of the projectile (+1 for protons); Z and A are the atomic number and
relative atomic mass of the target atom; I t is the I-value of the tissue;
C/Z is the shell correction; and δ/2 is the density correction. To allow
for comparison with other equations, we rewrite the formula of Bichsel
(equation 3.2) can be written as,
SB = K ×B (3.3)
where K is the term outside the brackets and B represents the terms
inside the brackets (the letter B used to represent Bichsel).
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Figure 3.2: Variation of (a) absolute stopping power and (b) relative stopping for a range
of tissue substitutes. In (b) the mean and error (calculated as the standard deviation) are
calculated over the range 5MeV to 250MeV. Graphs produced with data from Berger and
Zucker [2004].
This formulae, as well as the Janni and ICRU formulae in described in
sections (b) and (c) to follow, all compute the absolute stopping power.
The RSP can then be calculated by dividing by the stopping power of
water over the same energy range.
(b) Using these definitions, it is possible to write the stopping power as de-
fined by Janni [1982] SJ as,
SJ = K
{
B − 1
2
ln
[
1 +
2me
M
√
(1− β2) +
(m
M
)2]
+
piαzβ
2
+
zZα3F (β, Z)
β3
}
(3.4)
where M is the proton rest mass and the second term inside the brackets
forms part of the factor that accounts for the maximum kinetic energy
that can be transferred to an unbound electron at rest; α is the fine
structure constant, equal to 1/137.036, and the factor it is part of is
important relativistically; F (β, Z) is a function to account for the use of
the second Born approximation and is important only at low energies (it
is usually set to zero); and all other parameters are as defined previously.
To allow comparison with the ICRU formula (see below), the formula of
Janni (equation 3.4) can be rewritten as,
SJ = K {B + J1 + J2 + J3} (3.5)
where J1,2,3 are the second, third and fourth terms inside the brackets of
equation 3.4 (the letter J used to represent Janni).
(c) Similarly, the stopping power as defined by ICRU [1993] Report 49 can
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be written as,
SI = K
B + J1 + γJ3 −
(
zα
β
)2 ∞∑
n=1
[
n
(
n2 +
(
zα
β
)2)]−1 (3.6)
where γ comes from the use of the free-electron model and is approxi-
mately equal to
√
2 ; and all other parameters are as defined previously.
In the ICRU Report, there are I-values for elements (defined here as
‘condensed’) and for atomic constituents of compounds in the liquid and
solid phase (defined here as ‘compound’). Both can be used to compute
the stopping power SI .
(d) Alternatively, and more conveniently, the RSP can be approximated di-
rectly. As far as we are aware, this was first proposed by Schneider et al.
[1996],
RSP = ρrele
{ln [2mec2β2/I t(1− β2)]− β2}
{ln [2mec2β2/Iw(1− β2)]− β2} (3.7)
where ρrele is the volumetric electron density relative to water; I t and Iw
are the I-values of tissue and water respectively; and all other symbols
are as defined previously.
To account for the different formulae described in (a), (b) and (c), and be-
cause of their date of publication, each source uses different elemental I-values.
These values, together with the computed values for a range of Gammex tissue
substitutes and, importantly, water (Iw), are detailed in table 3.1.
One of the disadvantages of the stoichiometric method is the complexity of the
process and there is quite a lot of manual work required on the part of the user.
As such, many centres still use a tissue substitute calibration, described in section
3.1.1.2. Alternative methods have therefore been developed that try to incorporate
the accuracy of the stoichiometric method, but are easier to use, such as the poly-
binary model and dual energy imaging. These have not been readily taken up in
clinical practice and so are only briefly described in section 3.1.1.3.
3.1.1.2 Tissue-substitute calibration
The oldest, and most convenient, method of calibration is to use tissue-substitutes.
This process consists of three main steps:
1. Image tissue-substitute materials with known relative electron density ρrele and
density ρ. The composition is rarely known because it is considered confiden-
tial information by the vendor, but estimates have been made by Watanabe
[1999].
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I-value / eV
Element (Z) Bichsel [1972] Janni [1982] ICRU [1993]or Material Condensed Compound
H (1) 19.2 20.48 19.2 19.2
C (6) 78 73.8 81 81
N (7) 80 97.8 82 82
O (8) 95 115.7 106 106
F (9) 119 124.8 112 112
Na (11) 148 143 149 168
Mg (12) 156 151.1 156 176
Si (14) 174.5 174.5 173 195
P (15) 172 179.1 173 195
S (16) 180 183.6 180 203
Cl (17) 187 182.6 180 180
K (19) 193 186.8 190 214.7
Ca (20) 196 191.9 191 216
Fe (26) 280 278.2 286 323
I (53) 510 515.2 491 491
LN-300 Lung 70.3 71.2 73.1 74.1
LN-450 Lung 70.3 71.2 73.1 74.1
Adipose 65.7 66.4 68.4 68.4
CT Solid Water 67.1 68.1 70.1 70.2
Inner bone 72.4 72.4 74.5 74.5
CB2 30% CaCO3 76.3 78.5 79.6 80.7
CB2 50% CaCO3 87.1 90.9 91.0 93.2
Cortical Bone 98.2 103.8 102.7 106.1
Water 69.0 81.8 75.3 75.3
Table 3.1: I-values of elements, tissue substitutes and water, calculated using the different
sources.
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2. Calculate the RSP, for each tissue substitute using any of the formulae de-
scribed in section 3.1.1.1 - equations 3.2, 3.4, 3.6 or 3.7.
3. Plot the points (HU versus RSP) for the tissue-substitute materials and inter-
polate between the points to get a calibration curve.
Many authors have adopted this approach, with different tissue-substitute ma-
terials. Chen et al. [1979] used solutions of: water and potassium phosphate for
bone; ethanol and water mixtures for adipose tissue; and cork for lung. Constanti-
nou et al. [1992] used a commercial phantom with various solid water materials
of known atomic composition to deduce a relationship relating the CT number to
electron density for radiotherapy. Jakel et al. [2001] used solid tissue substitutes to
determine the relationship between CT number and RSP for heavy ion radiotherapy.
Schneider et al. [1996] and Matsufuji et al. [1998] estimated the inaccuracy in
using these tissue-substitutes to be a few percent in effective density, with a strong
dependence on the choice of materials used. The materials are selected as substitutes
for given tissues based on their electron density. However, photon attenuation is not
only caused by Compton scattering, which is proportional to electron density, but
also by photoelectric effect and coherent scattering, which depend on the effective
atomic number.
To address this problem, efforts have recently been made to manufacture tissue-
equivalent materials with greater consideration of their radiological properties and
less consideration of the chemical composition (Yohannes et al. [2012]). It was found
these materials allowed for the production of calibration curves that could match
the stopping powers of ICRU real tissues with a mean difference of 0.8%. The
Radiological Physics Center (RPC) in the United States has also approached the
problem for proton therapy, by measuring the RSP of 18 common tissue substitute
materials using a Bragg peak shift measurement (Grant et al. [2014]). It was found
that only 9 had a difference of less than 5% from the RSP assigned from their
stoichiometric calibration curve, and thus only these 9 are similar to human tissues.
These 9 tissues have been since used in phantoms designed to assess the HU-RSP
calibration curve at proton therapy facilities across the United States.
3.1.1.3 Other methods
The polybinary model, developed by Kanematsu et al. [2003], approximates all
body tissues by their mixtures with respect to muscle, because muscle occupies the
largest content of the body (ICRP [1975]) and is in the middle of the HU curve.
Lung tissues, soft tissues and bones are approximated to mixtures of muscle with
air, fat and bone mineral (40% K2HPO4) respectively. The authors suggest it offers
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the accuracy of the stoichiometric method (accuracy found to be 1.6% by Shinoda
et al. [2006]) and the convenience of the tissue-substitute method.
The accuracy of dual-energy CT (DECT) imaging in determining the RSP of
materials was tested by Yang et al. [2011]. Using a kV-MV pair, it was shown that
the calculation of the RSP was less sensitive to tissue composition variation than
the tissue-substitute method. It is, however, sensitive to CT number variations due
to image noise and other uncertainties in the imaging and image reconstruction
processes. Although still in its infancy, recent works investigating the use of kV-kV
DECT to improve RSP prediction have showed promising results (Bourque et al.
[2014]; Hünemohr et al. [2014]). This may not be the optimal solution however,
as unpublished work by Hansen et al. [2014] shows that proton CT offers an even
better accuracy.
3.1.2 Errors in the calibration curve
There are many potential errors when producing calibration curves, which can be
conveniently divided into uncertainties in the imaging and uncertainties in calculat-
ing the RSP. Summaries of these uncertainties from literature, often with quantita-
tive values, are listed in the following sections.
3.1.2.1 Uncertainty in the measured CT number
The distinctive Bragg peak shape means that proton beam dose calculations are
very sensitive to small changes in the CT number. The uncertainty in the number
from a CT scanner is a well-researched field, with many sources of error summarised
below.
1. Variations in CT numbers, for the same materials, has been shown in different
diagnostic scanners (Faulkner and Moores [1985]; Levi et al. [1982]). X-ray
attenuation depends not only on the electron density but also on the atomic
composition of the material (Kanematsu et al. [2003]; Schaffner and Pedroni
[1998]). As a result, different energy spectra (dependent on the tube voltage
and filter) from different scanners will produce varying HU values. Qi et al.
[2006] found that by changing the scanning voltage from 120 kVp to 140 kVp,
the HU of cortical bone changed by 12.7% (differences were lower for other
materials). Provided the scanning voltage is kept consistent, however, the
X-ray spectrum has been shown to have a smaller effect on the HU than
the chemical compositions of the tissue substitute materials. Cheng et al.
[2012] demonstrated this by separately measuring the HU of the same RMI 467
(Gammex Inc., Middleton, WI) phantom on different scanners, with variations
< 5% for lung substitutes, < 2% for soft tissues and < 1% for boney tissues.
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2. There are known to be CT scanner variations with time. Yang et al. [2012]
measured the same cylindrical inserts during monthly QA measurements and
found variations in the CT number of 1.0% for lung, 0.3% for soft tissue and
0.6% for bone.
3. The CT number of an object is shown to vary with its position in the scan
and the patient size, due to the beam hardening effect (Schaffner and Pedroni
[1998]).
Yang et al. [2012] estimated the effect of the patient size by scanning the
same insert at isocentre inside head and body phantoms (diameter 16 cm and
32 cm respectively). They found relatively large variations in the CT number
of 2.6%/0.3%/1.9% for lung, soft tissue and bone, respectively. A potential
solution to try to compensate for this, used at PSI, is to have different HU-
RSP calibration curves depending on the size of the object being imaged. Dose
distributions are then produced for three different calibration curves (standard,
maximal range error and minimal range error) to get an estimate of the effect
of uncertainty in the proton range (Schaffner and Pedroni [1998]).
Yang et al. [2012] also estimated the effect of the position within the scan by
scanning the same insert at the centre and periphery of a body phantom (32 cm
diameter). They found small variations in the CT number of 1.3%/0.1%/1.0%
for lung/soft tissue/bone.
4. The support table top also has an effect on the HU. CT scanners are typi-
cally calibrated by the manufacturer using phantoms suspended on a support
(essentially in air), but scans are conducted with patients on couches or, for
radiation treatment planning purposes, flat table tops (the latter may enhance
the effect). Qi et al. [2006] showed that this can result in HU changes of 26%
for water (although percentage errors are misleading for water as the HU value
is so close to zero). Yang et al. [2012] scanned the RMI 467 phantom with and
without the couch in the field of view, and found small variations in the CT
number of 1.1%/0.3%/0.5% for lung, soft tissue and bone, respectively.
5. Noise is present in most CT images, and Chvetsov and Paige [2010] investigated
its effect on the range of proton beams. They reported a standard deviation
of the range between 0.3% and 0.7%, assuming a CT grid of 3mm and a 2.5%
noise level.
6. CT artefacts, such as streaking, can be caused by the presence of metallic
implants (Verburg and Seco [2012]).
7. The detector sensitivity and (possibly) reconstruction algorithm can affect the
measured HU value (Kanematsu et al. [2003]).
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3.1.2.2 Uncertainty in calculating the RSP
Potential sources of uncertainty in the calculation of the RSP are listed below.
1. There is uncertainty in the real tissue composition, which is used to find the
theoretical CT values for the stoichiometric calibration method. The ICRU
tables (ICRU [1989], ICRU [1992]), Woodard and White [1986, 1982], White
et al. [1987] and White and Widdowson [1991] are often taken as accepted
compositions, however they contain uncertainties. In Report 44, ICRU [1989]
states explicitly that ‘the elemental compositions of most body tissues are
known to vary considerably between individuals of the same age’ and ‘the
composition of a given tissue within one individual may vary from one body
site to another’.
In their thorough analysis of the uncertainties affecting the RSP of tissues,
Yang et al. [2012] concluded that, for soft tissues, the dominant factor was
the uncertainties induced by tissue composition variation. Neglecting typical
patient-to-patient variations in density (4%), calcium content (2%) or hydro-
gen content (1%) causes inaccuracies in the RSP prediction of 2.2%, 2.0% and
1.3%, respectively (Yang et al. [2010]). This is an important result for our
work as we intend to produce patient-specific HU-RSP calibration curves that
remove the reliance on the average tissue compositions. The production of
patient-specific calibration curves at the time of treatment planning imaging,
first suggested by Schneider et al. [2005], is the subject of our work in chapter
5.
2. In calculating the RSP, the I-values of the element/tissue and water are re-
quired (equation 3.7), which are both difficult to obtain experimentally and
are known to vary between sources.
As detailed in section 3.1.1.1 and table 3.1, elemental I-values differ between
sources such as Bichsel [1972]; ICRU [1993]; Janni [1982]. Andreo [2009] sug-
gests that uncertainties in the I-value for tissues, estimated using Bragg’s ad-
ditivity rule (ICRU [1992]; Seltzer and Berger [1982]), are potentially 10-15%,
which translates to uncertainties in the RSP of 1.4-1.5% (Paganetti [2012];
Yang et al. [2012]).
As explained previously, the stopping power is often quoted relative to water,
so the I-value of water is therefore of critical importance. A range of values
have been suggested for water: 75±3 eV (ICRU [1993]), 77.8 eV (Emfietzoglou
et al. [2009]), 78.4 ± 1.0 eV (Kumazaki et al. [2007]), 80 ± 2 eV (Bichsel and
Hiraoka [1992]), 80.8 eV (Paul et al. [2007]) and 81.8 eV (Janni [1982]); which
can have a large impact on proton treatments. Andreo [2009] demonstrates
70
3. Uncertainties in computing the relative stopping power
that variation of I-values between 67.2 and 80 eV can have a substantial im-
pact on the proton beam range in water; while Paganetti [2012] shows that a
variation between 75 and 80 eV will result in a 0.8-1.2% difference in the pre-
dicted stopping power. Previous works, such as that by Schaffner and Pedroni
[1998], have taken the average of literature data.
As can be seen, there are many sources of uncertainty in the calculation of the
RSP. Yang et al. [2012] combined uncertainty in the real tissue composition and
uncertainty in the I-value to give combined uncertainties (1σ) of 5.0/1.6/2.4% for
lung/soft tissue/bone respectively (these uncertainties also include the uncertainty
from CT imaging). These uncertainties could be significantly reduced if the RSP
is measured directly. A potential method for this is proton radiography, which is
explored in chapters 4 and 5.
3.1.2.3 Other uncertainties
1. All of the methods detailed previously require the imaging of tissue-substitute
materials. There is a large difference between the energies used in the CT
image calibration, which is acquired at low kV, and the treatment, which uses
protons at MeV, and these materials respond differently in these different en-
ergy ranges. It is difficult to produce tissue-equivalent materials that respond
like real tissues over such a wide energy range.
2. A single calibration curve for the whole body is not really applicable, be-
cause there is not a perfect one-to-one correspondence between CT numbers
and RSPs of human tissues (Yang et al. [2012]). The CT number and RSP
describe two different physical properties and, even though both values are
dominated by the relative electron density, the elemental composition also
matters. As such, different organs can have the same HU value but different
RSPs. A possible solution to this is to produce different calibration curves for
different organs in the body. Schneider and Pedroni [1995] demonstrated that
this offered improvements over the stoichiometric method, however it requires
segmentation of each organ on the planning CT by the clinician, which takes
time.
3.2 Aim
As detailed in section 3.1.2, the HU-RSP calibration curve is subject to many un-
certainties. These lead to an error in the calibration curve of between 0.5-1.8%
(dependent on tissue type), which yields itself as a range uncertainty. Currently,
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clinical centres account for this uncertainty with increased planning margins, irra-
diating more tissue than necessary.
In this chapter an investigation is made into the error introduced by making
theoretical estimations of RSP, compared to the ideal scenario of measuring directly
with a proton beam. Most previous works have looked at the errors introduced by
the complete stoichiometric calibration procedure, but this work looks specifically
at the error introduced by step four of the stoichiometric procedure: the theoretical
calculation of the RSP.
3.2.1 Objectives
This work is separated into three components:
1. We look at the error introduced if the RSP is calculated using the separate
formulae of Bichsel, Janni and ICRU, but with their individual I-values. We
make comparisons with the Schneider approximation of the RSP, equation
3.7, but with the I-values of the different sources. We compute these errors
for tissue substitutes, by measuring the RSP directly in a proton beam.
2. Such systematic errors translate into proton range errors within the patient,
which could be critical to the target coverage and thus patient outcome. The
impact of these errors on the proton range is then investigated within the
Gammex phantom and on two patient sites, by implementing different cali-
bration curves within the proton treatment planning software, XiO. We look
only at the most-often used approach, the Schneider approximation. In the
patient cases the I-value of water is calculated: (i) using the elemental I-values
of the different sources; or (ii) set to the most recently recommended value, in
ICRU [2009] Report 73, of 78 eV.
3. Based on the previous set of results, it was possible to define a gold standard
that best matched our measurements. We compare this gold standard to
the conventional Schneider approximation, both with an I-value of 75.3 eV
(calculated using the elemental I-values of ICRU [1993] Report 49) and 78 eV
(the most recently recommended value), for a range of human tissues. In this
way we demonstrate the impact that systematic errors have in step four of the
stoichiometric calibration procedure, the theoretical calculation of the RSP of
human tissues.
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Substitute material ρe
ρ Measured CT number
[gcm−3] [Hounsfield units]
LN-300 Lung 0.276 0.280 -673
LN-450 Lung 0.462 0.470 -489
Adipose 0.926 0.943 -73
CT Solid Water 0.989 1.018 11
CB2 30% CaCO3 1.277 1.332 404
CB2 50% CaCO3 1.470 1.560 761
Cortical Bone 1.695 1.823 1036
Table 3.2: Gammex RMI 467 phantom tissue substitute materials.
3.3 Materials and methods
3.3.1 Computation of the RSP
A selection of the tissue substitute materials of the Gammex RMI 467 phantom
(Gammex Inc., Middleton, WI) were imaged using the standard arrangement sug-
gested by the manual. B200 bone mineral was excluded because it has a significant
proportion of fluorine (16.7%) and none of the human body tissues contain fluorine.
Measured CT values at 140 kVp, together with other information about our partic-
ular batch of tissue substitutes (inserts differ from batch to batch), are shown in
table 3.2.
Using estimates of the chemical composition from Watanabe [1999], the stopping
powers for these tissue inserts were calculated using the different formulae and their
listed mean excitation energies: (i) Bichsel [1972], equation 3.2; (ii) Janni [1982],
equation 3.4; and (iii) ICRU [1993], equation 3.6, with condensed and compound
I-values. The RSP for each tissue was then determined by dividing by the stopping
power of water (calculated using the same source) and taking the average over the
energy range relevant to proton therapy and proton imaging (80-330MeV), as we
intend to investigate the applicability of proton radiography in chapters 4 and 5.
The calibration curves were formed by joining the individual points together. These
calibration curves will be referred to as the ‘Bichsel’, ‘Janni’, ‘ICRU condensed’ and
‘ICRU compound’ calibration curves for the remainder of this chapter. The RSP
of each tissue was also calculated directly, using equation 3.7, but with the I-values
from each of the four sources (Bichsel [1972], Janni [1982], ICRU [1993] (condensed
and compound)). These calibration curves will be referred to collectively as the
‘Schneider calibration curves’ for the remainder of this work. These eight calibration
curves are shown in figure 3.3.
To investigate the systematic error introduced by this process, RSPs were mea-
sured directly using a Bragg peak shift measurement. The Bragg peak from a
pencil proton beam, smaller than the diameter of the Gammex insert, was recorded
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Figure 3.3: Calibration curves with RSP values calculated using the various formulae.
The inserts show zooms of particular regions for clarity (axes the same as main figure).
using the commercial stack of parallel plate ionisation chambers, the Zebra (IBA
Dosimetry, Belgium). The inserts were positioned end-on, so that the protons tra-
versed through the long side of the insert. The shift in the Bragg peak position was
recorded with and without the insert in front of the Zebra. This water equivalent
shift, together with the known length of the insert, allowed for computation of the
insert RSP.
3.3.2 Range errors
To investigate how differences in RSP translate into range errors, double scattering
plans were then made in XiO using single beams treating an octagonal target at the
centre of the Gammex phantom, as shown in figure 3.4. Separate plans were created
with beams at gantry angles 45◦ apart, so that the single beam passes through one
insert in each plan. An octagonal target was chosen so that the target appears
identical from each beam direction. All inserts were in the inner set of holes (so
that the effect of beam hardening was approximately consistent between plans).
Apertures and compensators were created using the measured calibration curve and
kept consistent for the other calibration curves. Apertures were generated with a
small 1mm lateral margin around the target to ensure the beam only passed through
the insert of interest. Compensators were generated to conform to the distal edge
without any range uncertainty margins, with distances between 17.86 g/cm2 (LN-
300 Lung) to 20.38 g/cm2 (Cortical Bone). The dose was computed using a fast
pencil algorithm (Hong et al. [1996]). Dose profiles were determined through the
centre of the beam in each plan for each of the calibration curves and the distal
R80 was assessed (the range at which 50% of the protons are stopped). This value
was used as it is invariant of the initial energy spread of the protons (Berger [1993];
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Figure 3.4: Example plan (in this case through a LN-300 lung insert) to investigate
the impact on the range within the Gammex phantom. Apertures are shown by the blue
rectangles, with (a) the octagonal target shown in yellow. (b) Dose distribution. (c) Dose
profile along the red arrow.
Bortfeld [1997]; Paganetti [2012]).
Two patients were tested to investigate how such range errors would translate in
the patient. We used the same approach as for the tests in the Gammex phantom: (i)
direct a single double scattering beam at the target and compute the apertures and
compensators required to treat to the distal edge, with no range uncertainty margin,
when using the measured calibration curve; (ii) compute the dose profile through the
centre of the beam for this measured calibration curve; (iii) alter the calibration curve
to one of Schneider calibration curves; (iv) recompute the dose; and (v) compute the
new dose profile. For both patients tested, apertures were created with a clinically-
realistic 1 cm lateral margin, but (as with the Gammex plans) compensators were
given no margin to account for range uncertainty. Additionally, no smearing was
applied to the compensators as this would only apply to the measured calibration
curve and we wanted to probe the range effects specifically.
The lung patient plans can be seen in figure 3.5. For this case, two realistic
beam arrangements were chosen: posterior-anterior (PA) and a right lateral (RLat)
beam. In the PA set up the radiological distance to the distal edge was 8.9 g/cm2
(set as our range) and the modulation to cover the tumour was 3.7 g/cm2 (both
for the measured calibration curve). For the RLat beam the range/modulation was
13.2/2.8 g/cm2.
The prostate patient plans can be seen in figure 3.6. For this case, two beam
arrangements were chosen. One plan was based on the typical opposing-pair ar-
rangement, but using just a single left lateral (LLat) beam so that the range ef-
fect through thick boney areas, such as the femoral heads, could be determined (it
would be impossible to investigate the impact on the range for overlapping beams).
In this set up the radiological distance to the distal edge was 21.4 g/cm2 and the
modulation to cover the tumour was 6.7 g/cm2. Another plan was created using a
single anterior-posterior (AP) beam, which has been suggested by Tang et al. [2011]
as an alternative to the opposing lateral beam pair arrangement commonly used
in proton therapy prostate treatments. For this case the range/modulation was
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Figure 3.5: Example dose distributions for the (a) PA and (b) RLat double scattering
plans for the lung case. The target to treat is shown by the red shaded region, apertures
by the blue rectangles and the beam direction by the orange arrows.
Figure 3.6: Example dose distributions for the (a) AP and (b) LLat double scattering
plans for the prostate case. The target to treat is shown by the pink shaded region, the
apertures by the blue rectangles and the beam direction by the black arrows.
11.5/3.6 g/cm2.
3.3.3 Systematic errors in the current stoichiometric calibra-
tion procedure
To quantify the error in step four of the stoichiometric calibration procedure, we
required a gold standard that best matched our measurements. In assessing the im-
pact on the range, it was found that the errors were lowest when using the elemental
Janni I-values, but it was also shown that the I-value of water plays a significant
role (these results can be found later in the report, in section 3.4.2). Given that the
I-value of water is currently disputed (section 3.1.2.2), we varied it between 78 eV
and 82 eV (in steps of 1 eV) to create 5 calibration curves. Plans were created in the
Gammex phantom in the same manner as previously described in section 3.3.2 and
the distal R80 was assessed. It was found that an I-value of 80 eV, together with the
elemental Janni I-values, produced RSP values that best matched our measurements
of tissue inserts. We therefore used this as the gold standard.
As described in detail in the introduction, the final step of the stoichiometric
calibration procedure is the theoretical calculation of the RSP of real tissues. As
discussed, the most convenient (and likely most frequently used in clinical practice)
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formula for performing such calculations is the Schneider approximation (equation
3.7). It is recommended that elemental I-values are taken from ICRU Report 49 and
the tissue I-values should be determined based on theoretical tissue compositions
from literature (ICRU [1993]; White et al. [1987]; Woodard and White [1986]). In
this manner the I-value of water is calculated to be 75.3 eV, (table 3.1), however
in a more recent publication, ICRU [2009] Report 73, a water I-value of 78 eV was
recommended. We therefore calculated the RSPs of 73 human tissues using Bragg’s
additivity rule (ICRU [1992]; Seltzer and Berger [1982]), using the ICRU compound
I-values together with these two water I-values. The accuracy of these estimates was
assessed by comparison with the RSPs of real tissues theoretically calculated using
the gold standard described above.
3.4 Results
3.4.1 Computation of the RSP
The theoretical values of RSP for the tissue substitutes, calculated using the Bichsel,
Janni and ICRU stopping power formulae (equations 3.2, 3.4 and 3.6) and averaged
over the energy range 80-330MeV, are detailed in table 3.3. Using the I-values from
these sources, but with the Schneider approximation for the RSP directly, equation
3.7, gives the theoretical values for RSP as detailed in table 3.4. It can be seen that
for both cases this theoretical calculation of RSP, step four of the stoichiometric
procedure, generally (not including Janni) results in a systematic underestimation
that varies across the CT numbers.
3.4.2 Range errors
A zoom of the fall-offs for the different Bichsel, Janni and ICRU calibration curves,
through the different inserts, can be seen in figure 3.7. The same set of results for
the Schneider calibration curves are shown in figure 3.8. In these two figures the
fall-offs for only three insert plans are shown, but the trend was similar for all other
inserts. The errors of each R80 with respect to the plans created using the measured
calibration curve is shown in figure 3.9.
The fall-offs for the different relative calibration curves, for the four patient
plans, can be seen in figure 3.10. The errors of these values with respect to the
plans created using the measured calibration curve is shown in figure 3.11.
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ICRU [1993]
Material Meas. Bichsel [1972] Janni [1982] Condensed Compound
RSP RSP Err RSP Err RSP Err RSP Err
LN-300 lung 0.280 0.272 -2.97 0.277 -0.96 0.273 -2.36 0.272 -2.73
LN-450 lung 0.475 0.456 -3.99 0.466 -2.00 0.459 -3.39 0.457 -3.75
Adipose 0.949 0.923 -2.73 0.942 -0.72 0.929 -2.14 0.917 -3.33
CT Solid Water 1.009 0.962 -4.67 1.013 0.38 0.999 -1.04 0.989 -1.95
Inner Bone 1.102 1.094 -0.71 1.118 1.49 1.103 0.04 1.101 -0.10
CB2 30% CaCO3 1.270 1.261 -0.69 1.284 1.13 1.268 -0.12 1.278 0.59
CB2 50% CaCO3 1.437 1.426 -0.77 1.449 0.85 1.433 -0.23 1.469 2.25
Cortical Bone 1.623 1.614 -0.55 1.638 0.90 1.623 -0.03 1.690 4.11
RMSE† 2.13 1.05 1.17 2.35
Mean -2.13 0.13 -1.16 -0.61
Max‡ -4.67 -2.00 -3.39 4.11
Table 3.3: RSP for the Gammex tissue substitutes, calculated using the individual source
formulae. The percentage error (‘Err’) with respect to the measurement is listed (may not
match the values in the table precisely because of rounding). †Root-mean-square-error.
‡Maximum error (in either positive or negative direction).
ICRU [1993]
Material Meas. Bichsel [1972] Janni [1982] Condensed Compound
RSP RSP Err RSP Err RSP Err RSP Err
LN-300 lung 0.280 0.275 -1.79 0.281 0.36 0.277 -1.07 0.277 -1.07
LN-450 lung 0.475 0.461 -2.95 0.470 -1.05 0.464 -2.32 0.463 -2.53
Adipose 0.949 0.933 -1.67 0.951 0.21 0.938 -1.16 0.938 -1.16
CT Solid Water 1.009 0.992 -1.68 1.011 0.20 0.997 -1.19 0.997 -1.19
Inner Bone 1.102 1.088 -1.27 1.110 0.73 1.095 -0.64 1.095 -0.64
CB2 30% CaCO3 1.270 1.262 -0.63 1.283 1.02 1.268 -0.16 1.266 -0.32
CB2 50% CaCO3 1.437 1.430 -0.49 1.452 1.04 1.437 0.00 1.433 -0.28
Cortical Bone 1.623 1.625 0.12 1.647 1.48 1.632 0.55 1.626 0.18
RMSE† 1.33 0.76 0.89 0.91
Mean -1.30 0.50 -0.75 -0.87
Max‡ -2.95 1.48 -2.32 -2.53
Table 3.4: RSP for the Gammex tissue substitutes, calculated using the Schneider ap-
proximation for the RSP, equation 3.7, but with the I-values of the different sources. Same
format as table 3.3.
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Figure 3.7: Dose profiles showing the distal fall offs for the Bichsel, Janni, ICRU (con-
densed) and ICRU (compound) calibration curves.
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Figure 3.8: Dose profiles showing the distal fall offs for the Schneider calibration curves.
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Figure 3.9: Errors in the distal R80 of each plan, compared to the measured values, for
all calibration curves. Results are shown in units of [%] (a) and [mm] (b), with mean/max
errors listed in the legend.
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Figure 3.10: Dose profiles showing the different fall offs in the patient cases, for the
Schneider calibration curves.
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Figure 3.11: Errors in the distal R80 of each patient plan, compared to plans created
with the measured calibration curves.
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Figure 3.12: Errors in the distal R80 for the 5 calibration curves with different water
I-values. The mean and standard deviation of errors across the HU range are listed in the
legend.
3.4.3 Systematic errors in the current stoichiometric calibra-
tion procedure
To determine the gold standard that best matched our measurements for tissue
inserts, we used the elemental Janni I-values with 5 different I-values of water to
create 5 calibration curves. The errors in the distal R80 with respect to the measured
values for these 5 calibration curves can be seen in figure 3.12.
From figure 3.12 it was determined that the gold standard was using a water I-
value of 80 eV with the Janni elemental I-values. Figure 3.13 shows the comparison
between the RSPs of real tissues theoretically calculated using the gold standard
and those calculated using ICRU elemental I-values with a water I-value of 75.3 eV
and 78 eV.
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Figure 3.13: Errors in human tissue RSPs, calculated using the Schneider approximation
with the ICRU compound I-values and with two water I-values.
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3.5 Discussion
3.5.1 Computation of the RSP
Different methods of calculating the stopping power result in different RSP values
and, thus, different calibration curves. It can be seen from inspection of tables 3.3
and 3.4 that these differences vary across the CT number range. Comparing to
direct measurements in a proton beam, the largest differences were found in the
LN-450 Lung insert (2-4% underestimation in the RSP). Such errors could have a
big impact on patient outcome, as it has been shown that correct proton beam range
prediction is critical in the lung (Seco et al. [2012]).
By first calculating the stopping power, the theoretical calculation of the RSP,
one of the fundamental steps of the stoichiometric calibration procedure, has a
mean/max error of: -2.1/-4.7% for Bichsel (equation 3.2); +0.1/-2.0% for Janni
(equation 3.4); -1.2/-3.4% for ICRU condensed (equation 3.6); and -0.6/+4.1% for
ICRU compound (equation 3.6). If calculated using the Schneider approximation
(equation 3.7), the mean/max errors are generally smaller: -1.3/-3.0% for Bich-
sel I-values; +0.5/+1.5% for Janni I-values (overestimation); -0.8/-2.3% for ICRU
condensed I-values; and -0.9/-2.5% for ICRU compound I-values.
For both methods, it can be seen that there is a general underestimation of
the RSP (except when using the Janni formulae and its I-values). Of course, a
possible cause of this systematic underestimation could be due to an error in the
measurement procedure, which should not be ruled out. However, what cannot be
denied is that there is a difference between the sources and techniques for computing
the RSP. Currently, ICRU guidelines suggest the use of their values, but we have
shown that use of the Janni formulae or Janni I-values (when computing the RSP
directly using equation 3.7) clearly shows the best match with measurements.
The likely approach for most centres will be to use the Schneider formula (for
convenience), together with one set of the ICRU I-values (given its later publication
date and recommendation for use). However, our results suggest that this results
in underestimations of up to -2.3/-2.5% (condensed/compound). Use of the Bichsel
set of I-values is not recommended, with an even poorer match to measurements,
but the Janni set of I-values proved to be a better match for our measurements.
3.5.2 Range errors - Gammex phantom
The impact on the range was assessed with single-beam double scattering plans on
a Gammex phantom, with the beam passing through the Gammex phantom holder
and the relevant insert. As expected, the errors in the RSP translated into range
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errors. For the majority of cases the RSP was underestimated, which resulted in
a systematic overestimation of the beam range (prescribed ranges between 17.86-
20.38 g/cm2). The mean/max errors were: Bichsel = 2.4/3.7%, 4.3/6.7mm; Janni
= -0.1/1.6%, -0.2/3.0mm; ICRU (condensed) = 0.7/2.3%, 1.3/4.2mm; ICRU (com-
pound) = 1.0/2.7%, 1.8/4.9mm. The mean/max errors for the Schneider calibra-
tion curves were: Bichsel = 1.0/2.5%, 1.8/4.5mm; Janni = -0.1/1.6%, -0.02/2.9mm;
ICRU condensed = 0.7/2.3%, 1.3/4.1mm; ICRU compound = 0.7/2.3%, 1.3/4.1mm.
It can be seen that, as one would expect from the results of the computation of the
RSP, both sets of Bichsel results perform the poorest. Also, as expected, the Janni
set of values matched our measurements best.
In our plans the set up is such that the errors are dominated by the errors in
the RSP of CT Solid Water. The largest geometric distance to the distal edge was
18.5 cm (the target had a curved distal edge), of which only 2.8 cm passed through
the specific insert being investigated. This equates to ≈ 15% of the total geometric
distance or ≈ 4 − 24% of the radiological distance (range between LN-300 and
Cortical Bone). We believe that although there is a bias towards the error in CT
Solid Water, this approach is still suitable because these proportions are similar to
those of water found in an actual patient.
3.5.3 Range errors - patient cases
It can be seen in figure 3.10 that using the water I-value of the source gives similar
results to the Gammex phantom, with mean/max errors across the four plans of:
Bichsel = 1.5/2.1%; Janni = -0.3/-0.4%; ICRU condensed = 1.1/1.6%; ICRU com-
pound = 1.1/1.6%. Altering the I-value of water to the most recently recommended
value of 78 eV resulted in a big reduction of range errors for most cases. The mean
errors were reduced by: Bichsel = 90%; ICRU condensed = 39%; and ICRU com-
pound = 41%. The absolute error for Janni changed from an underestimation to an
overestimation (with a minor increase in the absolute error of 7%). These results
are suggestive that the I-value of water has a very important role in predicting the
RSP of tissues.
3.5.4 Systematic errors in the current stoichiometric calibra-
tion procedure
The first task was to determine the gold standard that best matched our measure-
ments. It was clear from the results of section 3.4.1 that, when using the Schneider
approximation, use of the elemental I-values of Janni had the closest match to our
measured calibration curve. These values, together with the alteration of the water
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I-value from 81.8 eV to 80 eV, enabled a very good match to our measurements, with
a mean error ± standard deviation of −0.02± 0.11%. Thus our gold standard for-
mulation involved: using the Schneider approximation for the RSP (equation 3.7);
elemental Janni I-values; and a water I-value of 80 eV.
Using this gold standard the RSP values of 73 human tissues were theoretically
computed. The same values were computed twice more using the ICRU compound
I-values, once with a water I-value of 75.3 eV and another with a water I-value of
78 eV. The mean error (± standard deviation) between these and the gold standard
was found to be 2.20± 0.38% and 0.04± 0.37% for the 75.3 eV and 78 eV calibration
curves, respectively. It is clear that the most recently recommended ICRU water
I-value of 78 eV is better than the previous value, although there are still differences
of up to 0.8% from our gold standard (the gold standard itself has an uncertainty
of up to 0.1%). These differences are tissue dependent, with underestimations for
fatty and boney tissues and overestimations for soft tissues.
3.5.5 How to correct the stoichiometric calibration
In the previous sections it can be seen that systematic errors can be introduced
by the theoretical RSP calculation of human tissues. However, it is possible to
significantly reduce these errors by applying a correction when calculating the RSP
of any tissues that form the calibration curve. This requires an additional step in
the stoichiometric calibration procedure, between current steps 3 and 4, in which
the user conducts measurements to determine the RSP values of the tissue inserts
imaged in step 1. A comparison of the theoretical RSP values (calculated by the
method of the user’s choosing) and the measured RSP values will allow for the
systematic scaling and/or offset to be determined. This scaling/offset would then
be applied to the theoretically-calculated values for human tissues, step 4 of the
stoichiometric calibration procedure.
3.6 Conclusions
There are four clear methods for calculating the RSP of a given tissue. Three involve
the computation of the absolute stopping power of the tissue, which must then be
divided by the absolute stopping power of water over the same energy range (Bichsel
[1972], Janni [1982] and ICRU [1993]). To account for the different formulae and
corrections, each source has its own set of I-values (ICRU has two, for condensed and
compound materials). Comparing the RSPs of Gammex inserts determined using a
simple Bragg peak shift measurement in a proton beam, it was found that all of these
techniques, with the exception of the Janni formulae, result in a mean systematic
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underestimation of the RSP: Bichsel = -2.1%; Janni = +0.1%; ICRU (condensed) =
-1.2%; ICRU (compound) = -0.6%. The fourth method is an approximation in which
the RSP is computed directly (Schneider et al. [1996]), using any set of I-values. The
errors for this approach followed almost the same pattern but were generally lower in
magnitude. For our set of measurements, the Janni I-values showed the best match.
We showed that these RSP errors translate into proton beam range errors of
similar magnitudes, for plans within a Gammex phantom and in two patient cases
(lung and a prostate, each with two different beam directions). Mean range errors
across the four patient plans, for RSPs calculated using the fourth method only,
unsurprisingly followed the trend of the errors in the RSP computation.
Using the Schneider approximation, Janni elemental I-values and a water I-value
of 80 eV we produced a gold standard method that could match our measured RSP
values to within 0.02 ± 0.11% (mean ± standard deviation). We used this gold
standard to compute the RSPs of real tissues, and compared them with sets of
values computed using the ICRU elemental I-values together water values of either
75.3 eV or 78 eV. The latter matched to within 0.04 ± 0.37% (mean ± standard
deviation), confirming that a value of 78 eV should be used for the water I-value.
It is proposed that an additional step should be added to the current stoichio-
metric calibration procedure that involves actual measurement of the tissue insert
RSP in a proton beam. Any scaling/offsets required to match the theoretical cal-
culation of the tissue insert RSP to the measured RSP should then be also applied
to step 4 of the current stoichiometric procedure, the theoretical calculation of the
RSP of human tissues.
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Chapter 4
Dose ratio proton radiography
Work in this chapter can be found in the following journal article:
• (Under review) Doolan P, Royle G, Gibson A, Lu H-M Bentefour E H 2014
Dose ratio proton radiography using two pristine Bragg peaks Medical Physics
Practical measurements were made at MGH with E-H Bentefour and H-M Lu. The
complete theoretical basis and all analysis was conducted by myself.
4.1 Background
Proton radiography, first proposed by Cormack [1963], is based on measuring the
position and energy loss of protons after passing through a medium. This informa-
tion is then utilised to estimate the integral energy loss along the trajectory, which
is converted into a material WET.
Proton radiography offers the potential for higher tissue-to-tissue contrast and
better density resolution than X-ray imaging because of the sharpness of the Bragg
peak near the end of the proton range (Schulte et al. [2005]; Seco and Depauw
[2011]). The shape of the proton depth dose curve also enables the use of less dose
(Schneider et al. [2004]; Schulte et al. [2005]). One of the major advantages of proton
radiography is the potential to generate RSP maps of the patient directly, rather
than the current process of converting the patient’s X-ray CT dataset using a cali-
bration curve (Hurley et al. [2012]). As explained previously, this process is thought
to contribute between 0.5-1.8% to the proton beam range uncertainty, depending on
whether the uncertainties in the material I-values are considered (Paganetti [2012];
Schaffner and Pedroni [1998]). In addition to reducing the proton beam range un-
certainty in proton treatment planning, proton radiography has a number of other
potential applications, including: convenient patient set-up (Depauw et al. [2014]);
passive range verification (Schneider et al. [2005]); and active range verification
(Testa et al. [2013]).
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4.1.1 Classical proton radiography
One of the major disadvantages of proton radiography is due to the fact that protons
undergo MCS in the patient, which limits the spatial resolution compared to X-ray
imaging (Schneider et al. [2012]). This physical process has driven the classical
approach to proton radiography, in which attempts are made to correct for MCS by
tracking protons before and after the patient and by measuring the residual proton
energy at the patient exit. The proton trajectory and the energy loss across that
path can then be estimated. To keep the patient dose to a minimum this technique
requires the tracking of every proton, which places high demands on the speed of
device (typical proton dose rates are on the order of 109 protons per second). A
range of designs have been used for this high speed proton tracking: scintillators
(Pemler et al. [1999]; Schneider et al. [2004]; Shinoda et al. [2006]); semiconductors
(Poludniowski et al. [2014]; Schulte et al. [2004]; Sipala et al. [2011]; Talamonti
et al. [2010]); plasma panels (Ball et al. [2014]; Friedman et al. [2012]); nuclear
emulsion films (Braccini et al. [2010]); and gas-based devices (Hollebeek et al. [2012];
Watts et al. [2009]). The energy measurement is either performed directly, using
a calorimeter, or inferred from the proton range, in a range telescope design. A
variety of direct methods have been investigated: magnetic spectrometry (Akisada
et al. [1983]); NaI calorimeters (Schneider and Pedroni [1995]); CsI calorimeters
(Talamonti et al. [2010]), (Heimann [2005]; Petterson et al. [2006]; Talamonti et al.
[2010]); and scintillating crystals (Shinoda et al. [2006]; Vanzi et al. [2013]). Range
telescope designs have included: stacks of scintillators (Bashkirov et al. [2007]; Watts
et al. [2009]); and multi-layer ionisation chambers (Rinaldi et al. [2013, 2014]).
4.1.2 Single-detector proton radiography
Despite the promises and the extent of research on the topic, proton radiography has
not been routinely introduced into the clinical environment. The classical devices are
generally complex, they can often be bulky and the projected cost is high. As such,
there has been a recent movement towards using only a single detector positioned
beyond the patient. Individual proton paths cannot be reconstructed, but maybe
they can be approximated sufficiently well that the proton radiograph is still useful.
A variety of technologies have been explored, including: fluorescent screens coupled
to CCD cameras (Bentefour et al. [2013]; Muraishi et al. [2009]; Ryu et al. [2008]);
commercial flat-panel detectors (Telsemeyer [2012]); and complementary metal oxide
seminconductor active pixel pensors (CMOS APS) (Gelover-Reyes et al. [2011b];
Poludniowski et al. [2014]; Seco and Depauw [2011]).
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Figure 4.1: Dose ratio method steps to produce the dose ratio image. (a) Measure depth
dose curves in water for two pristine Bragg peaks. (b) Determine the dose ratio curve.
(c-d) Record the dose map beyond an object for each of the two energies. (e) Form a dose
ratio map by dividing (c) by (d). Finally, convert the dose ratio map to a WET map (f)
using the dose ratio curve.
4.1.3 Dose measurement for proton radiography
The measurement of dose offers a simple approach to proton radiography. A range of
such techniques have been tested. The use of pairs of sloped spread-out Bragg peaks
(SOBPs) was suggested by Lu [2008a]; Lu et al. [2010]. Another technique involves
measuring the time-resolved dose from a proton beam passively scattered by a range
modulator wheel (Gottschalk et al. [2011]; Lu [2008b]; Testa et al. [2013]), which
is discussed in much greater detail in section 5.1.2 as it was the technique used to
generate patient-specific calibration curves for proton treatment planning. Another
technique, suggested by Bentefour et al. [2012b], involves the measurement of the
ratio of doses of two pristine Bragg peaks, which is the subject of this work. The
technique works as follows: (1) measure depth dose curves in water for two pristine
Bragg peaks; (2) determine the ‘dose ratio curve’ for the energy pair by dividing
the lower energy by the higher energy; (3) record the dose map beyond an object
of unknown thickness/material for each of the two energies and calculate the dose
ratio map; and (4) convert the map to one of water-equivalent thicknesses (WETs)
using the dose ratio curve. This approach, known as the dose ratio method, is shown
schematically in figure 4.1.
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This method has a number of advantages. It requires the use of a single imaging
detector, which is more convenient and more likely to fit into the clinical environment
than the conventional trackers and energy measurement set up. Also, by taking the
dose ratio, the detector does not need to be able to measure absolute dose, rather it
must demonstrate high reproducibility. The technique also has the potential to be
applied to PBS treatments, as it uses pristine Bragg peaks rather than the spread-
out Bragg peaks used in passive scattering.
4.1.4 Aim
It was previously shown by Bentefour et al. [2012b] that this technique can achieve
millimetre accuracy in determining the WET, using the distal edge of the lower
energy Bragg peak. However, in this approach the dynamic range is limited by the
steep fall-off and the approximate material WET must be known to a high accuracy
to appropriately select the energy pair. Although on the proximal side of the Bragg
peak the fall-off is only from 100% to ≈ 30% (compared to the distal fall-off from
100% to 0%), the fall-off is much less steep, leading to a potentially much larger
dynamic range. It has not yet been explored how much of the proximal side of the
Bragg peak can be reliably used and for which patient treatment sites this imaging
technique could be applied. In this study we aim to do the following:
1. Investigate the theoretical limits of the dose ratio method for the proximal side
of the Bragg peak. We determine the dynamic range for different energy pairs,
different required accuracies in the WET and for a range of uncertainties in
the dose ratio map. Comparisons are made with use of the distal side of the
Bragg peak.
2. Determine the applicability of this technique. We follow the same theoretical
analysis as in step 1, for the energy pair most appropriate to the particular
clinical site, and then determine the area that can be imaged under different
sets of clinical requirements and proton imager performances.
3. Validate the theoretical predictions with real measurements using a CMOS
APS. After measuring the noise in the CMOS APS, we generate theoretical
limits and verify that the accuracy in imaging a sapphire sphere matches these
predictions.
91
4. Dose ratio proton radiography
4.2 Materials and methods
4.2.1 Theoretical limits
The dose ratio method relies on the measurement of pristine Bragg peaks in wa-
ter. To assess the theoretical limits of the technique, independent of the detector
used, pristine Bragg peaks of different energies were modelled using the analytical
approximation that considers both range straggling and an initial spread of beam
energies (Bortfeld [1997]). The range R0 was approximated by the range-energy
relation R0 = αEp, for a proton beam with initial energy E, where the constants
α = 0.0022 and p = 1.77 are for a proton beam in water (Bortfeld [1997]). The
width of the Gaussian energy spectrum was set to σE = 0.01E. Taking the ratio of
normalised depth doses curves of two energies, a theoretical dose ratio curve can be
generated.
Our approach to determining the theoretical limits, shown schematically in figure
4.2, is based on introducing uncertainties in dose ratio measurement and inspecting
the change in theWET estimate from the theoretical dose ratio curve (in figure 4.2(a)
the original dose ratio value is shown in green and the upper/lower uncertainties are
shown in blue/red). Then, very simply, right/left horizontal error bars are added to
the dose ratio curve for that particular dose ratio value (shown as blue/red arrows in
figure 4.2(b)). For a given uncertainty introduced, we used the spread in the proton
WET values to define the maximum achievable accuracy of the WET measurement
(figures 4.2(c) and 4.2(d)). If the user requires a very high accuracy in the WET (i.e.
the horizontal error bars cannot be too large), then the amount of the proximal side
of the Bragg peak that can be used for imaging is small. Conversely, if the accuracy
required in the WET is relaxed (i.e. the horizontal error bars can be bigger), more
of the proximal side of the Bragg peak can be reliably used for imaging. Dependent
on the accuracy required in the WET, the amount of the proximal side of the Bragg
peak that can be used for imaging (henceforth referred to as ‘proximal dynamic
range’) will vary.
In this analysis, the impact of an uncertainty in the dose ratio map of 1 to 10%
(in steps of 1%) is investigated. Uncertainties in the individual energy images will
combine in quadrature in the dose ratio map, with typical values of standard de-
viation (σ) in the dose ratio map found to be 1-3% in our measurements. In real
measurements, uncertainties will arise in the raw measured images from both statis-
tical uncertainties (dependent on the number of protons) and detector uncertainties
(such as quantum noise, shot noise, read noise, fixed pattern noise, etc.). To remove
the effect of statistical uncertainties, which would otherwise vary across the Bragg
peak, the error in the dose ratio was divided by the normalised dose at each depth.
92
4. Dose ratio proton radiography
Figure 4.2: Method of determining the proximal dynamic range. (a) Uncertainties in the
dose ratio translate into uncertainties in the WET (depth). (b) These are added to the
dose ratio curve as horizontal error bars. (c) The error bar magnitude defines the accuracy
in the WET. (d) Dependent on the required accuracy, the proximal dynamic range can be
determined.
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Figure 4.3: Normalised theoretical dose ratio curves (all paired with 230 MeV).
Setting Values used
Energy (low) 100-220MeV (in steps of 10MeV)
Energy (high) 230MeV (fixed)
Uncertainty in the dose ratio map 1-10% (in steps of 1%)
Required accuracy in WET 1-5mm (in steps of 1mm)
Table 4.1: Settings used in the theoretical analysis.
It is desirable to set the higher energy to always be the highest deliverable by
the machine, so that a flat proximal dose contributes to the dose ratio. Most pro-
ton machines have a maximum deliverable energy of 230MeV, so in this analysis
dose ratio curves were formed using pairs where the maximum energy was fixed
at 230MeV. The lower energy was varied between 100 and 220MeV, in steps of
10MeV, producing 13 theoretical dose ratio curves, as shown in figure 4.3. For all
these settings, summarised in table 4.1, proximal dynamic ranges were calculated
for required accuracies of 1 to 5mm. For comparison, the analysis was also repeated
on the distal edge of the Bragg peak and distal dynamic ranges were calculated.
Most proton centres currently add a margin of between 2.5-3.5% of the proton
range to account for range uncertainty (Paganetti [2012]), so a radiography technique
that could predict the range to a higher accuracy than this would be an improvement
on current practice. For a typical therapeutic proton beam with a range of 20 cm,
accuracies we are investigating (1-5mm) correspond to range uncertainties of 0.5-
2.5%, which would offer an improvement in current proton beam range predictions.
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4.2.2 Application to patient sites
The results of the theoretical analysis (of section 4.2.1) are two curves for each energy
pair, in which the proximal dynamic range is calculated for a given required WET
accuracy and for a given percentage error in the dose ratio. Using these curves, it
is possible to illustrate the application of the technique for different patient sites.
For any patient site there will be a range of WETs. Due to the shape of the proton
dose ratio curve (figure 4.3), the energy pair must be carefully selected so that the
lower energy exits the patient and an image can be recorded. This lower energy must
therefore have a range higher than that of the thickest WET in the patient site. Once
the appropriate energy pair has been selected, the proximal dynamic range can be
retrieved from the analysis of section 4.2.1, for different required accuracies in the
WET and for different noise levels in the dose ratio image. The steps for determining
the region that can be imaged is as follows:
1. Convert the X-ray CT dataset of each patient to RSPs using a calibration
curve. For this we used the tissue-substitute calibration curve used clinically
at MGH, which is formed of two straight lines (one with a gradient of 0.001
between HU=-1000 and 40, and one with a gradient of 0.0005 from HU=40 to
2995) and a correction above HU=2996 to account for titanium.
2. Parallel line ray tracing is then conducted through the volume using the open-
source software, Plastimatch (plastimatch.org).
3. Compute the digitally reconstructed radiograph WET (DRRWET) by summing
up the RSPs along the ray traces through the patient.
4. Calculate the maximum WET through the patient and convert to a minimum
energy to the distal edge using the range-energy relation (we rounded these
up to the nearest 10MeV).
5. Using the theoretical results for the specific energy pair (analysis of section
4.2.1), determine the WETs in the patient site that lie within the proximal
dynamic range.
All DRRWETs were produced with parallel ray tracing and with a pixel size of
1mm, as shown in figure 4.4. The cropped field sizes are: prostate, 61 × 101mm =
6161mm2; lung, white cropped field, 41 × 46mm = 1886mm2; lung, green cropped
field, 34 × 35mm = 1190mm2. Details of the maximum WET in the image, the
corresponding range and the lower energy selected are provided in table 4.2.
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Figure 4.4: DRRWETs of the different patient sites to be analysed: paediatric brain in (a)
LR and (b) AP directions; adult brain in (c) AP and (d) LR directions; (e) full prostate
field-of-view and (f) cropped region to analyse; (g) full lung field-of-view, with (h) white
and (i) green cropped regions of interest.
Case Field Maximum Minimum energy Minimum energy rounded
WET [cm] to distal edge [MeV] up to nearest 10MeV
Pead. brain AP 19.2 168.2 170
LR 16.8 156.1 160
Adult brain AP 22.0 181.9 190
LR 19.2 168.5 170
Prostate AP 24.2 191.9 200
Lung APw 17.2 158.5 160
APg 14.1 141.2 150
Table 4.2: Clinical sites investigated for applicability of dose ratio proton radiography.
Abbreviations: AP = anterior-posterior; LR = left-right; the cropped fields for the lung,
APw and APg are the white and green ROIs for the lung patient from figure 4.4.
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Figure 4.5: (Left) Experimental set up for depth dose measurements. (Right) Schematic
and photograph of experimental set up for dose ratio measurements.
4.2.3 Experimental demonstration in a single-detector CMOS
APS
The purpose of the experimental measurements was twofold: (1) to demonstrate that
it is possible to acquire accurate images using the dose ratio proton radiographic
method with a single CMOS APS; and (2) to show that the uncertainties in these
measurements follow the theoretical predictions.
4.2.3.1 Experimental details
Measurements were made at the Francis H. Burr Proton Therapy Facility, MGH. To
ensure the spot size was sufficiently large (to cover the whole sensor) the beam was
used in single scattering mode. Depth dose curves for the two energies, with ranges
(R90) of 17.7 and 22.5 cm, were acquired using a Markus chamber on a stepper motor
in a water tank, together with a reference entrance chamber. This arrangement is
shown in figure 4.5.
Dose ratio measurements were made using a CMOS APS, ‘Vanilla’. CMOS APSs
have shown promise in imaging for proton radiography (Poludniowski et al. [2014];
Seco and Depauw [2011]), with advantages such as low manufacturing costs, efficient
charge collection, high speed imaging, high spatial resolution and region of interest
(ROI) addressability. Full details of Vanilla and an assessment of its performance can
be found in literature (Bohndiek et al. [2007]), but for our application the important
features are: a sensitive area of 13mm × 13mm, comprised of an array of 520 × 520
pixels, each of 25µm pitch; and repetition rates between 1-1000 frames per second
(fps) (dependent on the ROI addressed). In our measurements we imaged the full
sensitive area at a frame rate of 44 fps.
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4.2.3.2 Dose ratio measurements with a sapphire sphere
Due to our small sensor size we were limited in the test objects that could be used.
A small red sapphire (Al2O3, doped with Chromium, Cr2O3) sphere with diameter
6.35mm was imaged. As detailed in sections 4.2.1 and 4.2.2, there is a limited
dynamic range using the dose ratio radiographic method, so to ensure we used the
sensitive part of the Bragg peak we needed to place solid water slabs between the
object and Vanilla, as shown in figure 4.5. The level of Cr2O3 doping was unknown
for our sample so a percentage weight of 0.05% was assumed, in accordance with
typical literature values for such synthetically-grown crystals (Basun et al. [2007];
Ganschow et al. [2011]). For such a composition, the effective atomic number Zeff
was calculated to be 11.40 (Boone and Chavez [1997]) and the relative electron
density ρe was calculated to be 3.51 (Berger and Zucker [2004]). The RSP was
estimated using the approximation of Schneider et al. [1996], equation 3.7, defined
previously. The sapphire RSP was found to be 3.44, giving a maximum sphere WET
of 21.8mm (sphere diameter, 6.35mm, multiplied by RSP, 3.44). As we wanted to
demonstrate the use of the proximal side of the Bragg peak only, solid water was
added before the phantom with a thickness of 14.27 cm WET. The total thickness
(solid water + sphere diameter) was therefore then close to, but still on the proximal
side of, the Bragg peak of the lower energy beam (17.7 cm).
4.2.3.3 Detector sensitivity calibration
The CMOS sensor is an optical sensor, not designed for the direct detection of
charged particles, and as such, it is not radiation hard. Decreases in detector sen-
sitivity have been observed with increasing dose in other CMOS sensors (Esposito
et al. [2012, 2014]; Meroli et al. [2013]), and the effect was also evident in our detec-
tor. The grayscale of the output image of Vanilla is usually distributed over 4096
digital numbers, but this dynamic range decreases as the sensitivity decreases. As
our detector could not be triggered to acquire when the beam switches on, however,
the dose to the detector was not carefully controlled and it was impossible to apply
a sensitivity correction. To resolve this problem the detector was calibrated before
each acquisition, using a minimal dose (10 frames only) through a known material
thickness.
4.2.3.4 Image processing
After averaging over 190 frames, images were processed in the same manner as the
dose ratio curve was produced: (1) normalise the grayscale images for each energy;
and (2) divide the lower energy by the higher energy to form a dose ratio image.
Before converting the dose ratio image to a WET map we applied two corrections.
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Figure 4.6: Fixed pattern noise removal. (a) Raw dose ratio image. The vertical stripes
are caused by fixed pattern noise. (b) Fourier transform of the dose ratio image, before
correction, and (c) after applying the interpolation notch reject filter. (d) Corrected, dose
ratio image. In all figures the x- and y-axes are pixel numbers.
The first correction was to remove the fixed pattern noise, induced by the manner
of the read out of the CMOS sensor. If the flux had been identical for the two
energies, the fixed pattern noise would have been identical (Stewart [2013]) and the
ratio of the images would have led to it cancelling out. As this was not the case,
we needed to use an interpolation notch-reject filter to the affected region on the
Fourier transform of the image (Konstantinidis et al. [2010]); the process of which
is shown in figure 4.6. In the second correction a 3 × 3 median filter was passed
over the image to remove the salt and pepper noise and the outer 20 pixels (in every
direction) were cropped to remove discrepancies at the detector edge. The dose ratio
image was then converted to WET using the measured dose ratio curve and finally
the image was rebinned into 0.1mm pixels.
4.3 Results
4.3.1 Theoretical limits
After following the steps in section 4.2.2, the user has the correct energy pair for the
site to be imaged. An example dose ratio curve (with a lower energy of 170MeV),
with right and left error bars for 1% and 3% uncertainties in the dose ratio, are
shown in figure 4.7. Plotting these error bars across the Bragg peak (also shown in
figure 4.7) allows for calculation of the proximal dynamic range.
The proximal dynamic range is a function of the lower energy selected, the
noise in the dose ratio map and the required accuracy in the WET. The theoretical
relationship between all of these factors is shown in figure 4.8. It should be noted
that, for some energy pairs, if the noise level is too high and the required accuracy
in the WET is too strict, no part of the Bragg peak can be used for imaging (thus
the lines in figure 4.8 are shortened).
For comparison the analysis was repeated on the distal side of the Bragg peak
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Figure 4.7: (a) Dose ratio curve for the 170/230MeV energy pair, with horizontal error
bars indicating the change in WET for a 1% uncertainty in the dose ratio. (b) Magnitude
of error bars plotted as a function of the depth, with different accuracies indicated. (c)
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Figure 4.8: Proximal dynamic ranges for required accuracies in the WET of (a) 1mm,
(b) 2mm, (c) 3mm, (d) 4mm and (e) 5mm.
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Figure 4.9: Comparison of proximal and distal dynamic ranges for required accuracies
in the WET of (a) 2mm, (b) 3mm, (c) 4mm and (d) 5mm.
and distal dynamic ranges were calculated. These results, together with those on
the proximal side of the Bragg peak, are shown in figure 4.9. Unlike the proximal
side, the distal dynamic ranges are almost independent of the required accuracy in
the WET.
4.3.2 Application to patient sites
The areas that can be imaged for the AP paediatric brain are shown in figure 4.10
as black regions superimposed on the original DRRWET, for different noise levels in
the dose ratio and for different required accuracies in the WET. Similar analyses
were conducted for all the patient sites tested.
For noise levels 1-3% and for WET accuracies of 1-3mm, the theoretically max-
imum size of the area that can be imaged for each of the clinical sites is detailed
in table 3. For the lung and prostate cases, the region being analysed is already a
cropped version of the full DRRWET, so results are displayed in terms of percentages
(of the cropped region size). Areas greater than an equivalent 50mm × 50mm field,
or covering more than 75% of the cropped region, are shown in bold and underlined
typefaces. These cases, considered to be clinically useful, are shown in figure 4.11
(the cropped regions are excluded from this figure).
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Figure 4.10: Areas that can be imaged (shown by dark region superimposed on brain)
for an AP paediatric brain using dose ratio proton radiography.
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Case Field Accuracy in Area Area Area
WET [mm] 1% Noise 2% Noise 3% Noise
Paed. brain AP 1 339 mm2 820 mm2 2016 mm2
2 4011 mm2 2060 mm2 1319 mm2
3 5904 mm2 3083 mm2 2122 mm2
LR 1 66 mm2 4 mm2 3 mm2
2 2305 mm2 71 mm2 9 mm2
3 5355 mm2 614 mm2 73 mm2
Adult brain AP 1 3 mm2 3 mm2 —
2 116 mm2 — —
3 1401 mm2 13 mm2 —
LR 1 336 mm2 63 mm2 22 mm2
2 1683 mm2 370 mm2 134 mm2
3 4535 mm2 1071 mm2 396 mm2
Prostate AP 1 — — —
2 3.4% — —
3 44.2% 1.1% 0.1%
Lung APw 5.5% 1.7% 0.9%
2 29.6% 5.5% 2.7%
3 78.8% 14.5% 5.5%
APg 1 0.2% — —
2 18.2% 0.2% —
3 77.6% 2.9% —
Table 4.3: Magnitude of areas, for a variety of clinical sites, that can be imaged using
dose ratio proton radiography. Areas greater than an equivalent 50mm × 50mm field, or
covering more than 75% of the cropped region, are shown in bold and underlined typefaces.
Abbreviations: AP = anterior-posterior; LR = left-right; Small fields, APw and APw, are
shown in figure 4.4.
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Figure 4.12: (a) Measured dose ratio curve. (b) Theoretical and (c) measured WET maps
for the sapphire sphere. (d) Difference (measured-theoretical) WET map. (e) Difference
histogram within the sphere radius. (f) Theoretical and measured radial profiles of the
0.1mm pixel WET maps. The x-axis is the distance from the sphere centre.
4.3.3 Experimental demonstration in a single-detector CMOS
APS
4.3.3.1 Accuracy and suitability of CMOS APS
The measured dose ratio curve is shown in figure 4.12(a). The theoretical and
measured WET maps are shown in figures 4.12(b) and 4.12(c), respectively. The
difference between the theoretical and measured WET maps for the sapphire sphere
is shown in figure 4.12(d). The max/min/mean errors were found to be 1.23/-1.10/-
0.05 cm. The RMSE and standard deviation were found to be 0.16 cm and 0.20 cm,
respectively. In figure 4.12(f), the measured WET values as a function of distance
from the centre of the sphere were determined.
4.3.4 Validation of theoretical predictions
The calibration dose ratio image (acquired using a single solid water thickness,
with no sphere), after rebinning into 0.1mm pixels, was found to have a standard
deviation, σ = 1.2%. It can be seen in figure 4.12(e) that the error in the WET
follows an approximately Gaussian shape. If we set the uncertainty in the dose
ratio to be 1.96σ, or 2.35%, we would expect 95% of our results to fall within the
confidence intervals of our theoretical predictions. To test this, we determined the
theoretical limits using the same procedure as in section 4.2.1, for the two energies
used in the measurements (160.8 and 184.2MeV). As a reminder, these steps were:
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Figure 4.13: Theoretical limits (red and blue lines) for a 2.35% (1.96σ) noise in the dose
ratio, for the energies used in measurements. The measured data of each 0.1mm pixel are
shown by the black dots. Given the measured data follows an approximately Gaussian
distribution, we would expect 95% of the pixels to fall below the theoretical limits.
(1) determine the spread in WET values for a given change in the dose ratio (here
2.35%); and (2) add right and left horizontal error bars to the dose ratio curve for
that particular dose ratio value. The theoretical error bars for a change of the dose
ratio of 2.35%, together with the absolute measured WET errors, are shown in figure
4.13. The experimental measurements fall below the theoretical right/left horizontal
error bars in 89.1/93.9% of cases, respectively.
4.4 Discussion
4.4.1 Theoretical limits
Using the analytical approximation for the Bragg peak, we were able to define
theoretical limits for the dose ratio method on the proximal side of the Bragg peak.
Horizontal right and left error bars were added to theoretical dose ratio curves and
used to determine the proximal dynamic range for varying energy pairs and different
levels of noise in the dose ratio map. A requirement from the user is knowledge of
the expected uncertainty in their dose ratio map (defined in our study to be dose
independent), which is a quadratic sum of the uncertainties in the images from each
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energy. For a given required WET accuracy, the user can then look up the proximal
dynamic range for their energy pair (figure 4.8) and set up their measurement so
that the object/region to be imaged has the correct total WET. Provided the object
has a WET falling within this proximal dynamic range, as defined in figure 4.2, the
accuracy remains within the required level.
It was found that the maximum proximal dynamic range for a given noise level
was not obtained by the largest separation between the energy pair; rather there
is an optimum value (typically ≈ 190MeV). The reason for this can be explained
with reference to figure 4.3. Although the proximal value of the dose ratio decreases
with a greater separation in energies, at lower energies there is less range straggling
and so the Bragg peak is narrower, shortening the proximal dynamic range. The
optimum value arises because, although it is beneficial to have a lower value for the
dose ratio in the plateau region, some Bragg peak broadening is also desirable.
For comparison, the analysis was repeated on the distal side of the Bragg peak
and distal dynamic ranges were calculated. Across all settings, the largest distal
dynamic range was 2.42 cm (lower energy of 220MeV, 5mm required accuracy in
the WET and 1% noise level). Comparatively, with the same required accuracy and
noise level, a proximal dynamic range of 5.31 cm could be utilised. It can be seen
from figure 4.9 that the use of the proximal side of the Bragg peak allows for the
use of a larger dynamic range, but only for low noise levels (1-2%). When the noise
levels become too high, the use of the distal side of the Bragg peak becomes more
reliable and larger dynamic ranges can generally be utilised.
4.4.2 Application to patient sites
As mentioned in section 4.2.1, most proton centres currently employ a margin of
between 2.5-3.5% of the proton range to account for range uncertainty (Paganetti
[2012]). Therefore, proton radiography would offer an improvement on current clin-
ical practice if it could predict the proton range with an error of less than 2.5%, or
5mm for a 20 cm range proton beam. Given the investment (both time and money)
required to start using proton radiography routinely, the technique should offer a
significant improvement on current clinical practice. We consider that a 1% accu-
racy, or 2mm of a 20 cm range beam, would be a sufficiently high improvement to
enable its introduction.
For such an accuracy, for a noise level in the dose ratio map of 1%, dose ratio
radiography on the proximal side of Bragg peak has a proximal dynamic range of
up to 2.91 cm (dependent on the lower energy). This is quite a small range and
it was found the technique can only feasibly be applied to a specific set of patient
sites and within each site only a specific region can be imaged. The following sites
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were tested for feasibility: brain (paediatric and adult, AP and LR); prostate (AP
only); and two small regions in the lung (AP only). The brain cases (in particular
the paediatric brain) demonstrated the best possible application of the technique.
Provided the noise in the dose ratio map is no more than 1%, equivalent square field
sizes in the paediatric brain of 6.3/7.6 cm2 could be imaged under required accuracies
of 2/3mm, respectively. It should be commented, however, that the shapes of these
areas were not always connected (figure 4.11).
Although not explored in this work, it would be possible to increase the region
that can be imaged by using additional energy pairs, although this has the drawback
of increasing the patient dose. Another possibility is the use of a proton beam with
a higher maximum energy. All of our analysis was based on using a fixed higher
energy of 230MeV, but some proton systems can generate energies up to 330MeV.
This would reduce the contribution of the higher beam to the dose ratio, which may
allow for a larger dynamic range for imaging.
One disadvantage of the technique is the requirement of prior knowledge of the
approximate WET of the patient site, so that the appropriate energy pair for imaging
can be selected. The suggested approach for this is to convert the patient X-ray CT
dataset into a dataset of RSPs, and generate a DRRWET that can then be used as
an indication to select the best energy pair.
4.4.3 Experimental demonstration in a single-detector CMOS
APS
Our experimental work demonstrated the use of the dose ratio method on the prox-
imal side of the Bragg peak. We imaged a small sapphire sphere in a high energy
proton beam line using a small (13mm × 13mm) CMOS APS sensor. Using two
Bragg peaks, of 160.8 and 184.2MeV, a dose ratio curve was formed and, after some
image processing, a WET map was generated.
4.4.3.1 Accuracy and suitability of CMOS APS
After determining the precise sphere location, radial profiles of the measured data
were compared to the theoretical WET radial profile, showing excellent agreement
(RMSE = 1.6mm). This accuracy is not much worse than previous works in which
the distal edge of the Bragg peak was used (WET accuracy up to 0.9mm in Bentefour
et al. [2012b]). It can be seen in figures 4.12(d) and 4.12(f) that the measurements
overestimate the sphere WET at the wider radii. This is likely to be caused by
MCS, which has the effect of scattering the protons outwards from the sphere centre
(where the WET is larger). This effect would have less of an impact if larger objects
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were imaged (and a larger CMOS sensor could be used to image them). Despite this,
the CMOS APS demonstrated good suitability as a detector for dose ratio proton
radiographic imaging, with a WET mean error of 0.5mm.
As discussed above in section 4.4.2, to be used clinically, the noise level in the
dose ratio map generated needs to be not higher than 1%. If it exceeds this level,
the region that can be imaged (for the clinical sites assessed) is too small to prove
useful. In this regard, the CMOS APS, with a 1.96σ noise level of 2.35% (see section
4.4.3.2 below), is probably too noisy.
Another problem of the CMOS APS used was the fact that it is not radiation
hard. To be able to make reliable measurements, the sensitivity of the detector had
to be characterised with a calibration image prior to each measurement. Although
inconvenient, detector calibration would be required to account for other detector
factors such as temperature and day-to-day fluctuations anyway. Provided the mea-
surement is quick and automated, we do not consider this to be a big problem.
Alternatively, radiation-hard detectors could be used or careful measurements of
the sensitivity response of the detector with dose could be made.
4.4.3.2 Validation of theoretical predictions
The noise level in our dose ratio map was estimated from a calibration image, in
which a single solid water thickness was imaged, to be σ = 1.2%. Following the same
procedure as the theoretical analysis of section 4.2.1, theoretical error bars could be
determined for the energy pair and for a noise level of 1.96σ. It was found that
the measured error in the WET agreed with the theoretical predictions well, falling
under the horizontal right/left errors bars 89.1/93.9% of the time (figure 4.13). These
values are in good agreement with the prediction that a noise level of 1.96σ should
encompass 95% of the measured data points, given that the measured errors follow
an approximately Gaussian shape. It can be concluded that the method of analysis
to generate the theoretical predictions, in section 4.2.1 and 4.2.2, is appropriate.
4.4.4 Study limitations
One of the limitations of our theoretical application to patient sites is that the WET
maps were generated using straight line DRRs, but it is well known that protons
take longer paths due to the effect of MCS. This would have the effect of spreading
the range of WETs in the patient, thus decreasing the region of the patient we could
image. A potential solution to this, as suggested in section 4.4.2, would be to use
multiple energy pairs, with each pair designed to image different regions.
Our theoretical analysis was verified using a CMOS APS. However, because of
the small detector size, 13mm× 13mm square, we were restricted to imaging objects
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with a small maximum WET (a sapphire sphere with a maximum WET of 21.8mm
was imaged). It is expected that the verification would still hold at high WET, but
this requires confirmation, particularly as the WETs used in the theoretical analysis
were much higher (maximum 242mm).
4.4.5 Outlook of the dose ratio technique
Based on this theoretical analysis, the potential use of this technique appears quite
limited. Only in the imaging of sites with a small maximum WET, namely pae-
diatrics, it is possible to image reasonably-sized fields (greater than an equivalent
5 cm × 5 cm square). This also requires the accuracy in the WET to be no stricter
than 2mm, and the user to have a detector with a noise level of no higher than 1%.
In addition to the limited dynamic range of this technique, it requires the measure-
ment of dose from two pristine Bragg peaks, and consequently twice the amount
of dose with respect to any radiographic techniques that use only one. If, as has
been suggested previously, the dynamic range were to be increased using additional
energy pairs, the dose would be increased further.
Despite these limitations, the technique does have some potential. Firstly, it
only requires the use of a single detector, which, as discussed in the introduction,
can be more conveniently introduced into the clinical environment than classical
proton radiographic devices. Additionally, it provides a potential solution for PBS,
which appears to increasingly become the standard mode of delivery for proton
therapy. Dose was not explored in this work, but given that relative images are
required, it may be possible to deliver a very small dose for each energy (provided
the signal-to-noise ratio is not too low).
4.5 Conclusions
The dose ratio method has been systematically assessed using a set of theoretical
pristine Bragg peaks. Look-up graphs that list the range that one can use on the
proximal side of the Bragg peak, dependent on the energy pair, noise level in the
dose ratio image and the required accuracy in the WET, were generated. These the-
oretical predictions were validated with experimental measurements using a CMOS
APS, which was found to have a noise of σ = 1.2%. The CMOS APS proved to be
a sufficiently accurate detector for this technique, with a RMSE of 1.6mm WET in
the imaging of a small sapphire sphere.
Provided the noise level is less than 2%, it was shown that the proximal side of
the Bragg peak has a larger dynamic range (maximum 5.31 cm) than when using the
distal side of the Bragg peak (maximum 2.42 cm). The dose ratio on the proximal
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side of the Bragg peak has some potential as a proton radiographic method, although
the technique can only be applied to clinical sites with small maximum WETs such
as for paediatric brains. For an example paediatric brain it is possible to use the
technique to image a region with a square field equivalent size of 7.6 cm2, for a 3mm
accuracy in the WET and 1% noise level in the dose ratio image.
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Chapter 5
Patient-specific calibration using
proton radiography
Work in this chapter can be found in the following journal article and was presented
at the following meetings:
• (Under review) Doolan P, Testa M, Sharp G, Bentefour E H, Royle G, Lu
H-M 2014 Patient-specific stopping power calibration for proton therapy plan-
ning based on single-detector proton radiography Physics in Medicine and
Biology
• Doolan P, Sharp G, Testa M, Bentefour E H, Royle G, Lu H-M 2014 Re-
ducing proton beam range uncertainty with patient-specific CT HU to RSP
calibrations based on single-detector proton radiography American Association
of Physics in Medicine 56th Meeting, Austin, TX, USA (Oral presentation)
• Doolan P, Sharp G, Testa M, Bentefour E H, Royle G, Lu H-M 2014 An
optimization scheme to produce patient-specific calibration curves for proton
therapy Particle Therapy Co-Operative Group (PTCOG) 53rd Meeting, Shang-
hai, China (Oral presentation)
• Doolan P, Sharp G, Testa M, Bentefour E, Royle G, Lu H-M 2014 A method
to produce patient-specific calibration curves for proton therapy using proton
radiography NEAAPM Young Investigators’ Symposium, Boston, MA, USA
(Oral presentation)
• Testa M,Doolan P, Bentefour E H, Paganetti H, Lu H-M 2014 Experimental
investigation of proton radiography based on time-resolved dose measurements
American Association of Physics in Medicine 56th Meeting, Austin, TX, USA
(Poster)
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• Testa M, Doolan P, Bentefour E H, Paganetti H, Lu H-M 2014 Proton
radiography based on time-resolved dose measurements Particle Therapy Co-
Operative Group (PTCOG) 53rd Meeting, Shanghai, China (Oral presentation)
As can be seen, there were many contributors to the work in this chapter. Practical
radiographic measurements were made at MGH with M Testa, E-H Bentefour and
H-M Lu, while some CT scans were conducted with G Sharp. M Testa developed
the code to analyse the radiographic data. G Sharp edited Plastimatch to allow
its use in our project and helped with the deformable registration of the real tissue
phantom. All other work and analysis was conducted by myself.
5.1 Background
5.1.1 Improving the calibration curve with proton radiogra-
phy
As discussed in detail in chapter 3, the final step of the stoichiometric calibration
procedure involves calculation of the theoretical RSPs of human biological tissues,
using composition data for average, healthy, adults (ICRU [1989]; White et al. [1987];
Woodard and White [1986]). As such, the stoichiometric calibration is not specific to
the patient being imaged. Yang et al. [2010] showed that neglecting typical patient-
to-patient variations in density (4%), calcium content (2%) or hydrogen content (1%)
causes inaccuracies in the RSP prediction of 2.2%, 2.0% and 1.3%, respectively.
One solution to remove the reliance on literature tissue compositions, and the
uncertainties associated with patient-to-patient variations, is to generate an RSP
map directly. Proton CT would be able to generate such a 3D map, but the tech-
nology is not currently available to acquire this for the size of a patient. Proton
radiography is much more readily available but, due to MCS, it lacks the required
spatial resolution for treatment planning.
However, it has been shown in one previous work by Schneider et al. [2005]
(we are not aware of any other publications) that the RSP information from the
proton radiograph can be combined with the high resolution spatial information
from the X-ray CT to optimise the HU-RSP calibration curve. In their work, a
digitally reconstructed radiography (DRR) through the X-ray CT dataset (in the
same direction as the proton radiograph) was converted to a ‘DRRWEPL’ map. This
involved conversion of the HU values to RSPs using a calibration curve, followed
by summation of the RSPs along the ray trace. Starting with a curve produced
using the stoichiometric method (section 3.1.1.1), portions of the curve across a
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small CT number range (800-1135HU) were randomly varied 20,000 times. Chi-
squared differences between the DRR and proton radiograph were determined until
a minimum solution was found. The resultant calibration curve is then an optimised
one, specific to that patient.
The technique showed promise, with a reduction in the mean difference between
the DRRWEPL and the proton radiograph from 3.6mm to 0.4mm following opti-
misation. However, upon speaking to the corresponding author of the work, the
procedure was not taken up clinically for a number of reasons. (i) The speed of
the electronic read-out was limited because each proton had to be detected in co-
incidence. (ii) It was difficult to include an imaging device into a control system
designed for radiotherapy, because the dose rates used were much lower. (iii) Also,
the radiographic system was too bulky. In our work we propose the use of a detector
that addresses all three of these issues, by (i) measuring a bulk dose over 10 cycles
of the range modulator wheel, so that the total acquisition time is 1 second (ii) at
a clinical dose rate (iii) using a single detector behind the patient.
5.1.2 The ‘time-resolved’ principle
It was first suggested by Lu [2008b] that range verification measurements could
be made using the time dependence of the dose distribution delivered by range-
modulated passively scattered fields. As detailed in section 2.1.3, passively scattered
beams consist of a beam of fixed energy intercepted by various beam modifiers.
A range modulator (RM) wheel, an example of which is shown in figure 5.1(a), is
usually used for this task. It is composed of a series of stepwise segments of absorber
material with increasing thickness. When a mono-energetic proton beam passes a
particular step, its range is reduced, or pulled back, by the WET of the absorber.
Rotation of the RM wheel, at a typical 600 revolutions per minute, results in the
beam passing through the wheel one segment at a time along the track, delivering a
series of Bragg peaks spread out in depth. The RM wheel rotation frequency, step
sizes and thicknesses and the beam current are all carefully controlled so that the
beams of different energies combine to form a spread-out Bragg peak (SOBP), as
shown in figure 5.1(b).
At different depths in the target volume, the dose received is dependent on the
pattern of the range modulator wheel and the incoming energy. Lu [2008b] suggested
that by measuring the time dependence of the dose at any point in the target
volume, the residual range of the beam at that point could be determined. Provided
the initial energy is known, the integrated energy loss, and therefore the WEPL of
materials traversed and the approximate depth in tissue, could be estimated.
The dose rate pattern as a function of time, shown in figure 5.2, varies consid-
113
5. Patient-specific calibration using proton radiography
(a) (b)
Figure 5.1: (a) Range modulator wheel (courtesy of Ion Beam Applications, Louvain-La-
Neuve, Belgium). (b) Demonstration of how individual pristine Bragg peaks of differing
energy and weight (green) can be combined to form a spread-out Bragg peak (orange).
Reproduced from Slopsema [2009].
erably and uniquely with depth. Differences between theoretical (figure 5.2(a)) and
measured patterns (figure 5.2(b)) arise because of range straggling, range mixing
caused by the beam spot size being larger than some of the step sizes, and also
beam current modulation in some systems.
To determine the water-equivalent depth it is necessary to first acquire a library
of patterns in water. The measured dose rate pattern can then be compared to
the library using a least squares minimisation. It has been shown that such an
approach can achieve an accuracy in the WEPL (water-equivalent path length) of
< 1mm using ionisation chambers, provided the depths being measured are within
the SOBP region (Lu [2008b]).
Alternatively, a calibration curve can be formed based on statistical measures
of the dose rate patterns in the library. Gottschalk et al. [2011] showed that using
semiconductor diodes it was possible to achieve a 0.3mm accuracy using the inverse
of the time-width of each pulse, over 10 rotations of the RM wheel. Further details
of this technique, used in our study, are provided in section 5.2.3.
5.1.2.1 Applications
So far there have been numerous suggested uses of the method. One use is as an
in vivo pre-treatment proton range check for prostate treatments, the most com-
mon malignancy in elderly males. Treatments are generally formed of two laterally
opposed proton beams, but a higher conformality (the lateral penumbra are not as
sharp as the distal Bragg peak) and sparing of the concavely-shaped anterior rec-
tal wall could be achieved using anterior beams (either directly anterior or slightly
oblique, ±30◦) (Tang et al. [2010, 2011]). Such a technique is risky because of the
high dose deposition at the end of Bragg peak. Additionally, these proton beams
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(a) Theoretical (b) Experimental
Figure 5.2: Dose rate patterns at a series of depths in a SOBP. Images reproduced from
Gottschalk et al. [2011] (a) and Lu [2008b] (b).
must pass through tissue whose WEPL can vary considerably (e.g. variable bladder
filling, Andreo [2009]). It has been suggested that detectors attached to endo-rectal
balloons could provide a measure of the proton range of anterior beams below the
prostate based on this time-resolved technique (Bentefour et al. [2010, 2009]; Samuel
et al. [2013]). Once the proton range has been verified pre-treatment, the range re-
quired for treatment on the particular day could be tuned to avoid giving dose to
the rectum. Additionally, these detectors could provide a backup dose measurement
during treatment.
It has also been suggested that the technique could be used as a crude imaging
method (Lu [2008b]). Recently this has been demonstrated on simple geometric
objects and a human skull by Testa et al. [2013]. Spatial resolution was limited by
the detector used, a 2D diode array (Sun Nuclear Corporation - Melbourne, Florida,
USA) with 249 semiconductor diodes, to the smallest linear pitch between the diodes
(7.07mm), but the results were promising. The same equipment is used in this work.
5.1.2.2 Range mixing
As detailed in section 4.1, using only a single detector positioned beyond the patient
is a more convenient way to introduce proton radiography into the clinical environ-
ment than the classical approach, which involves trackers before and after patient
and some energy measurement device. However, while convenient, not tracking pro-
tons means the individual paths cannot be reconstructed. Since protons undergo
MCS, they take a curved trajectory through the body and thus there can be multi-
ple paths to a given point. If all of the most probable paths pass through the same
amount of water-equivalent material, then all the protons at the given point will
have a well-defined energy distribution (assuming the protons entering are mono-
energetic) and it is possible to define the WEPL. If, however, protons can get to
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Figure 5.3: Schematic of the DRR optimisation procedure. Plastimatch operations are
shown in blue, measurements in green and optimisation processes in orange. xCT = X-ray
CT.
the point of interest via two (or more) equally probable paths with different energy
losses, then the energy distribution is not well-defined and the final signal becomes
mixed. Methods therefore have to be introduced to detect and handle this effect,
known as ‘range mixing’ (Bentefour et al. [2012a]). In our work, parts of the image
that are subject to range mixing needed to be identified as the WEPL values are
not reliable and should not be used as part of the optimisation.
5.2 Materials and methods
5.2.1 Optimisation scheme
The modular structure of the DRR optimisation procedure is shown schematically
in figure 5.3. DRRs are created using the Siddon [1985] transform implemented in
Plastimatch (plastimatch.org) and the length of intersection of each ray trace with
every voxel, together with the voxel HU value, is stored in a matrix file for future
computations. The HU values are then converted into RSPs using the generic HU-
RSP calibration curve. For a single ray trace i, the individual intersection lengths
lj multiplied by the RSP of the voxel, summed across all the voxels j the ray passes
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through, gives the calculated WEPL, wic , of the ray trace:
wic =
∑
j
ljF (Hj) (5.1)
where lj is the length of intersection and Hj the HU value of voxel j; and F (Hj)
is a function that converts the HU values to RSPs. As described previously, we
call the WEPL map produced in this manner the DRRWEPL. The number of ray
traces matches the resolution required in the DRRWEPL map. In equation 5.1, F
is a function that describes the calibration curve and is typically a single piecewise
linear function F ,
F =

0 if H ≤ −1000;
a+ bH if −1000 < H ≤ 0;
a′ + b′H if 0 < H ≤ 40;
...
...
(5.2)
The division of the linear sections is a choice of the user. In this work all results
are compared to a ‘generic’ calibration curve, formed of three linear portions (-1000
to 40HU with a gradient of 0.001, 40 to 2990HU with a gradient of 0.0005, and a
line with zero gradient between 2995 and 9960HU for titanium). For optimisation,
this curve was split into 25 linear sections or ‘material bins’, based on the material
binning suggested for Monte Carlo simulations by Schneider et al. [2000], with an
additional bin edge at the point of water. The 26 bin edges were: -1000; -950;
-120; -83; -53; -23; 0; 7; 18; 80; 120; 200; 300; 400; 500; 600; 700; 800; 900; 1000;
1100; 1200; 1300; 1400; 1500; 2990. The titanium correction was excluded from the
optimisation procedure as this would ordinarily be overridden as part of treatment
planning.
For the optimisation, the parameters a, b, a′, b′ . . . in equation 5.2 are varied until
the difference between the DRRWEPL map and the proton radiography WEPL image
reaches a minimum. The cost function describing this difference ∆, which must be
minimised, was thus defined:
∆i =
(wmi − wci )2
(wmi )
2
, (5.3)
where wmi is the proton radiography (measured) value of the ith pixel and wci is the
DRRWEPL (calculated) value of the ith pixel.
The optimisation was performed using Matlab’s built-in Nelder-Mead optimi-
sation function, ‘fminsearch’. In addition to the convenience of a Matlab built-in
function, Nelder-Mead optimisations are more robust to local minima and do not
require an equation to be provided for the derivative of the cost function (Lagarias
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Variable Details Value used
MaxFunEvals Maximum number of evaluations of the
cost function
200 ∗ n
TolFun Absolute tolerance on function value 1 ∗ 10−4
Linear sections Number of individual lines that make up
the piecewise linear calibration curve
24
Limitations Must pass through the points of air and
water
Air: HU = -1000,
RSP = 0.001
Water: HU = 0,
RSP = 1
Must be monotonic
Table 5.1: Input variables for the optimisation. n is the number of parameters being
optimised (27 in our case).
et al. [1998]). Details of the input variables used in optimisation scheme can be
found in table 5.1. When optimising, 24 spline points (two points were fixed, see be-
low) were allowed to vary in the y-direction only (HU stays fixed but RSP changes).
The number of variables, n, therefore was equal to 24. We also imposed other re-
strictions, namely that: (i) the curve must be monotonic; and (ii) that the curve
must pass through the points of air (HU = -1000, RSP = 0.001) and water (HU = 0,
RSP = 1); by introducing a high cost penalty in the optimisation if these constraints
were not met.
For the synthetic datasets, for which the desired solution was known, repeats ran
on a while loop until the solution converged. For the real measured datasets we ran
two repeats, each of 100 ∗ n iterations.
5.2.1.1 Plastimatch validation
Plastimatch was utilised for computation of the DRRs, but it was important to
ensure that using this does not introduce any additional errors. Thus a multiple
material, uniform shape, phantom (figure 5.4(b)) was used for this purpose. To
validate Plastimatch a known WEPL map was produced using the theoretical RSPs
for the 28 tissues (based on the literature tissue compositions from ICRU [1989];
White et al. [1987]; Woodard and White [1986]) multiplied by the geometric thick-
ness of the phantom (5 cm). This was compared with a DRRWEPL map, created by
converting the CT values in each voxel to their corresponding RSP values (based on
literature), summing up the (length of intersection) × (value of voxel) of each ray
and summing up across all rays. Two DRRWEPL maps were created, with an SAD
consistent with that of the proton gantry (2.27m) and with an SAD of 1000m. The
latter was tested to remove divergence in the ray tracing, which may impact on the
final result.
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Figure 5.4: Synthetic phantoms used to validate the optimiser. (a) Single, homogeneous
material (example shown here is a sphere of breast material) in a 15 cm radius spherical
shape. (b) Multiple material phantom in (left) 2D view and (right) 3D view. There are
28 materials arranged in 4 rows and each block is 5 cm thick. (c) Heterogeneous phantom,
composed of two layers. (Left) first layer, (middle) second layer, (right) 3D and sagittal
views. Each layer is 5 cm thick. (d) Anthropomorphic pelvic phantom with each organ
overridden to a single CT number. (e) Lung patient, with each organ overridden to a single
CT number. (Right) Cropped region on which optimisation was performed.
5.2.2 Validation of the optimiser against synthetic datasets
To validate the function of the optimiser we worked with synthetic data. Real CT
datasets contain noise and real proton radiographs are subject to MCS, so it would
be otherwise difficult to discern whether the optimiser had reduced the errors to the
theoretical minimum. Using theoretical CT numbers and RSPs for tissue (based on
the literature tissue compositions from ICRU [1989]; White et al. [1987]; Woodard
and White [1986]) simulated phantoms were constructed and perfect, known, WEPL
maps were generated. The calibration curves were optimised against these known
WEPL maps, for a range of synthetic datasets shown in figure 5.4.
5.2.2.1 Single materials, multiple materials and heterogeneous phantom
The simplest task for the optimiser is to alter the calibration curve at a single point
only, which is the case for homogeneous objects composed of one material. To test
this, 30 individual spherical phantoms were simulated, each with a radius of 15 cm
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and composed of a single homogeneous material. An example for the breast tissue is
shown in figure 5.4(a). The known WEPL maps were created using the theoretical
RSP values and the known geometry.
The next test for the optimiser was to simultaneously reduce the error for mul-
tiple materials at once. A synthetic phantom was created, shown in figure 5.4(b),
of 5 cm × 5 cm × 5 cm blocks of 28 different materials across the whole HU range.
Voxels were 5mm × 5mm × 5mm in size, so each material block contained 10 ×
10 × 10 pixels. As before, the known WEPL map was created using the theoretical
RSP values, multiplied by the geometric thickness (5 cm).
To verify that the optimiser works through heterogeneous materials, the synthetic
phantom shown in figure 5.4(c) was tested. The phantom was composed of two of
the multiple material phantoms (described in the paragraph above) in succession,
except that the rows of the second phantom were reordered. The known WEPL
map was determined using the theoretical RSP values of the first half multiplied by
5 cm, added to the theoretical RSP values of the second half multiplied by 5 cm.
5.2.2.2 Anthropomorphic phantom and real patient
To avoid discrepancies due to CT artefacts (e.g. beam hardening between the
femoral heads) and to allow a known WEPL map to be constructed, the CT num-
bers of each organ in an anthropomorphic pelvic phantom were overridden to a
single value and assigned a single RSP: bladder HU=0, RSP=1; prostate HU=58,
RSP=1.03; muscle HU=66, RSP=1.05; rectum HU=66, RSP=1.05; cortical bone
HU=1194, RSP=1.60). The resultant phantom is shown in figure 5.4(d). As men-
tioned previously, better proton range prediction could allow for the use of anterior
proton fields for prostate treatments, which would offer a significant dose sparing
advantage over photon treatments (Tang et al. [2011]). As such, optimisation was
applied over an anterior field.
As with the pelvic phantom, the CT numbers of each organ in a lung patient
were overridden to a single value. For real patients we only need to know how the
curve should be optimised for the field to be treated, so for speed the optimisation
was performed on a smaller cropped region, as shown in figure 5.4(e).
5.2.2.3 Impact of CT noise and multiple Coulomb scattering
In all previous validation tests, the optimisation has involved minimising the differ-
ence between two perfect images: (i) a DRR formed through a CT with no noise;
and (ii) a simulated known WEPL map. In real patient cases the CT will contain
noise and the WEPL map generated by proton radiography will include MCS. The
robustness of the optimiser was therefore assessed for these cases.
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Figure 5.5: Anthropomorphic pelvic phantom with Gaussian noise (standard deviation
in percentage) added to the HU values of each organ.
Noise in CT images is a stochastic phenomenon, usually assumed to have a
Gaussian distribution (Chvetsov and Paige [2010]). To investigate the impact on
the optimisation in a controlled manner, Gaussian noise was introduced into perfect
CT datasets by modification of the overriding function of Plastimatch. The CT
numbers of each organ in the pelvic phantom (figure 5.4(d)) were overridden to a
Gaussian distribution of values. Optimisation was performed on datasets in which a
range of noise levels (standard deviations of 1%, 2%, 3%, 5% and 10%) were applied
to the scaled CT numbers (+1000HU compared to usual values) of each organ.
These phantoms are shown in figure 5.5.
To investigate the impact of MCS, an ideal proton radiograph was simulated by
Monte Carlo using the platform TOPAS (Perl et al. [2012]). The multiple material
phantom (figure 5.4) was ‘imaged’ with a flat beam of 300MeV protons (an energy
sufficient to traverse the object) of no energy spread and with a width sufficient
to fully cover the phantom. Monte Carlo simulations require the composition and
density of each material, rather than the CT number, and these were acquired from
the usual sources (ICRU [1989]; White et al. [1987]; Woodard andWhite [1986]). The
final energy was scored in a plane behind the phantom and 10 million histories were
acquired. Figure 5.6 shows the geometry used in the simulation. The 28 material
blocks are shown by the white squares, the scoring plane behind the phantom is
shown by the purple rectangle and the source begins at the face of the phantom.
Different phantom thicknesses were tested: 5 cm, 10 cm, 15 cm and 20 cm.
No detector-specific factors were simulated in an attempt to isolate the effect
MCS alone. Subtracting the range in water of the final energy protons from the range
in the water of the initial energy allowed the WEPL of the object to be determined.
Range mixing will result in a distribution of WEPLs per pixel (Bentefour et al.
[2012a]), the mean of which was used as the known WEPL map against which to
optimise. This WEPL map is then essentially the best map that could be produced
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(a) (b)
Figure 5.6: (a) Geometry of the Monte Carlo simulation of the multiple material phantom
(white) and scoring volume (purple). Illustrative events are shown in (b).
by a single-detector proton radiographic system (i.e. in which reconstruction of the
individual proton tracks is not possible).
5.2.3 Proton radiographic measurements
All radiographic measurements were made in the proton gantry at MGH, using
a spread-out-Bragg peak with a range of 20 cm and a modulation width of 18 cm
(allowing us to capture all WEPLs within the range 2-20 cm). Proton radiographs
were acquired using the time-resolved proton radiographic method as detailed in
section 5.1.2. A diode array was used for imaging, consisting of 249 semiconductor
diodes arranged on an octagonal matrix (see figure 5.16, top middle), with a diagonal
pitch of 7.07mm and a linear pitch of 10mm separating diodes on the same row.
The diodes have a sampling time of 2ms, which is sufficiently small to capture the
100ms cycle of the RM wheel.
To calibrate each diode in the device, dose rate functions were recorded through
different thicknesses of solid water, spanning the range of modulation to be imaged.
Dose rate functions were averaged over ten successive RM wheel cycles to reduce
the impact of fluctuations in the detector or the proton beam current. The integral
acquisition time was thus 1 sec. It has been shown previously that a number of
moments can be computed from these dose rate functions (Gottschalk et al. [2011]).
In our calibration, we use the third moment, the root-mean-square (RMS) deviation
of each modulator cycle, given by,
σt =
(
1
S
N∑
i=1
mi(ti − µ)2
)1/2
(5.4)
where S is the sum of all the measurements, m, between the index at the start and
end of the RM cycle; mi is the measurement sampled at time ti; and µ is the mean
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Figure 5.7: Average calibration across all diodes in the detector.
time. Separate calibrations were applied to each diode in the imaging device but
the average across all diodes is shown in figure 5.7 as an illustration.
5.2.3.1 Phantoms
To test the optimisation procedure we imaged the phantoms shown in figure 5.8.
They are both composed of two halves. The reason for this is that radiographs
are made through the entire patient, but we really want to know the WEPL to a
therapeutic depth. If we assume the therapeutic depth is the distal edge of the
top half of the phantom, the procedure consists of the following three steps: (i)
acquire time-resolved proton radiograph through the entire phantom; (ii) optimise
the calibration curve by minimising the difference between the DRRWEPL and the
proton radiographic WEPL; and (iii) predict the WEPL to the distal edge of the
top half using the optimised calibration curve. To validate that the optimisation
improves the WEPL estimate, we needed an independent measure of the WEPL to
the distal edge of the top half. We therefore split apart the phantoms and conducted
dose extinction measurements (section 5.2.3.2) on the top half only.
In the top half of the plastic phantom, there are eight inserts from the Gammex
467 phantom (Gammex Inc., Middleton, WI), arranged in a 12 cm lucite box (1 cm
thick walls) with a central divider. Water was used to fill in the gaps, up to the
insert height (70mm). The insert materials ranged from RSPs of 0.94 (Adipose)
to 1.60 (Cortical bone), which together with the thickness of the lucite box, gave a
range of WEPLs from 6.6 to 11.2 cm. The bottom half of the plastic phantom was
a piece of homogeneous solid water, equivalent to 5.12 cm of water.
For the real tissue phantom, the top half (same 12 cm lucite box as for the
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Figure 5.8: Phantoms imaged with proton radiography. (Top) Plastic phantom. Left-
right: top-down view showing insert locations; oblique view of CT scan showing water-
filling between the inserts; phantom positioned for proton radiography. (Bottom) Real
tissue phantom, (left-right) top and bottom halves of real tissue; oblique view of CT scan;
transverse/ sagittal/coronal views at two different window levels to show the bone locations
and plastic boxes.
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plastic phantom) was filled with a single piece of boneless beef chuck (fat left on), a
non-smoothed pork bone and a strip of veal liver along the base. The bottom half
was composed of a simple commercial lunchbox filled with another single piece of
boneless beef chuck and another non-smoothed pork bone. The bones in the top and
bottom halves were oriented 90◦ to each other, with some overlap. Given that the
real tissue was not frozen or fixed during the experiment, CT scans were acquired
approximately 1 hr before and 30mins after the proton radiographic measurements
(that lasted for 4 hrs) to allow for quantification of any changes in tissue shape.
The latter volume was warped to the former volume using a b-spline deformable
registration in Plastimatch and tissue changes were computed along each direction.
5.2.3.2 Dose extinction measurements
To determine if the optimisation procedure results in a more accurate WEPL map
at the therapeutic depth, it was necessary to compare with an independent mea-
surement. For this we used the simple, robust method of dose extinction. In this
method a controlled dose (10MU) was delivered and increasing thicknesses of water-
equivalent material were placed between the proton beam and the phantom until
the dose to all of the detectors is zero. Depth dose curves for each diode were then
formed, from which the thickness that stops 50% of our protons, also known as the
R80, was computed. These R80 values were subtracted from the beam range (20 cm)
to compute the WEPL as measured by dose extinction (DEWEPL).
5.2.3.3 Handling range mixing
As stated in section 5.1.2.2, range mixing is a problem for single detector proton
radiography as individual proton paths cannot be reconstructed. To ensure it did
not impact on our optimisation, it was imperative that any diodes subject to range
mixing were masked when calculating the cost function. For our purposes we applied
a simple method to remove potentially range mixed diodes, by assuming that range
mixing occurs at the boundaries of two materials. To identify the boundaries, we
converted a 1mm resolution DRRWEPL map into a map of local standard deviation
by assessing the standard deviation of all surrounding pixels (on a 3 × 3 square).
Any pixels having a standard deviation of > 1% were considered to be close to a
boundary and thus could be subject to range mixing. These were then masked out
during optimisation and any further analysis. This is shown schematically in figure
5.9.
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Figure 5.9: (a) Local standard deviation map for plastic phantom, showing edges of
objects. (b) Mask based on standard deviations > 1% and diode locations (black =
masked).
5.3 Results
5.3.1 Validation of the optimiser
5.3.1.1 Plastimatch validation
The results using a source-to-axis-distance (SAD) of 2.27m (matches the MGH
proton gantry geometry) and 1000m (to remove divergence), is shown in figure 5.10.
At the top is the known WEPL map. In the middle row are the set of results using
an SAD of 2.27m. The difference between the DRRWEPL map and the known WEPL
map shows the divergence of the beam, and the histogram of these differences shows
the overestimation of the WEPL. On the bottom row is the same set of results for
an SAD of 1000m. The difference image and histogram show that the beam enters
parallel and the negligible difference confirms that Plastimatch does not introduce
any additional errors. The errors remaining are caused by truncation of floating
point numbers and other rounding errors.
5.3.2 Single material, multiple material and heterogeneous
phantoms
Optimisation results for the synthetic phantoms are shown in figure 5.11. At the
top of the figure are the known WEPL maps, created using the known RSPs and the
known geometry. The middle row shows the difference between the DRRWEPL maps
created using the generic HU-RSP calibration curve, both in image and histogram
format. The bottom row shows the same set of results as the middle row, but for
the HU-RSP curves following optimisation. For single materials, it was a simple
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Figure 5.10: Comparison between DRR and physical WEPL maps using an SAD of
2.27m or 1000m.
task to converge to the optimal solution. An example result, for breast tissue,
is shown on the left of figure 5.11. The root-mean-square-error (RMSE) for each
individual material, and its reduction following optimisation, can be seen in figure
5.12. The optimiser can clearly eliminate the errors for all tissues. The result for
the multiple material phantom can be seen in the centre of figure 5.11, with the
optimised curve reducing the RMSE significantly, from 0.69mm to 0.09mm. The
optimisation result for the heterogeneous phantom can be seen on the right of figure
5.11, with the optimised curve reducing the RMSE significantly, from 0.94mm to
0.19mm.
5.3.2.1 Anthropomorphic phantom and real patient
With an anterior field for the pelvic phantom, it can be seen (figure 5.13, left) that
using the generic calibration curve results in an overestimation of the WEPL of
RMSE = 4.1mm, which is reduced to 0.1mm following optimisation.
The optimisation over a small, field-sized region in a real patient geometry al-
lowed for complete eradication of the RMSE, as shown in figure 5.13 (right). Com-
pared to the case where the entire field-of-view was used for optimisation, the time
significantly reduced. The increase in speed is dependent on the relative decrease in
image sizes, which in this case was a factor of 7-8.
5.3.2.2 Summary
A summary of the results of the previous validation tests is detailed in table 5.2.
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Figure 5.11: Optimisation results for synthetic phantoms: (left) individual homogeneous
phantoms; (middle) multiple material phantom; (right) heterogeneous phantom. Top row:
known WEPL maps, created using the known RSP values assigned to each CT number.
Middle row: difference between the DRRWEPL produced by the generic calibration curve
and the known WEPL map, and the histogram of these differences. Bottom row: same as
middle row, but for the optimised calibration curves.
Figure 5.12: RMSE in the difference image for individual uniform spheres of homogeneous
human tissues, before (blue squares) and after (red diamonds) optimisation.
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Figure 5.13: Optimisation results for the pelvic phantom (left) and for the lung patient
(right).
5.3.2.3 Impact of CT noise and multiple Coulomb scattering
The optimiser was shown to handle noise in the CT number well, with results before
and after optimisation detailed in table 5.3. To investigate the impact of MCS on
the optimiser, optimisation against a WEPL map produced by Monte Carlo was
tested, the results of which can also be found in table 5.3. An example result is
shown in figure 5.14 for the 5 cm thick phantom. Before optimisation there was
a mean underestimation of -3.8%, which reduced to -0.1% following optimisation.
The largest differences were found at the borders of two materials of very different
density, where range mixing becomes an issue.
5.3.3 Optimisation against time-resolved proton radiographs
Calibration curves were produced using the optimisation procedure, using real pro-
ton radiographs acquired with the time-resolved technique. Figure 5.15 shows the
results of the optimisation for the plastic phantom after 120mins. On the top row
are the proton radiographic images, the middle/bottom rows show the results using
the generic/optimised calibration curves, and the histogram of differences is shown
in the bottom right corner. Further details are given in the figure caption.
Figure 5.16 shows the set of results for the real tissue phantom after an optimisa-
tion time of 125mins (in the same format). From the registration it was found that
the tissue remained quite static during the course of the 3 hr experiment. With ref-
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Test Generic OptimisedRMSE µ/σ RMSE µ/σ
CT noise (1%) 0.84% -0.84 / 0.10% 0.03% 0.00 / 0.03%
CT noise (2%) 0.90% -0.89 / 0.08% 0.03% 0.00 / 0.03%
CT noise (3%) 0.85% -0.85 / 0.07% 0.02% 0.00 / 0.02%
CT noise (5%) 0.72% -0.72 / 0.07% 0.01% 0.00 / 0.01%
CT noise (10%) 0.56% -0.55 / 0.09% 0.02% 0.00 / 0.02%
Monte Carlo (5 cm) 4.24% -3.76 / 1.95% 1.95% -0.13 / 1.95%
Monte Carlo (10 cm) 3.61% -3.06 / 1.90% 1.69% -0.11 / 1.69%
Monte Carlo (15 cm) 3.13% -2.35 / 2.06% 1.81% -0.15 / 1.80%
Monte Carlo (20 cm) 3.92% -1.24 / 3.72% 2.75% -0.38 / 2.72%
Table 5.3: Differences between DRRWEPL and known WEPL maps, before (generic) and
after (optimised) optimisation, for the different robustness tests.
Figure 5.14: Results before and after optimisation for the multiple material phantom,
with 5 cm thickness, using WEPL maps produced by Monte Carlo to simulate proton
scattering.
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Figure 5.15: Optimisation results for the plastic phantom. (Top, left-right): insert ar-
rangement (rotated 45◦ counterclockwise with respect to the proton radiographic images);
3D proton radiographic WEPL map; 2D proton radiographic WEPL map; and 2D proton
radiographic WEPL map with range mixing mask applied. (Middle, left-centre) DRRWEPL
map produced with the generic calibration; and difference between generic DRRWEPL and
proton radiographic WEPL. (Bottom, left-centre) Optimised calibration curve; and dif-
ference between optimised DRRWEPL and proton radiographic WEPL. (Bottom right)
Histogram of differences for the generic and optimised calibration curves.
erence to the directions in figure 5.8, it was found the mean/max deformations were:
-0.5/-1.5mm in the LR direction; -0.5/-2.0mm in the AP direction; and 0.1/-1.5mm
in the SI direction.
5.3.4 Estimation of the WEPL at the therapeutic depth
To validate that the optimised calibration curve offers an improvement in the WEPL
estimate at a therapeutic depth, independent measurements of the top half of the
phantom were made using dose extinction. Integrated doses were recorded by the
imager behind the top halves of the phantom, for a number of thicknesses on top.
These dose maps, for the plastic phantom, are shown in figure 5.17. It can be seen
that with increasing thicknesses of solid water on top the dose readings in the diodes
steadily decreases. The insert with the highest WEPL (Cortical bone) is the first
to disappear, while the one with the lowest WEPL (Adipose) is the last. Depth
dose curves were created for each diode. The R80 of each fall off, together with the
known R80 of the beam, allowed for the calculation of the WEPL to each diode.
The WEPL maps for the two phantoms are shown in figure 5.18.
A comparison of the DRRWEPL maps at the therapeutic depth (constructed using
the generic and optimised calibration curves) with the WEPL maps measured by
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Figure 5.16: Real tissue phantom results. Same format as figure 5.15.
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Figure 5.17: Integrated dose maps for the plastic phantom as part of the dose extinction
measurement.
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Figure 5.18: (a) Depth dose curves for all diodes behind the top half of the plastic
phantom. (b) DEWEPL map. (c,d) Same as (a,b), for the top half of the real tissue
phantom.
dose extinction is shown in figure 5.19.
5.4 Discussion
5.4.1 Validation of the optimiser
5.4.1.1 Plastimatch validation
It can be seen (figure 5.10) that an SAD of 2.27m introduces noticeable divergence
in the ray tracing. By increasing the SAD to 1000m, the rays effectively enter
parallel and the error is significantly reduced (max error from 0.4% to 4.6× 10−6%
in the WEPL). The remaining errors are caused by precision errors in Plastimatch
(i.e. truncation of floating point numbers).
5.4.1.2 Validation against simulated datasets
The use of synthetic datasets made it possible to validate the optimiser. Based
on the assigned RSPs for the HU values in the synthetic dataset, perfect WEPL
maps could be created against which to optimise. In all cases the error defining
the cost function was either completely eradicated or significantly reduced. The
only cases where the optimiser failed to completely minimise the error were for the
multiple material and heterogeneous phantoms. In these phantoms there were 28
different materials, but the optimised calibration curve was only split up into 25
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different materials. As such, it was not very likely for the optimiser to completely
eradicate the errors. The fact that there was a significant reduction demonstrates
the optimiser’s robustness to potentially conflicting requirements. The results also
showed that the complexity of the dataset does not impact on the results, with
significant reduction and complete eradication of the error for the anthropomorphic
phantom and real patient geometries, respectively.
5.4.1.3 Robustness of the optimiser against CT noise and multiple Coulomb
scattering
The perfect datasets were critical in constructing the optimiser, but it was also
important to validate that the optimiser was robust in the more realistic case of CT
noise. It can be seen from table 5.3 that the optimiser was robust to varying noise
levels, with an almost identical final error following optimisation. As to be expected,
there is an intrinsic spread in the errors that the optimiser cannot remove due to
the noise. Despite this, the optimiser was still able to find a minimal solution and
functioned as well as could be expected.
In the validation tests described previously the calibration curve had been opti-
mised against a perfect WEPL map, formed using RSP values assigned to specific
CT numbers. However, in the real situation the WEPL map will be generated from
a proton radiograph and so will include MCS and uncertainties from the detection
method. The optimiser showed robustness against this, as shown by the statistics in
table 5.3. It can be seen in figure 5.14 that the WEPL generated from the DRR is,
prior to optimisation, underestimated compared to that generated from the Monte
Carlo simulation. This is expected as the DRR is a straight line approach and in
the simulation the protons traverse a longer path due to MCS. Additionally, similar
to when CT noise was introduced, MCS leads to a spreading of the errors. As one
would expect, with increasing phantom thickness, there is an increase in the error
and spread in errors. Following optimisation, the offset due to the underestimation
was removed and the spread in errors was also reduced. Reductions in the RMSE
following optimisation were found to be 64/72/77/30% for the 5/10/15/20 cm thick-
nesses, respectively.
5.4.2 Optimisation against time-resolved proton radiographs
The results in figures 5.15 and 5.16 demonstrate that the procedure works when
optimising against real proton radiographs. For both the plastic and real tissue
phantoms the optimisation improved the results. Following optimisation on the
plastic phantom: the RMSE difference was reduced from 3.4% to 2.6%; the mean
was reduced from 1.8% to 0.4%; and the standard deviation was reduced slightly
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from 2.9% to 2.6%. For the real tissue phantom: the RMSE was reduced from 3.6%
to 2.9%; the mean error was reduced from -2.1% to -0.2%; and the standard deviation
remained constant at 2.9%. As expected the improvements are more modest than
for the synthetic datasets that had a known solution, but they are sufficiently large
to warrant use of the technique.
For the real tissue phantom the tissue shape changes were small during the course
of the experiment. Maximum changes of -1.5/-2.0/-1.5mm in the LR/AP/SI direc-
tions were found between the pre- and post-radiographic CT images, which were
acquired 4 hours apart in time. The time difference between the pre-radiographic
CT image, upon which the optimisation was performed, and the proton radiographic
measurement was around 1 hour. Assuming a constant rate of shape change, dif-
ferences in the real tissue between the CT image and the proton radiograph would
be less than 0.5mm in all directions. Given the pitch between adjacent diodes was
never less than 7mm, we assume that such changes did not impact on our results.
5.4.3 Estimation of the WEPL at a therapeutic depth
After splitting apart the phantoms, dose extinction measurements allowed for the
generation of WEPL maps at therapeutic depths. Comparing the DEWEPL maps
with DRRWEPL maps at the same depth, it was clear that for both phantoms the
optimised curve matched the DEWEPL better than the generic curve. The RMSEs
for plastic phantom were 3.4/2.5% for generic/optimised calibration curves. The
same statistics for the real tissue phantom were 2.0/1.4%. These improvements
are similar to those of the previous section, suggesting that optimisation of the
calibration curve using proton radiography across the whole patient allows for a
more accurate estimate of the WEPL at a therapeutic depth. Additionally, this
independent measurement validates the accuracy of the original proton radiograph.
5.4.4 Technique limitations
The technique proposed here relies on the ability to produce an accurate proton
radiographic image. Optimising against an inaccurate proton radiographic image
would result in an inaccurate calibration curve being produced and an inaccurate
estimate of the RSPs in the patient. We are confident, however, that the single-
detector time-resolved approach we utilised in this study was able to produce ac-
curate WEPL values. Previous studies have shown the accuracy in the WEPL to
be < 1mm using ionisation chambers (Lu [2008b]) or 0.3mm when using diodes
(Gottschalk et al. [2011]). Additionally, the agreement with the independently mea-
sured DEWEPL was better following optimisation.
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Another source of uncertainty is the applicability of straight-line DRR ray tracing
to proton paths. It is well known that protons do not take straight line paths due
to the effect of MCS, and thus a straight line approximation would underestimate
the WEPL. One potential solution would be to use the optimised calibration curve
as input for a Monte Carlo simulation so that the effects of MCS are accounted for.
The optimised calibration curve could then be fine-tuned, based on the results of
the simulation. We believe this underestimation to be a second order effect in our
results, however. The maximum WEPL was 17.32 cm for the plastic phantom and
13.31 cm for the real tissue phantom. The Highland [1975] formula to compute the
root mean square projected angle of scattering σs [radians] is given by,
σs = S2
√
X/X0
pβc
[1 + εlog(X/X0)] (5.5)
where S2 = 14.1MeV and ε = 1/9 are empirical factors; X is the thickness of
the scatterer; X0 is the radiation length (36.08 cm for water in our case as we use
WEPLs); p is the momentum [MeV/c]; and β is the particle velocity. At the energy
used (approximately 175 MeV) and at largest thicknesses of our phantoms, σs =
0.0292 rad for the plastic phantom and σs = 0.0253 cm for the real tissue phantom.
An angular deflection leads to a projected lateral deflection D [cm] as described by
Leroy and Rancoita [2009]:
D =
σs√
3
X (5.6)
In our experiments the average lateral deflections were thus D = 0.29 cm for the
plastic phantom and D = 0.19 cm for the real tissue phantom. Given the closest
pitch between adjacent diodes (0.7 cm) was larger than both of these values, we
believe that a straight line approximation was valid. If the protons travel through
material with a composition different from water, such as bone, it is possible these
deflections will increase. The deflections will also increase if the distance between
the patient and the detector is increased.
It is likely more accurate results will be produced by assuming a cubic spline
path (Li et al. [2006]) or a most likely path (Williams [2004]), however this requires
the tracking of individual particles (which is not possible with a single detector).
Additionally, we are not aware of any software that can currently easily compute
the length of intersection of such paths with the CT dataset. This is suggested as
an area of future work.
In the current implementation the optimisation times are probably too long. This
time is dependent on three main factors. (i) The voxel size and number of voxels
in the CT dataset determines the number of intersections stored in the ray tracing
matrix file, which affects the time to calculate the DRRWEPL map. This has to be
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recomputed for each iteration. (ii) The number of pixels in the two images, between
which the difference is trying to be minimised, affects the time to calculate the cost
function. (iii) The stopping tolerance of the optimisation directly affects how long
the optimisation takes to converge. The first of these, computation of the DRRWEPL
map using the ray tracing details, was the major factor for slow optimisation times
in our implementation. This could be significantly reduced, however, by producing
field-specific calibration curves over much smaller volumes. The proton radiograph
would be acquired in the same direction as the intended treatment beam, so only
those tissues in the field of view would need to be optimised. It is also possible that
an alternative optimisation scheme, such as a gradient descent, could speed up the
minimisation.
Another limitation of our specific set of measurements is the limited spatial
resolution (pitch between diodes up to 1 cm) of the proton imager. This could
be easily improved by using one of the various promising technologies currently
available such as fluorescent screens coupled to CCD cameras (Bentefour et al. [2013];
Muraishi et al. [2009]; Ryu et al. [2008]), commercial flat-panel detectors (Telsemeyer
[2012]) or CMOS APS (Gelover-Reyes et al. [2011a]; Poludniowski et al. [2014]; Seco
and Depauw [2011]). Additionally, production of the DRRWEPL map is reliant on the
accuracy of the CT. As such, removal or reduction (with improved reconstruction
algorithms or dual-energy CT) of artefacts such as beam hardening or streaking
must be considered when producing the DRR.
5.4.5 Application to other proton radiographic techniques
The optimisation scheme developed in this work is insensitive to the method of
production of the proton radiograph. Although we used the time-resolved single
detector proton radiographic method, the optimisation scheme could, in theory,
be used for classical proton radiographic devices. Provided the ray tracing of the
DRR can be effectively modelled (i.e. the source-to-isocentre and source-to-imager
distances are known), patient-specific curves could be generated.
5.4.6 Introduction into the proton treatment planning work-
flow
While in its infancy, this proof of concept work demonstrates how proton radiography
could be utilised and implemented into the proton treatment planning workflow.
With a single radiograph imaged using a single detector, it is possible to generate
a calibration curve that is specific to the patient being treated. The treatment
planning workflow could be updated as follows: (i) acquire X-ray CT for treatment
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planning; (ii) acquire a proton radiograph in the intended treatment beam direction;
(iii) generate a patient-specific HU-RSP calibration curve by optimisation; and (iv)
create a treatment plan using the patient-specific calibration curve.
It is clear that adding an additional procedure into the patient treatment work-
flow will impact on patient throughput. Logistically it may be difficult for a centre
to apportion beam time specifically to imaging. We believe that in order for this
to be introduced routinely into the clinic it would be necessary to have a dedicated
beam line for imaging. If, as has been suggested by this preliminary work, the tech-
nique can offer a large improvement in WEPL prediction, companies may develop
and eventually offer dedicated single-room imaging beam lines.
5.4.7 Future work
In addition to an improvement on the limitations outlined in section 5.4.4, there are
a number of areas of future work. A comparison with DECT is required, as this
has shown a great deal of promise recently (Bourque et al. [2014]; Hünemohr et al.
[2014]) and offers a more convenient solution than attempting to introduce a new
step into the proton treatment planning workflow.
It seems logical that taking radiographs from additional angles would offer an
improvement, particularly in the estimation of the WEPL at a therapeutic depth
(which may be affected by tissues distal to the target). An investigation into the
optimal number of angles and the potential improvement offered is warranted. This
would lead to a comparison with proton CT, which is argued by Hansen et al.
[2014] to offer better accuracy than DECT. Experimental validation of this claim is
required.
Range mixing is a hindrance to single-detector proton radiography and a thor-
ough study into how it can be effectively detected and removed is needed. A variety
of methods have been suggested, one of which is the assessment of the 4th and 5th
moments of the dose rate pattern. Gottschalk [2014] shows that deviations from the
natural (measured in a homogeneous water phantom) skewness and kurtosis can be
used to quantitatively determine if a diode is subject to range mixing.
5.5 Conclusions
It has been shown that it is possible to construct a robust optimiser that can pro-
duce patient-specific calibration curves, using the information from simple single-
detector proton radiographs. Following validation with a range of perfect (containing
no noise) synthetic datasets, the robustness of the optimiser was confirmed using
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CT datasets containing noise and proton radiographs produced with Monte Carlo
simulations.
The technique was demonstrated experimentally with real proton radiographs
produced using a simple diode array and with the time-resolved radiographic tech-
nique. For a phantom composed of real tissues, the optimisation procedure was
able to reduce the mean error between a DRRWEPL map and a proton radiograph
from -2.1% using a generic calibration curve to -0.2% using an optimised calibration
curve. Using this optimised calibration curve, produced using proton radiography
through the entire patient, it was demonstrated that a more accurate estimate of
the WEPL at a therapeutic depth could also be made. By splitting the phantom in
half, the RMSE difference between the DRRWEPL map and an independent DEWEPL
map decreased from 2.0% to 1.4% using the optimised calibration curve.
Based on these promising results further work is justified, with the view to in-
troducing an additional step in the current proton treatment planning procedure.
A single proton radiography in the intended treatment direction could be used after
the treatment planning X-ray CT, allowing for the production of a patient-specific
calibration curve that is subsequently used in treatment planning.
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Overall conclusions and final remarks
In this thesis we looked at two themes. The first involved the assessment of three
proton TPSs, with the aim of informing the procurement process for the new proton
centre at UCLH. The second theme was centred around the range uncertainty arising
from the use of a single HU-RSP calibration curve in proton treatment planning.
6.1 Treatment planning system comparison
In this work we make a timely comparison of the optimisation algorithms of pro-
ton TPSs of three major vendors, Varian (Eclipse), Philips (Pinnacle3) and Elekta
(XiO), based on the treatment of meningiomas with an SFUD horizontal fixed beam
arrangement. The comparison was built upwards from the beam data and it was
found that both Eclipse and Pinnacle3 modelled the measured data to within clin-
ical tolerances. Pinnacle3 consistently overestimated the Bragg peak position (max
0.5mm) for the depth dose curves, while Eclipse overestimated the effect of build up
at higher energies (< 175MeV). It was also concluded that additional measurements
are needed to model the long, non-Gaussian tails from large angle scattering and
nuclear interactions.
In the treatment plans Pinnacle3 generally gave lower OAR doses and a lower
integral dose outside the target. This was attributed to the flexibility of available
spot positions and the ability of the optimiser to be able to adjust the relative
weighting of the two fields. It was also found that Pinnacle3 distributed its spots
more uniformly than the other systems. All conclusions are subject to validation of
the accuracy of the dose calculation algorithms of each system.
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6.2 Errors in the HU-RSP calibration curve
It has been suggested that the use of a single calibration curve, to convert the
patient’s X-ray CT into RSPs for proton treatment planning, contributes up to 1.8%
uncertainty to the proton beam range. Being able to reduce this range uncertainty
will allow for tighter planning margins and a reduction in the irradiation of healthy
tissue.
6.2.1 Range effects
We began the investigation by first assessing the errors and range effects caused
by the stoichiometric procedure, which is used to produce the HU-RSP calibration
curve. We specifically look at the theoretical calculation of the RSP.
Four methods of calculating the RSP were assessed (Bichsel [1972], Janni [1982],
ICRU [1993] and Schneider et al. [1996]). Comparing to measured values of Gammex
inserts, it was found that there were errors in all techniques, with a mean underesti-
mation of up to 2.1% for the Bichsel approach. Using the Schneider approximation
with the Janni I-values showed the best match to our measurements. These RSP
errors were shown to translate directly into proton beam range errors of similar
magnitudes, for plans within a Gammex phantom and in two patient cases.
To assess the error in the theoretical calculation of human tissues, it was nec-
essary to define a gold standard that matched the measurements best. Given that
the I-value of water is still disputed, the Schneider approximation, Janni elemental
I-values and a water I-value of 80 eV was used to form a gold standard that matched
our measurements excellently. Comparing this to the method used by most centres
(Schneider approximation, ICRU elemental I-values and a water I-value of 78 eV),
there were errors of up to 0.8% across 73 human tissues.
An RSP measurement of the inserts is therefore suggested as a solution to min-
imise this error, although this assumes the scaling in plastics also applies to human
tissues. Even if this may not be the case, patient-to-patient variations from liter-
ature tissue compositions point to proton radiography as a more viable solution,
leading to the next two chapters of the thesis.
6.2.2 Dose ratio proton radiography
A number of different approaches of proton radiography have been attempted. How-
ever the fact that it has not yet been introduced into the clinic suggests that none
have so far been successful. In this thesis an investigation was made into a novel
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single-detector method termed ‘dose ratio’ proton radiography that is both simple
and has the potential to be applied to PBS treatments.
The application of the technique to a range of patient sites was conducted using
theoretical pristine Bragg peaks. The proportion of the site that could be reliably
imaged was determined based on the energy pair, noise level in the dose ratio image
and the required accuracy in the WEPL. These theoretical predictions were validated
with experimental measurements using a CMOS APS. It was showed that use of the
proximal side of the Bragg allowed for a wider range of WEPLs than the distal
side, but in general the choice of patient sites is limited. A more established proton
radiographic method was therefore used in the final chapter of the thesis.
6.2.3 Reducing range uncertainty with proton radiography
In the final chapter of the thesis an approach was developed that uses proton radio-
graphic images to generate patient-specific HU-RSP calibration curves. The function
of the optimiser was first validated on synthetic datasets and its robustness to noise
was demonstrated. Using a simple diode array, time-resolved proton radiographic
images were used to generate specific calibration curves for a plastic and a real tissue
phantom. The optimised curve enabled the mean error between a DRRWEPL map
and the proton radiograph to be reduced from -2.1% to -0.2% for the real tissue
phantom. It was also shown that with this curve a more accurate prediction of the
WEPL at a therapeutic depth could be obtained.
If these promising results could be built upon, this approach could lead to an
update to the current treatment planning workflow for proton therapy patients.
Proton radiographs would be acquired at the same time as the treatment planning
X-ray CT and patient-specific HU-RSP calibration curves would be determined.
These would then be utilised when creating the treatment plan and the reduced
range uncertainty would allow for tighter target margins and hopefully improved
patient outcomes.
6.3 Areas for future work
One area of future work for the TPS comparison project is a thorough investigation
into the accuracy of the dose calculation algorithm, which was beyond the scope of
this work. Throughout the work, the reader was reminded that all conclusions were
made on the provision that the dose calculation algorithms were validated. The
most straightforward approach to this would be to make identical plans in water on
each system, with the only difference being the dose calculation algorithm, and to
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then deliver the plans and measure the dose experimentally. Following this, more
complicated geometries could be tested to investigate the impact of heterogeneities.
For prospective buyers of the software it would also be of interest to look at a
number of other areas: the ability to utilise multiple imaging sets (from MRI or
positron emission tomography, PET) and the registration of these to the original
X-ray CT; the performance and accuracy of photon treatment planning, as many
centres will deliver combined treatments; the integration of photon and proton treat-
ment plans; adaptive planning, taking into account additional daily or weekly imag-
ing; and biological modelling (among others). Comments on the user interface and
the planning experience would also be of benefit, although these are subjective and
were thus avoided in our work.
In the application of proton radiography project there are many areas of fu-
ture work. There have been many recent publications investigating the potential
of DECT as a tool to estimate the tissue stopping powers, with some promising
results. There is also unpublished work comparing the performance of a Monte
Carlo-generated proton CT to DECT and single-energy CT, but as yet no experi-
mental comparison. There is certainly a need for an experimental comparison of pro-
ton radiography (we believe that the most developed and promising single-detector
technique is the time-resolved approach) and DECT.
If proton radiography fares favourably to DECT, there is justification to take the
procedure developed here one step closer to the clinical environment. In order for
this to happen, there would need to be a number of improvements to the imaging
system. The spatial resolution of the detector would need to be increased. A mini-
mum/maximum pitch between diodes of 7/10mm is too large for a clinical detector
and could lead to important physical features being missed. Spatial resolution on
the order of 1-2mm, comparable to X-ray CT, would be more appropriate. Addi-
tionally, the detector would need to have a larger imaging area. It is possible that
treatment fields could be delivered larger than the area of the current proton imager
(12 cm × 12 cm), so an imaging area of at least 20 cm × 20 cm would be more ap-
propriate. Time constraints made it difficult in this work (we instead relied on the
accuracy determined in previous works), but the accuracy and density resolution of
the proton imager should be fully determined. Additionally, a comparison of the
dose delivered by both techniques would be essential.
In the optimisation procedure one of the biggest sources of uncertainty is the
use of straight-line ray tracing when producing the DRR. Using only one detector,
however, does not allow us to reconstruct proton paths so estimates must be made
as to the shape of the path. Based on the effective source size and source-to-
axis distance, the beam divergence could be estimated and a Gaussian spreading
from this path could be assumed. It would then be necessary to write software (or
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make modifications to Plastimatch) that could compute the length of intersection
of these cubic spline paths with the CT dataset. Improvements in the speed of
optimisation should also be introduced. This could involve either introducing field-
specific optimisations or by using a more efficient optimiser such as a gradient descent
approach.
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Gamma analysis, a standard in the radiotherapy field, assesses the quality of the
fitting in terms of dose difference (DD) and distance-to-agreement (DTA), through-
out two dose maps. Here we use a one-dimensional implementation, by comparing
two curves. The DD measures the dose difference between the measured data and
the fit, effectively assessing the fit in the y-direction. The DTA measures the spatial
distance between a measured data point and a fitted point, and thereby effectively
assesses the fitting in the x-direction. Depending on the situation the DD or DTA
alone may be insufficient and they are actually complementary to each other. The
dose difference gives suitable results in low dose gradient regions but not in high
dose gradient regions, with DTA the opposite. The gamma evaluation method is a
combination between the dose difference and the DTA evaluation methods.
Perfect fitting at a given point of the curve is defined if both DD and DTA
are zero. The gamma index, first proposed by Low et al. [1998], is a function that
performs composite analysis of the DD and DTA by collapsing them both into one
parameter. The gamma index γ between a given measurement position rm and
fitted position rc is defined as,
γ(rm) = min {Γ(rm, rc)} ∀ {rc} (1)
where
Γ(rm, rc) =
√(
r(rm, rc)
∆dM
)2
+
(
δ(rm, rc)
∆DM
)2
(2)
and where r(rm, rc) = |rc− rm| is the DTA and δ(rm, rc) = Dc(rc)−Dm(rm) is the
DD, both at the position rm; ∆dM is the DTA acceptance criteria; and ∆DM is the
DD acceptance criteria. A visual representation of this is shown and explained in
figure A.1.
In radiotherapy a two-dimensional gamma analysis is usually used to compare
two dose distributions. For example, before an intensity modulated radiotherapy
(IMRT) treatment, patient-specific quality assurance involves delivering the planned
treatment to a water phantom loaded with an array of diodes. The delivered and
planned fluence from a given beam direction are compared using gamma analy-
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Figure A.1: Geometric representation of the gamma index in one-dimension. All pa-
rameters are as defined in equation 2. rm (measured point, purple) and rc (fitted point,
orange) are the points being compared. The red line given by r(rm, rc) is the distance-
to-agreement, the green line given by δ(rm, rc) is the dose difference and Γ is the vector
combining these two differences. ∆DM and ∆dM are the criteria for passing in the dose
difference and distance-to-agreement directions respectively. The circle representing the
accepted region is shaded in ochre.
sis, typically with a DD/DTA criteria of 2%/2mm or 3%/3mm (depending on the
precision required).
To assess the quality of the fitting, a one-dimensional gamma analysis code was
written in Matlab. The code compared each measured point with all points in the
fits by determining the Γ value. The minimum of these Γ values was selected as
the gamma index γ for that measurement position. This process of comparison was
repeated for all measured points. To ensure there were no artefacts in the analysis
and to make the comparison fair for all systems, all datasets were resampled to a
high resolution (points equally spaced, every 0.1mm). A criteria of 2%/2mm was
used for proton integrated depth doses, but a much tighter 2%/0.05mm was used
for the proton spot profiles.
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